

## Bibliography of Sublingual Immunotherapy Publications v. 12/20

### Introduction

The current understanding of clinical efficacy, safety, mechanisms and indications for the use of sublingual immunotherapy (SLIT) in the treatment of allergies is embodied in the studies, papers and publications referenced in this document. Over 1,000 citations are contained in this bibliography, including hundreds of peer-reviewed studies published since 1995.

Internationally, SLIT is used widely (50% in some European countries), with full regulatory and government backing. U.S. allergy leaders are writing in support of SLIT. (See section 1) The World Health Organization indicated its use in its 1998 position paper. In 2007, for the second time (originally in 2001), an international workgroup, including U.S. allergists, published the ARIA (Allergy Rhinitis and its Impact on Asthma) guidelines indicating SLIT as a viable treatment approach. The ARIA paper indicates that not only is there more modern research on SLIT compared to SCIT, but it is also of higher quality in terms of the WHO guidelines for research studies. A Cochrane Review, the most trusted independent, evidence based, meta-analysis organization in the world, released their analysis in 2003 and determined SLIT both safe and effective (see section 1).

Two additional pivotal studies to note are the “10 year study...” showing the long lasting effect of SLIT (see section 1), and the 2004 head-to-head study of SLIT to injection in a double-blind, double-dummy approach (see section 2). Few studies have shown that SLIT was not effective, and those results are equivocal or dated.

Additional research efforts are underway in the U.S. and internationally; this document is updated periodically to include recent publications. Last updated 12/11/20.

### Scientific research and related publications

The following pages are a comprehensive bibliography of studies divided into six categories, with citations presented in chronological order:

- 1. Recent Major Texts, Guidelines, Reviews, Papers and Editorials;** includes more than 300 major position papers
- 2. Studies/Abstracts;** includes over 200 studies
- 3. Comparison Studies of Sublingual, Subcutaneous and Other Allergen Therapies**
- 4. Mechanisms of Sublingual Immunotherapy;** current understanding of mucosal immunity
- 5. Safety, Quality-of-Life and Adherence Related Studies;** growing body of evidence
- 6. Other Indications for Treatment;** other sensitizations where SLIT has worked
- 7. Allergic Trends and Supporting Data**

The scrutiny of SLIT has been intense, particularly in the past five to 10 years. The volume of research and its consistency in showing safety and efficacy is evidence of the value of SLIT to patients. We thank you for your interest in this topic and invite you to provide us feedback and let us know if you would like to receive updates of new research and publications as they are added.

## I) Recent Major Texts, Guidelines, Reviews, Papers and Editorials

1. Agache I, Laculiceanu A, Cojanu C, et al. Advances in allergen immunotherapy for asthma. *Current Opinion in Allergy Clinical Immunology*. 2020 August 6. doi: 10.1097/ACI.0000000000000686
2. Bahceciler N, Yuruker O. Planning and approach to allergen-specific immunotherapy in polyallergic patients. *Immunotherapy*. 2020 May 21; 12(8). doi: 10.2217/imt-2019-0182
3. Chen L, Lei L, Cai Y, et al. Specific sublingual immunotherapy in children with perennial rhinitis: a systemic review and meta-analysis. *International Forum of Allergy and Rhinology*. 2020 September; 10(9). doi: 10.1002/alr.22589
4. Compalati E, Incorvaia C, Cavaliere C, et al. The role of allergoids in allergen immunotherapy: from injective to sublingual route. *European Annals of Allergy and Clinical Immunology*. 2020 September; 52(5). doi: 10.23822/EurAnnACI.1764-1489.142
5. Dykewicz M, Wallace D, Amrol D, et al. Rhinitis 2020: A Practice Parameter Update. *Journal of Allergy and Clinical Immunology*. 2020 July 1. doi: 10.1016/j.jaci.2020.07.007
6. Field K, Blaiss M. Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations? *Current Allergy and Asthma Reports*. 2020 June 16; 20(45).
7. Fortescue R, Kew K, Leung M. Sublingual immunotherapy for asthma. *Cochrane Database of Systematic Reviews*. 2020 September 14. doi: 10.1002/14651858.CD011293.pub3
8. Hossenbaccus L, Linton S, Garvey S, et al. Towards definitive management of allergic rhinitis: best use of new and established therapies. *Allergy, Asthma and Clinical Immunology*. 2020 May 27; 16(39). doi: 10.1186/s13223-020-00436-y
9. Incorvaia C, Al-Ahmad M, Ignacio A, et al. Personalized Medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. *European Journal of Allergy and Clinical Immunology*. 2020 September 1. doi: 10.1111/all.14575
10. Incorvaia C, Ciprandi G, Makri E, et al. Subcutaneous and sublingual allergen-specific immunotherapy: a tale of two routes. *European Annals of Allergy and Clinical Immunology*. 2020 May 6. doi: 10.23822/EurAnnACI.1764-1489.150
11. Jensen-Jarolim E, Bachmann M, Bonini S, et al. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). *European Journal of Allergy and Clinical Immunology*. 2020 April; 75(4). doi: 10.1111/all.14134
12. Larenas-Linnemann D, Rodriguez-Perex N, Luna-Pech J, et al. Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines. *World Allergy Organization Journal*. 2020 August 21; 13(8). doi: 10.1016/j.waojou.2020.100444
13. Lin S. Sublingual immunotherapy in the United States: history and current relevance in the time of COVID-19. *International Forum of Allergy and Rhinology*. 2020 August 11. doi: 10.1002/alr.22670
14. Malipiero G, Heffler E, Pelaia C, et al. Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model. *Clinical and Translational Allergy*. 2020 June 18; 10(23). doi: 10.1186/s13601-020-00333-y
15. Memon R, Persaud Y, Mohammedi N, et al. Allergy Desensitization. *StatPearls*. 2020 August 16.
16. Nelson H. Allergy immunotherapy: Future directions for the 2020s. *Allergy and Asthma Proceedings*. 2020 September 1; 41(5). doi: 10.2500/aap.2020.41.200041
17. Pfaar O, Agache I, Bergmann K, et al. Placebo effects in allergen immunotherapy - an EAACI Task Force Position Paper. *European Journal of Allergy and Clinical Immunology*. 2020 April 23. doi: 10.1111/all.14331
18. Trivedi A, Katelaris C. Presentation, diagnosis, and the role of subcutaneous and sublingual immunotherapy in the management of ocular allergy. *Clinical and Experimental Optometry*. 2020 September 17. doi: 10.1111/cxo.13129
19. Passalacqua G, Bagnasco D, Canonica G. 30 years of sublingual immunotherapy. *European Journal of Allergy and Clinical Immunology*. 2019 Nov 12. doi: 10.1111/all.14113

20. Nelson H. Allergy immunotherapy for inhalant allergens: Strategies to improve efficacy. *Allergy and Asthma Proceedings*. Jan 1 2020; 41(1). doi: 10.2500/aap.2020.41.190013
21. Klimek L, Bachert C, Pfaar O, et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. *Allergologie Select*. 2019 Dec 30; 3(1). doi: 10.5414/ALX02120E
22. Li H, Chen S, Cheng L, et al. Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma. *Journal of Thoracic Disease*. 2019 Dec 1; 11(12). doi: 10.21037/jtd.2019.12.37
23. Tankersley M, Han J, Nolte H. Clinical Aspects of Sublingual Immunotherapy Tablets and Drops. *Annals of Allergy, Asthma & Immunology*. 2020 Jan 7. doi: 10.1016/j.anai.2019.12.025
24. Waldron J, Kim E. Sublingual and Patch Immunotherapy for Food Allergy. *Immunology and Allergy Clinics of North America*. Feb 2020; 40(1). doi: 10.1016/j.iac.2019.09.008
25. Bonini M, Jutel M. Allergen immunotherapy for asthma: looking “Back to the Future.” *European Journal of Allergy and Clinical Immunology*. 2019 July 20. doi: 10.1111/all.13995
26. Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. *European Journal of Allergy and Clinical Immunology*. 2019 April 7. doi: 10.1111/all.13805
27. Bright D, Pollart SM, Franko J. Allergy immunotherapy: Who, what, when...and how safe? *The Journal of Family Practice*. 2019 June.
28. Cui L, Li J, Li Y, Xia Z, et al. Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study. *International Archives of Allergy and Immunology*. 2019 Jun 28; 180(2). doi: 10.1159/000500524
29. Emeryk A, Emeryk-Maksymuik J, Janeczek K. New guidelines for the treatment of seasonal allergic rhinitis. *Advances in Dermatology and Allergology*. 2019 June; 3. doi: 10.5114/ada.2018.75749
30. Harrill WC, Setzen G, Farquhar D, et al. Contemporary analysis of otolaryngic allergy. *The Laryngoscope*. 2019 Apr 14. doi: 10.1002/lary.28002
31. Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. *The Journal of Allergy and Clinical Immunology*. 2019 Aug 29. doi: 10.1016/j.jaci.2019.07.030
32. Tortajada-Girbés M, Mesa Del Castillo M, Larramona H, et al. Decision-making for pediatric allergy immunotherapy for aeroallergens: a narrative review. *European Journal of Pediatrics*. 2019 Aug 14. doi: 10.1007/s00431-019-03444-2
33. Wong AG, Lomas JM. Allergy Testing and Immunotherapy. *Pediatrics in Review*. 2019 May; 40(5). doi: 10.1542/pir.2018-0126
34. Dantzer J, Wood R. Next-Generation Approaches for the Treatment of Food Allergy. *Current Allergy and Asthma Reports*. 2019 Jan; 19(5). doi: 10.1007/s11882-019-0839-5
35. Hellings PW, Pugin B, Marien G, et al. Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement. *Clinical and Translational Allergy*. 2019 Feb 4; 9(1). doi: 10.1186/s13601-019-0243-1
36. Joo Chan C, Richardo T, Lim RLH. Current Trend in Immunotherapy for Peanut Allergy. *International Reviews of Immunology*. 2019 Jan 13; 37(6). doi: 10.1080/08830185.2018.1509967
37. Leonardi A, Silva D, Perex Formigo D, et al. Management of ocular allergy. *European Journal of Allergy and Clinical Immunology*. 2019 Mar 19. doi: 10.1111/all.13786
38. Memon RJ, Savliwala MN. Allergy Desensitization. *StatPearls Publishing*. 2018 Dec 13.
39. Parrish C. Management of Peanut Allergy: A Focus on Novel Immunotherapies. *AJMC Managed Markets Network*. 2018 Oct 19; 24.
40. Pfaar O, Lou H, Zhang Y, et al. Recent developments and highlights in allergen immunotherapy. *European Journal of Allergy and Clinical Immunology*. 2018 October 29; 73(12). doi: 10.1111/all.13652

41. Reitsma S, Subramaniam S, Fokkens WWJ, et al. Recent developments and highlights in rhinitis and allergen immunotherapy. *European Journal of Allergy and Clinical Immunology*. 2018 Sept 27; 73(12). doi: 10.1111/all.13617
42. Sampson HA, Berin MC, Plaut M, et al. The Consortium for Food Allergy Research (CoFAR): The first generation. *The Journal of Allergy and Clinical Immunology*. 2019 Feb; 143(2). doi: 10.1016/j.jaci.2018.12.989
43. Scurlock AM. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. *Clinical Reviews in Allergy & Immunology*. 2018 Oct; 55(2). doi: 10.1007/s12016-018-8677-0
44. Wang Y, Li Y, Zhao CQ, et al. A Meta-analysis of sublingual immunotherapy in the treatment of seasonal allergic rhinitis. 2019 Jan; 33(1). doi: 10.13201/j.issn.1001-1781.2019.01.005
45. Anagnostou K. Food immunotherapy for children with food allergies: state of the art and science. *Current Opinions in Pediatrics*. 2018 Aug 27. doi: 10.1097/MOP.0000000000000684.
46. Arasi S, Corsello G, Villani A, et al. The future outlook on allergen immunotherapy in children: 2018 and beyond. *Italian Journal of Pediatrics*. 2018 July 11; 44(80). doi: 10.1186/s13052-018-0519-4.
47. Cheng L, Zhou W. Sublingual immunotherapy of house dust mite respiratory allergy in China. *Allergologia et Immunopathologia*. 2018 Jun 16. doi: 10.1016/j.aller.2018.02.008.
48. Creticos P. Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. *UpToDate*. 2017 April 28.
49. Dhami S, Agarwal A. Does evidence support the use of cat allergen immunotherapy? *Current Opinion in Allergy and Clinical Immunology*. 2018 Aug; 18(4). doi: 10.1097/ACI.0000000000000457.
50. Dhami S, Mosges R, Pfaar O, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. *European Journal of Allergy and Clinical Immunology*. 2018 Dec 1; 72(12). doi: 10.1111/all.13208.
51. Di Bona D, Frisenda F, Albanesi M, et al. Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review. *Clinical and Experimental Allergy*. 2018 Aug 6. doi: 10.1111/cea.13242.
52. Falk N. Allergy and Asthma: Asthma Management. *FP Essentials*. 2018 Sept.
53. Feuille E, Nowak-Wegrzyn A. Allergen-Specific Immunotherapies for Food Allergy. *Allergy Asthma Immunol Res*. 2018 May; 10(3). doi: 10.4168/aa.2018.10.3.189.
54. Ghosn J, Spertini F, Comte D. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma : a practical approach. *Revue Medicale Suisse*. 2018 April 4; 14(601).
55. Larenas-Linnemann D, Luna-Pech A. What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017. *Current Opinion in Allergy and Clinical Immunology*. 2018 Jun; 18(3). doi: 10.1097/ACI.0000000000000439.
56. Pajno G, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. *Allergy*. 2018 April; 73(4). doi: 10.1111/all.13319.
57. Masuyama K, Matsuoka T, Kamijo A. Current status of sublingual immunotherapy for allergic rhinitis in Japan. *Allergology International*. 2018 July; 67. doi: 10.1016/j.alit.2018.04.011.
58. Nagarajan S, Ahmad S, Quinn M, et al. Allergic sensitization and clinical outcomes in urban children with asthma, 2013-2016. *Allergy and Asthma Proceedings*. 2018 May; 39. doi: 10.2500/aap.2018.39.4147.
59. Nelson H. Immunotherapy for house-dust mite allergy. *Allergy and Asthma Proceedings*. 2018 Aug. <https://doi.org/10.2500/aap.2018.39.4145>.
60. Porcaro F, Corsello G, Pajno G. SLIT's Prevention of the Allergic March. *Current Allergy and Asthma Reports*. 2018 April 21; 18(5). doi: 10.1007/s11882-018-0785-7 .
61. Ramesh M, Karagic M. New modalities of allergen immunotherapy. *Human Vaccines and Immunotherapeutics*. 2018 Sep 5. doi: 10.1080/21645515.2018.1502126.
62. Sakurai, Yonekura, Iinuma, et al. The Relationship of Pollen Dispersal with Allergy Symptoms and Immunotherapy: Allergen Immunotherapy Improves Symptoms in the Late Period of Japanese Cedar Pollen Dispersal. *International Archives of Allergy and Immunology*. 2018 Jul 18; 1-10. doi: 10.1159/000490314.
63. Titulaer J, Arefian H, Hartmann M, et al. Cost-effectiveness of allergic rhinitis treatment: An exploratory study. *SAGE Open Medicine*. 2018 Aug 8; 6 (1-9). doi: 10.1177/2050312118794588.

64. Tosca M, Licari A, Olcese R, et al. Immunotherapy and Asthma in Children. *Frontiers in Pediatrics*. 2018 Aug 21; 6(231). doi: 10.3389/fped.2018.00231.
65. Quirt J, Hildebrand K, Mazza J, et al. Asthma. *Allergy, Asthma & Clinical Immunology*. 2018 Sep 12; 14(50). doi: 10.1186/s13223-018-0279-0.
66. Wahn U, Bachert C, Heinrich J, et al. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. *European Journal of Allergy and Clinical Immunology*. 2018 June 29. doi: 10.1111/all.13598.
67. Lin S, Azar A, Suarez-Cuervo C, et al. The role of immunotherapy in the treatment of asthma. *Comparative effectiveness review*. 2018 Mar; 196. doi: <https://doi.org/10.23970/AHRQEPCCER196>.
68. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. *Annals of Allergy, Asthma & Immunology*. 2016 Dec 13; 118. doi: <http://dx.doi.org/10.1016/j.anai.2016.12.009>.
69. Zhang W, Lin C, Sampath V, et al. Impact of allergen immunotherapy in allergic asthma. *Immunotherapy*. 2018 Mar 23. doi: 10.2217/imt-2017-0138.
70. Cho S, Han D, Kim J, et al. House dust mite sublingual immunotherapy in allergic rhinitis. *Immunotherapy*. 2018 Mar 22. doi: 10.2217/imt-2018-0013.
71. Liu X, Ng C, Wang Y. The efficacy of sublingual immunotherapy for allergic diseases in Asia. *Allergology International: official journal of the Japanese Society of Allergology*. 2018 Mar 15. doi: 10.1016/j.alit.2018.02.007.
72. Larenas-Linnemann D, Antolin-Amerigo D, Parisi C, et al. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. *European Journal of Allergy and Clinical Immunology*. 2018 Mar; 73(3). doi: 10.1111/all.13316.
73. Passalacqua G, Bagnasco D, Ferrando M, et al. Current insights in allergen immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2018 Feb; 120(2). doi: 10.1016/j.anai.2017.11.001.
74. Passali D, Cingi C, Staffa P, et al. The international study of allergic rhinitis survey: Outcomes from 4 geographical regions. *Asia Pacific Allergy*. 2018 Jan 25; 8(1). doi: 10.5415/apallergy.2018.8.e7.
75. Tang L, Yang X, Wang P, et al. Efficacy and safety of sublingual immunotherapy with Dermatophagoides farina drops in pre-school and school-age children with allergic rhinitis. *Allergologia et Immunopathologia*. 2018 Mar; 46(2). doi: 10.1016/j.aller.2017.09.022.
76. Jerzynska J, Stelmach W, Majak P, et al. Comparison of the effect of 5-grass pollen sublingual immunotherapy tablets and drops in children with rhinoconjunctivitis. *Allergy & Asthma Proceedings*. 2018 Jan 1; 39(1). doi: 10.2500/aap.2018.39.4099.
77. van de Griendt E, Tuut M, de Groot H, et al. Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review. *BMJ Open*. 2017 Dec 28; 7(12). doi: 10.1136/bmjopen-2017-016326.
78. Edwards T, Wise S. Clinical applications of sublingual immunotherapy. *Otolaryngologic Clinics of North America*. 2017 Dec; 50(6). doi: 10.1016/j.otc.2017.08.010.
79. Halken S, Larenas-Linnemann D, Roberts G, et al. EACCI guidelines on allergen immunotherapy: Prevention of allergy. *Pediatric Allergy and Immunotherapy*. 2017 Dec; 28(8). doi: 10.1111/pai.12807.
80. Dahdah L, Pecora V, Riccardi C, et al. How to predict and improve prognosis of food allergy. *Current Opinion in Allergy and Clinical Immunology*. 2018 Mar 29. doi: 10.1097/ACI.0000000000000446.
81. Morjaria J, Caruso M, Emma R, et al. Treatment of allergic rhinitis as a strategy for preventing asthma. *Current Allergy and Asthma Reports*. 2018 Mar 24; 18(4). doi: 10.1007/s11882-018-0781-y.
82. Hopper J, Hopp C, Durbin J. Peanut allergy reduction in high-risk pediatric patients. *The Nurse Practitioner*. 2018 Mar 12; 43(3). doi: 10.1097/01.NPR.0000530210.24654.36.
83. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: Executive statement. *European Journal of Allergy and Clinical Immunology*. 2018 Jan 30. doi: 10.1111/all.13420.



84. Roger A, Basagana M, Teniente-Serra A, et al. Immunotherapy in allergic diseases. *Current Pharmaceutical Design*. 2018 Jan 15. doi: 10.2174/1381612824666180116094048.
85. Lombardi C, Elenora S, Erminia R, et al. Is allergic sensitization relevant in severe asthma? Which allergens may be culprits? *World Allergy Organization Journal*. 2017; 10(2). doi: 10.1186/s40413-016-0138-8.
86. Asamoah F, Kakourou A, Dhimi S, et al. Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. *Clinical and Translational Allergy*. 2017 Aug 2;7(25). doi: 10.1186/s13601-017-0160-0.
87. Luk LJ, Rotella MR, Stillman LJ, et al. Assessing asthma in the otolaryngologist's office. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2017 Jun;25(3):223-230. doi: 10.1097/MOO.0000000000000351.
88. Charpin D, Pichot C, Belmonte J, et al. Cypress pollinosis: From tree to clinic. *Clinical Reviews in Allergy & Immunology*. 2017 Apr 11. doi: 10.1007/s12016-017-8602-y.
89. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis. *European Journal of Allergy and Clinical Immunology*. 2017 Sep 23. doi: 10.1111/all.13317.
90. Feng B, Xiang H, Jin H, et al. Efficacy of sublingual immunotherapy for house dust mite-induced allergic rhinitis: A meta-analysis of randomized controlled trials. *Allergy, Asthma & Immunology Research*. 2017 May; 9(3):220-228. doi: 10.4168/aa.2017.9.3.220.
91. Nelson HS. Immunotherapy coming of age: notable advances during the first hundred years. *Expert Review of Clinical Immunology*. 2017 May;13(5):389-392. doi: 10.1080/1744666X.2017.
92. Jin JJ, Li JT, Kilmek L, et al. Sublingual immunotherapy dosing regimens: What is ideal? *American Academy of Allergy, Asthma & Immunology: Clinical Management Review*. 2016 Sept 13. doi: 10.1016/j.jaip.2016.09.027.
93. Cox LS. Sublingual Immunotherapy: Historical perspective and practical guidance. *American Academy of Allergy, Asthma & Immunology: Theme Editorial*. 2016 Nov 16. doi: 10.1016/j.jaip.2016.11.016.
94. Turkalj M, Banic I, Anzic, SA. A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (*ambrosia artemisiifolia*). *Patient Preference and Adherence*. 2017; 11:247-257. doi: 10.2147/PPA.S70411.
95. Pepper AN, Calderon MA, Casale TB. Sublingual immunotherapy for the polyallergic patient. *American Academy of Allergy, Asthma & Immunology: Grand Rounds Review*. 2016 June 23. doi: 10.1016/j.jaip.2016.06.019.
96. Battista Pajno G, Bernardini R, Peroni D, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. *Italian Journal of Pediatrics*. 2017 Jan 23. doi: 10.1186/s13052-016-0315-y.
97. Brunton S, Nelson HS, Bernstein DI, et al. Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma. *Postgraduate Medical Journal*. 2017 Mar 27;1-9. doi: 10.1080/00325481.2017.1308208.
98. Gernez Y, Nowak-Wegrzyn A. Immunotherapy for food allergy: Are we there yet? *Journal of Allergy and Clinical Immunology: In Practice*. 2017 Mar-Apr; 5(2):250-272. doi: 10.1016/j.jaip.2016.12.004.
99. Feng B, Wu J, Chen B, et al. Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: A meta-analysis of randomized controlled trials. *American Journal of Rhinology & Allergy*. 2017 Jan 1;31(1):27-35. doi: 10.2500/ajra.2017.31.4382.
100. Demoly P, Passalacqua G, Pfaar O, et al. Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. *Allergy, Asthma & Clinical Immunology*. 2016 Jul 29;12:34. doi: 10.1186/s13223-016-0140-2.
101. Ferrando M, Bagnasco D, Passalacqua G, et al. MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. *Expert Opinion on Biological Therapy*. 2016 Nov;16(11):1435-1441.
102. Ponce M, Diesner SC, Szépfalusi Z, et al. Markers of tolerance development to food allergens. *Allergy*. 2016 Oct;71(10):1393-404. doi: 10.1111/all.12953.

103. Miceli Sopo S, Battista A, Greco M, et al. Grass pollen sublingual immunotherapy and pediatric allergic rhinitis: A patient-oriented decision. *Allergologia et Immunopathologia*. 2016 Jul-Aug;44(4):382-6. doi: 10.1016/j.aller.2015.05.004.
104. Larenas-Linnemann D, Baxi S, Phipatanakul W, et al. Clinical Evaluation and Management of Patients with Suspected Fungus Sensitivity. *Journal of Allergy and Clinical Immunology*. 2016 May-Jun;4(3):405-14. doi: 10.1016/j.jaip.2015.10.015.
105. Benedé S, Blázquez AB, Chiang D, et al. The rise of food allergy: Environmental factors and emerging treatments. *EBioMedicine*. 2016 May;7:27-34. doi: 10.1016/j.ebiom.2016.04.012.
106. Hanci D, Sahin E, Muluk NB, et al. Immunotherapy in all aspects. *European Archives of Oto-Rhino-Laryngology*. 2016 Jun;273(6):1347-55. doi: 10.1007/s00405-015-3553-5.
107. Pesek RD, Jones SM. Current and Emerging Therapies for IgE-Mediated Food Allergy. *Current Allergy and Asthma Reports*. 2016 Apr;16(4):28. doi: 10.1007/s11882-016-0610-0.
108. Commins SP, Kim EH, Orgel K, et al. Peanut Allergy: New Developments and Clinical Implications. *Current Allergy and Asthma Reports*. 2016 May;16(5):35. doi: 10.1007/s11882-016-0613-x.
109. Wood RA. Food allergen immunotherapy: Current status and prospects for the future. *Journal of Allergy and Clinical Immunology*. 2016 Apr;137(4):973-82. doi: 10.1016/j.jaci.2016.01.001.
110. Nowak-Węgrzyn A. Using Food and Nutritional Strategies to Induce Tolerance in Food-Allergic Children. *Nestlé Nutrition Workshop Series*. 2016;85:35-53. doi: 10.1159/000439484.
111. Slavyanakaya TA, Derkach VV, Sepiashvili RI. Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. *World Allergy Organization Journal*. 2016 Apr 18;9:15. doi: 10.1186/s40413-016-0106-3.
112. Larsson O, Hellkvist L, Peterson-Westin U, et al. Novel strategies for the treatment of grass pollen-induced allergic rhinitis. *Expert Opinion on Biological Therapy*. 2016 Sep;16(9):1143-50. doi: 10.1080/14712598.2016.1190829.
113. Canonica GW, Virchow JC, Ziegelmayer P, et al. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. *Expert Review of Clinical Immunology*. 2016 Aug;12(8):805-15. doi: 10.1080/1744666X.2016.1200467.
114. Trendelenburg V, Blümchen K. Allergen-specific immunotherapy for food allergies in childhood. Current options and future perspectives. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2016 Jul;59(7):855-64. doi: 10.1007/s00103-016-2372-1.
115. Saporta D. Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice. *BioMed Research International*. 2016;2016:9323804. doi: 10.1155/2016/9323804.
116. Creticos PS, Bernstein DI, Casale TB, et al. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. *Journal of Allergy and Clinical Immunology*. 2016 Jun 24. pii: S2213-2198(16)30153-2. doi: 10.1016/j.jaip.2016.05.014.
117. Đuric-Filipovic I, Caminati M, Kostic G, et al. Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. *World Journal of Pediatrics*. 2016 Aug;12(3):283-90. doi: 10.1007/s12519-016-0022-1.
118. Cardona V, Luengo, Labrador-Horrillo M. Immunotherapy in allergic rhinitis and lower airway outcomes. *Allergy*. 2016 Jul 20. doi: 10.1111/all.12989.
119. Lawrence MG, Steinke JW, Borish L. Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2016 Aug;117(2):138-42. doi: 10.1016/j.anai.2016.06.027.
120. Yukselen A. Allergen-specific immunotherapy in pediatric allergic asthma. *Asia Pacific Allergy*. 2016 Jul;6(3):139-48. doi: 10.5415/apallergy.2016.6.3.139.
121. Passalacqua G, Derkach A, Canonica GW. Local Side Effects of Sublingual and Oral Immunotherapy. *Journal of Allergy and Clinical Immunology*. 2016 Aug 12. pii: S2213-2198(16)30263-X. doi: 10.1016/j.jaip.2016.06.020.

122. Demoly P, Okamoto Y, Yang WH, et al. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. *Expert Review of Clinical Immunology*. 2016 Nov;12(11):1141-1151. Epub 2016 Sep 29.
123. Kobernick AK, Burks AW. Active treatment for food allergy. *Allergology International*. 2016 Oct;65(4):388-395. doi: 10.1016/j.alit.2016.08.002.
124. Oktemer T, Altıntoprak N, Muluk NB, et al. Clinical efficacy of immunotherapy in allergic rhinitis. *The American Journal of Rhinology & Allergy*. 2016 Sep;30 suppl. 1(5):4-7.
125. Alterio T, Manti S, Colavita L. Sublingual immunotherapy in children: State of art. *Journal of Biological Regulators & Homeostatic Agents*. 2015 Apr-Jun;29(2 Suppl 1):120-4.
126. Cox LS, Didier A, Demoly P, et al. Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. *Journal of Allergy and Clinical Immunology*. 2016 Apr 12. doi: 10.1016/j.jaci.2016.01.039.
127. Mims JW. Current concepts: diagnosis and management of food allergy in children. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2016 Mar 15. doi: 10.1097/MOO.0000000000000261.
128. Jutel M, Bartkowiak-Emeryk M, Breborowicz A, et al. Sublingual immunotherapy (SLIT) - indications, mechanism, and efficacy position paper prepared by the Section of Immunotherapy, Polish Society of Allergy. *Annals of Agricultural and Environmental Medicine*. 2016 Mar;23(1):44-53. doi: 10.5604/12321966.1196851.
129. Nguyen NT, Raskopf E, Shah-Hosseini K, Zadoyan G, Mösges R. A review of allergoid immunotherapy: Is cat allergy a suitable target? *Immunotherapy*. 2016 Mar;8(3):331-349. doi: 10.2217/imt.15.121. .
130. Poddighe D, Licari A, Caimmi S, et al. Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence. *World Journal of Clinical Pediatrics*. 2016 Feb 8;5(1):47-56. doi: 10.5409/wjcp.v5.i1.47.
131. Song TW. A practical view of immunotherapy for food allergy. *Korean Journal of Pediatrics*. 2016 Feb;59(2):47-53. doi: 10.3345/kjp.2016.59.2.47. Epub 2016 Feb 29.
132. Larenas-Linnemann D, Baxi S, Phipatanakul W, Portnoy JM, Environmental Allergens Workgroup. Clinical evaluation and management of patients with suspected fungus sensitivity. *Journal of Allergy and Clinical Immunology: In Practice*. 2016 Jan 2. pii: S2213-2198(15)00625-X. doi: 10.1016/j.jaip.2015.10.015.
133. Cox L. The role of allergen immunotherapy in the management of allergic rhinitis. *American Journal of Rhinology & Allergy*. 2016 Jan;30(1):48-53. doi: 10.2500/ajra.2016.30.4253.
134. Sur DK, Plesa ML. Treatment of allergic rhinitis. *American Family Physician*. 2015 Dec 1;92(11):985-992.
135. Didier A, Campo P, Moreno F, Durand-Perdriel F, Marin A, Chartier A. Dose-dependent immunological responses after a 6-month course of sublingual house dust mite immunotherapy in patients with allergic rhinitis. *International Archives of Allergy and Immunology*. 2015;168(3):182-192. doi: 10.1159/000442467.
136. Passalacqua G, Canonica GW. Allergen immunotherapy: History and future developments. *Immunology and Allergy Clinics of North America*. 2016 Feb;36(1):1-12. doi: 10.1016/j.iac.2015.08.001. .
137. Canonica GW, Bagnasco D, Ferrantino G, Ferrando M, Passalacqua G. Update on immunotherapy for the treatment of asthma. *Current Opinion in Pulmonary Medicine*. 2016 Jan;22(1):18-24. doi: 10.1097/MCP.0000000000000227.
138. Larenas-Linnemann, D. Allergen immunotherapy: an update on protocols of administration. *Current Opinion in Allergy and Clinical Immunology*. 2015 Dec;15(6):556-567. doi:10.1097/ACI.0000000000000220.
139. Masuyama K, et al. Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. *Auris Nasus Larynx*. 2015 Nov 23. pii: S0385-8146(15)00225-4. doi: 10.1016/j.anl.2015.08.015.
140. Incorvaia C, Mauro M, Ridolo E. Sublingual immunotherapy for allergic rhinitis: where are we now? *Immunotherapy*. 2015 Oct 28. doi:10.2217/imt.15.72.
141. Arasi S, Passalacqua G, Caminiti L, Crisafulli G, Fiamingo C, Pajno GB. Efficacy and safety of sublingual immunotherapy in children. *Expert Review of Clinical Immunology*. 2015 Oct 17;1-8. doi: 10.1586/1744666X.2016.1102058.



142. Mener DJ, Lin SY. Improvement and prevention of asthma with concomitant treatment of allergic rhinitis and allergen-specific therapy. *International Forum of Allergy & Rhinology*. 2015 Sep;5 Suppl 1:S45-50. doi: 10.1002/alr.21569. Epub 2015 Jun 13.
143. Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. *Drug Discovery Today*. 2015 Sep 2. doi: 10.1016/j.drudis.2015.07.010.
144. Leatherman BD, et al. Dosing of sublingual immunotherapy for allergic rhinitis: evidence-based review with recommendations. *International Forum of Allergy & Rhinology*. 2015 Sep;5(9):773-83. doi: 10.1002/alr.21561.
145. Pleskovic N, Bartholow A, Gentile DA, Skoner DP. The future of sublingual immunotherapy in the United States. *Current Allergy and Asthma Reports*. 2015 Aug; 15(8):44. doi: 10.1007/s11882-015-0545-x.
146. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis. *JAMA Internal Medicine*. 2015 Aug;175(8):1301-9. doi: 10.1001/jamainternmed.2015.2840.
147. van der Valk JP, de Jong NW, Gerth van Wijk R. Review on immunotherapy in airway allergen sensitised patients. *Netherlands Journal of Medicine*. 2015 Jul;73(6):263-9.
148. McDonnell AL, et al. Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis. *Allergy, Asthma & Clinical Immunology*. 2015 Jun 10;11(1):19. doi: 10.1186/s13223-015-0085-x. eCollection 2015.
149. Cox L. Allergy immunotherapy in reducing healthcare cost. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2015 Jun;23(3):247-54. doi: 10.1097/MOO.0000000000000150.
150. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. *The New England Journal of Medicine*. 2015 Jan 29;372(5):456-63. doi: 10.1056/NEJMcpl412282.
151. Nelson, HS. Allergen immunotherapy: what's new, what's next? *Expert Review of Clinical Immunology*. 2015;11(9):959-61. doi: 10.1586/1744666X.2015.1062726. Epub 2015 Jul 1.
152. Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. *Expert Opinion on Drug Safety*. 2015 May;14(5):777-88. doi: 10.1517/14740338.2015.1017468. Epub 2015 Mar 3.
153. Scadding GK. Optimal management of allergic rhinitis. *Archives of Disease in Childhood*. 2015 Jun;100(6):576-582. doi: 10.1136/archdischild-2014-306300. Epub 2015 Apr 2.
154. Nony E, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v I in birch pollen-allergic patients. *Allergy*. 2015 Apr 2. doi: 10.1111/all.12622.
155. Lee S, Nolte H, Benninger MS. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. *American Journal of Rhinology & Allergy*. 2015 Mar-Apr;29(2):106-14. doi: 10.2500/ajra.2015.29.4148.
156. El-Qutob D, Reche P, Subiza JL, Fernandez-Caldas E. Peptide-based allergen specific immunotherapy for the treatment of allergic disorders. *Recent Patents of Inflammation & Allergy Drug Discovery*. 2015;9(1):16-22.
157. Kim ST. Outcome of sublingual immunotherapy in patients with allergic rhinitis sensitive to house dust mites. *Allergy, Asthma & Immunology Research*. 2015 Mar;7(2):99-100. doi: 10.4168/aair.2015.7.2.99.
158. Ihler F, Canis M. Ragweed-induced allergic rhinoconjunctivitis: current and emerging treatment options. *Journal of Asthma and Allergy*. 2015 Feb 16;8:15-24. doi: 10.2147/JAA.S47789. eCollection 2015.
159. Choi JS, et al. Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. *Annals of Dermatology*. 2015 Feb;27(1):82-6. doi: 10.5021/ad.2015.27.1.82. Epub 2015 Feb 3.
160. Seidman MD, et al. Clinical practice guideline: Allergic rhinitis. *Otolaryngology Head and Neck Surgery*. 2015 Feb;152(2):197-206. doi: 10.1177/0194599814562166.
161. Hsiao KC, Smart J. Comment on 'Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. *Pediatric Allergy and Immunology*. 2015 Feb;26(1):92. doi: 10.1111/pai.12329.

162. Gendelman SR, Lang DM. Sublingual immunotherapy in the treatment of atopic dermatitis; a systematic review using the GRADE system. *Current Allergy and Asthma Reports*. 2015 Feb;15(2):498. doi: 10.1007/s11882-014-0498-5.
163. Refaat M, Ashour ZA, Farres MN, Eissa AM, Elsayed MM. Effect of tonsillectomy on the efficacy of house dust mite sublingual immunotherapy. *Allergologia et Immunopathologia (Madrid)*. 2015 Jan-Feb;43(1):108-11. doi: 10.1016/j.aller.2013.09.007. Epub 2014 Jan 2.
164. Nakonechna A, Hills J, Moor J, Dore P, Abuzakouk M. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy? *Annals of Allergy, Asthma & Immunology*. 2015 Jan;114(1):73-4. doi: 10.1016/j.anai.2014.10.013. Epub 2014 Nov 14.
165. Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? *Current Allergy and Asthma Reports*. 2014 Dec;14(12):482. doi: 10.1007/s11882-014-0482-0.
166. Wang C, Zhang L. Specific immunotherapy for allergic rhinitis in children. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2014 Dec;22(6):487-94. doi: 10.1097/MOO.000000000000101.
167. Makatsori M, Calderon MA. Sublingual allergen immunotherapy for respiratory allergies: what is new? *Expert Review of Clinical Immunology*. 2014 Dec;10(12):1641-7. doi: 10.1586/1744666X.2014.982536.
168. Yoon, HI. Respiratory review of 2015: asthma. *Tuberculosis and Respiratory Diseases*. 2014 Dec;77(6):237-42. doi: 10.4046/trd.2014.77.6.237. Epub 2014 Dec 31.
169. Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. *Expert Review of Vaccines*. 2014 Dec;13(12):1463-73. doi: 10.1586/14760584.2014.948861. Epub 2014 Sep 4.
170. Bahceciler NN, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair). *Expert Review of Vaccines*. 2014 Dec;13(12):1427-38. doi: 10.1586/14760584.2014.972949. Epub 2014 Oct 27.
171. Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. *World Journal of Clinical Cases*. 2014 Dec 16;2(12):859-65. doi: 10.12998/wjcc.v2.i12.859.
172. Aboshady OA, Elghanam KM. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. *Clinical & Experimental Otorhinolaryngology*. 2014 Dec;7(4):241-9. doi: 10.3342/ceo.2014.7.4.241. Epub 2014 Nov 14.
173. Ishida W, Fukuda K, Harada Y, Yagita H, Fukushima A. Oral immunotherapy for allergic conjunctivitis. *Cornea*. 2014 Nov;33 Suppl 11:S32-6. doi: 10.1097/ICO.0000000000000241.
174. Nelson HS. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. *Expert Review of Clinical Immunology*. 2014 Nov;10(11):1437-51. doi: 10.1586/1744666X.2014.963556.
175. Lin SY. Sublingual immunotherapy: current concepts for the U.S. practitioner. *International Forum of Allergy & Rhinology*. 2014 Sep;4 Suppl 2:S55-9. doi: 10.1002/alr.21388.
176. Didier A, Wahn, Horak F, Cox L. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen induced allergic rhinoconjunctivitis: 5 years of experience. *Expert Review of Clinical Immunology*. 2014 Oct;10(10):1309-24. doi: 10.1586/1744666X.2014.957677. Epub 2014 Sep 10.
177. Ryan MW, Marple BF, Leatherman B, Mims JW, Fornadley J, Veling M, Lin SY. Current practice trends in allergy: results of a United States survey of otolaryngologists, allergist-immunologists, and primary care physicians. *International Forum of Allergy & Rhinology*. 2014 Oct;4(10):789-95. doi: 10.1002/alr.21359.
178. Yalaoui T, de Beaumont O. Comments on: "Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation". *Pediatric Allergy and Immunology*. 2014 Oct 9. doi: 10.1111/pai.12290.
179. Leatherman B, et al. The Allergies, Immunotherapy and Rhinoconjunctivitis (AIRS) survey: provider practices and beliefs about allergen immunotherapy. *International Forum of Allergy & Rhinology*. 2014 Oct;4(10):779-88. doi: 10.1002/alr.21349. Epub 2014 Aug 14.
180. Pleskovic N, Bartholow A, Skoner DP. Sublingual immunotherapy in children: the recent experiences. *Current Opinion in Allergy and Clinical Immunology*. 2014 Dec;14(6):582-90. doi: 10.1097/ACI.000000000000112.

181. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? *Current Opinion in Allergy and Clinical Immunology*. 2014 Dec;14(6):542-8. doi: 10.1097/ACI.000000000000104.
182. Grundmann SA, Mosers P, Brehler R. [Specific immunotherapy] [Article in German]. *Hautärzte*. 2014 Jul;65(7):633-45; quiz 646-7. doi: 10.1007/s00105-014-2817-0.
183. Anolik RI, Schwarz AM, Sajjan S, Allen-Ramey F. Patient initiation and persistence with allergen immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2014 Jul;113(1):101-7. doi: 10.1016/j.anai.2014.04.008. Epub 2014 May 9.
184. Pfaar O, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. *Allergy*. 2014 Jul;69(7):854-67. doi: 10.1111/all.12383. Epub 2014 Apr 25.
185. Castillo J, Dimov V. Investigational drugs for the treatment of allergic rhinitis. *Expert Opinion on Investigational Drugs*. 2014 Jun;23(6):823-36. doi: 10.1517/13543784.2014.907271. Epub 2014 Apr 8.
186. Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2014 Jun;22(3):208-10. doi: 10.1097/MOO.0000000000000042.
187. Skoner DP, et al. The Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) survey: patients' experience with allergen immunotherapy. *Allergy & Asthma Proceedings*. 2014 May-Jun;35(3):219-26. doi: 10.2500/aap.2014.35.3752.
188. Häfner D, Gödicke V, Narkus A. Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies. *Clinical and Translational Allergy*. 2014 May 22;4:18. doi: 10.1186/2045-7022-4-18. eCollection 2014.
189. Riedmann EM. Human Vaccines & Immunotherapeutics: News. FDA approval for Stallergenes' sublingual grass pollen allergy immunotherapy. *Human Vaccines & Immunotherapeutics*. 2014 May;10(5):1141-42. doi: 10.4161/hv.29344.
190. Wu YY, Xie XM, Han D, Li SJ, Liu L, Li MX. [A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma]. [Article in Chinese]. *Zhonghua Nei Ke Za Zhi*. [Chinese Journal of Internal Medicine]. 2013 Oct;52(10):844-848.
191. Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *Journal of Allergy and Clinical Immunology: In Practice*. 2013 Jul-Aug;1(4):361-369.
192. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, Barton P, Dretzke J. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. *Health Technology Assessment*. 2013 Jul;17(27):vi, xi-xiv, 1-322.
193. Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis 2009-2012. *Annals of Allergy, Asthma & Immunology*. 2013 Jun;110(6):402-415.
194. Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. *Journal of Asthma*. 2014 Feb;51(1):20-33.
195. Milani M. Allergen-specific immunotherapy for allergic rhinitis in the elderly: is it never too late? *Immunotherapy*. 2013 July;5(5):699-702.
196. Canonica et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. *World Allergy Organization Journal*. 2014;7:6:1-52.
197. Passalacqua G, Garelli V, Scilfo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. *Immunotherapy*. 2013;5(3):257-64.
198. Incorvaia C, Barbera S., Makri E, Mauro M. Allergic rhinitis: pathology of general interest. *Recenti Progressi in Medicina*. 2013;104(3):116-9.

199. An update on the management of hay fever in adults. *Drug and Therapeutics Bulletin*. 2013;51(3):30-3.
200. Potter P. Sublingual immunotherapy in southern Africa: Lessons learned. *Journal of Allergy and Clinical Immunology*. 2013. Epub ahead of print retrieved May 13, 2013, from <http://www.ncbi.nlm.nih.gov/pubmed/23587331>
201. Klimek L, Pfaar O. A comparison of immunotherapy delivery methods for allergen immunotherapy. *Expert Review of Clinical Immunology*. 2013;9(5):465-75.
202. Kim JM, Lin SY, Suarez-Cuervo C., Chelladurai Y, Ramanathan M, Segal JB, Erekosima N. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review. *Pediatrics*. 2013. Epub ahead of print retrieved May 13, 2013, from <http://www.ncbi.nlm.nih.gov/pubmed/23650298>.
203. Bae, JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. *Journal of Allergy and Clinical Immunology*. 2013. Epub ahead of print retrieved May 13, 2013, from <http://www.ncbi.nlm.nih.gov/pubmed/23647790>.
204. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, Ward D, Segal JB. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *Journal of American Medical Association*. 2013;309(12):1278-88.
205. Dretzke J., Meadows, A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison. *Journal of Allergy and Clinical Immunology*. 2013;131(5):1361-6.
206. Vitaliti G, Pavone P, Guglielmo F, Falsaperla R. Sublingual immunotherapy in preschool children: an update. *Expert Review of Clinical Immunology*. 2013;9(4):385-90.
207. Ramsey S. Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. *BMJ*. 2013;346:f2056.
208. Brehler R, Klimek L, Kopp MV., Christian Virchow J. Specific immunotherapy-indications and mode of action. *Deutsches Ärzteblatt International*. 2013;110(9):148-58.
209. Nelson HS. Is sublingual immunotherapy ready for use in the United States? *Journal of American Medical Association*. 2013;309(12):1297-8.
210. Burks AW, Calderón MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. *Journal of Allergy and Clinical Immunology*. 2013;131(5):1288-1296.e3.
211. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in allergic rhinitis: indications, efficacy, and safety. *Rhinology*. 2013;51(1):9-17.
212. Bahceciler NN, Galip N, Cobanoglu N. Multiallergen-specific immunotherapy in polysensitized patients: where are we? *Immunotherapy*. 2013;5(2):183-190.
213. Purkey MT, Smith TL, Ferguson BJ, Luong A, Reisacher WR, Pillsbury HC 3rd, Toskala E. Subcutaneous immunotherapy for allergic rhinitis: an evidence based review of the recent literature with recommendations. *Int Forum Allergy Rhinol*. 2013 Jul;3(7):519-31. doi: 10.1002/alr.21141. Epub 2013 Jan 11.
214. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. *Clinical and Experimental Allergy*. 2013;43(1):22-8.
215. Wolthers OD, Host A, Frederiksen B, Halcken S. Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis. *Ugeskr Laeger*. 2012;174(35):1989-92.
216. Yacoub MR, Colombo G, Caminati M, Sensi L, Di Cara F, Frati F, Incorvaia C. Effects of sublingual immunotherapy on allergic inflammation: an update. *Inflammation & Allergy Drug Targets*. 2012;11(4):285-91.
217. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. *Allergy*. 2012;67(9):1087-105.

218. Wise SK, Schlosser RJ. Evidence-based practice: sublingual immunotherapy for allergic rhinitis. *Otolaryngology Clinics of North America*. 2012;45(5):1045-54.
219. Park D, Daher N, Blaiss MS. Adult and pediatric clinical trials of sublingual immunotherapy in the USA. *Expert Review of Clinical Immunology*. 2012;8(6):557-64.
220. Mailhol C, Didier A. Specific immunotherapy in grass pollen allergy. *Human Vaccines and Immunotherapeutics*. 2012 Oct 1; 8(10): 1544–1547. Published online 2012 Oct 1. doi: 10.4161/hv.22357.
221. Moingeon P. Adjuvants for allergy vaccines. *Human Vaccines and Immunotherapeutics*. 2012 Oct 1; 8(10): 1492–1498. Published online 2012 Oct 1. doi: 10.4161/hv.21688.
222. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory disease. *Human Vaccines and Immunotherapeutics*. 2012 Oct 1; 8(10): 1499–1512. Published online 2012 Oct 1. doi: 10.4161/hv.21629
223. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderón MA. Adjuvants for immunotherapy. *Current Opinions in Allergy and Clinical Immunology*. 2012;12(6):648-57.
224. Bahceciler NN. Mucosal immunity and sublingual immunotherapy in respiratory disorders. *Journal of Allergy (Cairo)*. 2012;2012:725719. doi: 10.1155/2012/725719. Epub 2012 Sep 17.
225. Kroker GF, Sabnis VK, Morris MS, Thompson JC. Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review.” *Journal of Allergy*. 2012;2012:969861. doi:10.1155/2012/969861.
226. Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: An updated review. *Current Opinions in Allergy and Clinical Immunology*. 2012 Aug; 12(4): 427–433. doi: 10.1097/ACI.0b013e328354e540.
227. Calderón MA, Cox L, Casale T, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patient: looking at the published evidence. *Journal of Allergy and Clinical Immunology*. 2012;129(4):929-34.
228. Paiano S. Allergen specific immunotherapy celebrated 100 years in 2011! *Revue Médicale Suisse*. 2012; 8(323):7-10.
229. Valovirta E, et al. Update on current care guidelines: Allergen specific immunotherapy. *Duodecim*. 2012;128(1):108-9.
230. Wise SK., Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? *American Journal of Rhinology and Allergy*. 2012;26(1):18-22.
231. Hedlin G, van Hage M. The role of immunotherapy in the management of childhood asthma. *Theories of Advanced Respiratory Diseases*. 2012;6(13):137-46.
232. Fujimura T, Okamoto Y, Taniguchi M. Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review. *Journal of Allergy*. 2012;2012:381737. doi:10.1155/2012/381737.
233. Larenas Linnemann DE. One hundred years of immunotherapy: review of the first landmark studies. *Allergy and Asthma Proceedings*. 2012;33(2):122-8.
234. Larenas-Linnemann D, Esch R., Plunkett G, Brown S, Maddox D, Barnes C, Constable D. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. *Annals of Allergy, Asthma & Immunology*. 2011;107(5):448-58.
235. Han DH, Rhee CS. Sublingual immunotherapy in allergic rhinitis. *Asia Pacific Allergy*. 2011;1(3):123-29.
236. Calderón MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. *Clinical and Experimental Allergy*. 2011;41(9):1263-72.
237. Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: Subcutaneous and sublingual. *Immunology and Allergy Clinics of North America*. 2011;31(5):561-99.
238. Passalacqua G, Canonica GW. Sublingual immunotherapy for allergic respiratory diseases: Efficacy and safety. *Immunology and Allergy Clinics of North America*. 2011;31(2):265-277.



239. Radulovic S, Wilson D, Calderón M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). *Allergy*. 2011;66(6):740-52.
240. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy for allergic rhinitis: an update, *Current Opinion in Otolaryngology and Head and Neck Surgery*. 2011;19(1):43-7.
241. Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. *Journal of Allergy and Clinical Immunology*. 2011;127(1):44-5.
242. Incorvaia C, Fuiano N, Leo G. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability. *La Clinica Terapeutica*. 2010;161(6):543-7.
243. Incorvaia C, Masieri S., Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. *Allergy Asthma and Clinical Immunology*. 2010;6(1):29.
244. Mosges R, El Hassan E, Passali D. Sublingual specific immunotherapy. *Discovery Medicine*. 2010; 10(53):348-54.
245. Casale T, Stokes J. Future forms of immunotherapy. *Journal of Allergy and Clinical Immunology*. 2010; 10(34):1-7.
246. Cox L., Compalati E, Canonica W. Will Sublingual Immunotherapy Become an Approved Treatment Method in the United States? *Current Allergy and Asthma Reports*. 2010; 11(1):4-6.
247. Marogna M, Spadolini I, Massolo A, Canonica G, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. *Journal of Allergy and Clinical Immunology*. 2010;126(5):969-75.
248. Passalacqua G, Compalati E, Canonica GW. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. *World Allergy Organization Journal*. 2010 Jul;3(7):216-219.
249. Incorvaia C, Riario-Sforza G, Incorvaia S, Frati F. Sublingual immunotherapy in allergic asthma: current evidence and needs to meet. *Annals of Thoracic Medicine*. 2010;5(3).
250. Di Bona D, Plaia A, Scafidi V, Leto-Barone M, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and met-analysis. *Journal of Allergy and Clinical Immunology*. 2010;126(3):558-66.
251. Fujimura T, Okamoto Y. Antigen-Specific Immunotherapy against Allergic Rhinitis: The State of the Art. *Allergology International*. 2010;59(1).
252. Theodoropoulos D, Morris M, Morris D. Emerging concepts of sublingual immunotherapy for allergy. *Drugs of Today*. 2009;45(10):737-750.
253. Thompson JC, Morris MS. Case reports by Cochard and Eigenmann. *Journal of Allergy and Clinical Immunology*. 2010;125:277.
254. Canonica GW, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R, et.al. Sub-Lingual Immunotherapy World Allergy Organization Position Paper 2009. *World Allergy Organization Journal*. 2009.
255. Incorvaia C, Mauro M. Do indications to sublingual immunotherapy need to be revised? *Journal of Allergy and Clinical Immunology*. 2010;125:277.
256. Marseglia G, Incorvaia C, LaRosa M., Frati F, Marcucci F. Sublingual immunotherapy in children: facts and needs. *Italian Journal of Pediatrics*. 2009;35:31.
257. Milgrom H, Tran ZV. Sublingual immunotherapy, meta-analysis, and knowledge in the age of information. *Journal of Allergy and Clinical Immunology*. 2009;124:162-3.
258. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. *Journal of Allergy and Clinical Immunology*. 2009;124(1):157-61.
259. Canonica G, Passalacqua G, Villa E, Baena-Cagnani C, Compalati E. Sublingual immunotherapy (SLIT) for House Dust Mites (HDM) in respiratory allergy: update of meta-analysis results. *Journal of Allergy and Clinical Immunology*. 2009;123(2):S155.
260. Emanuel I, Parker M, Traub O. Under treatment of allergy: Exploring the utility of sublingual immunotherapy. *Otolaryngology – Head and Neck Surgery*. 2009;140:615-621.

261. Krouse J. Sublingual immunotherapy for inhalant allergy: Cautious optimism. *Otolaryngology – Head and Neck Surgery*. 2009;140:622-624.
262. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. *Current Opinion in Allergy and Clinical Immunology*. 2009;9:168-76. Passalacqua G, Pawankar R, Baena-Cagnani C, Canonica G. Sublingual immunotherapy: where do we stand? Present and future. *Current Opinion in Allergy and Clinical Immunology*. 2009;9:1-3.
263. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. *Current Opinion in Allergy and Clinical Immunology*. 2008;8:585-589.
264. Durham S. Sublingual immunotherapy: what have we learnt from the ‘big trials’? *Current Opinion in Allergy and Clinical Immunology*. 2008;8:577-584.
265. Gerth van Wijk R. When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies. *Current Opinion in Allergy and Clinical Immunology*. 2008;8:565-570.
266. Rodriguez-Perez N, Penagos M, Portnoy JM. New Types of Immunotherapy in Children. *Current Allergy and Asthma Reports*. 2008;8:484-492.
267. Cox L. Sublingual Immunotherapy and Allergic Rhinitis. *Current Allergy and Asthma Reports*. 2008;8:102-110.
268. Mondello W. Hope for the food allergic: New research may lead to a cure. *Living Without, editorial*. 2008; Oct-Nov Issue:22-28.
269. Morogna M. Preventative effects of sublingual immunotherapy in childhood: An open randomized controlled study. *Annals of Allergy, Asthma, and Immunotherapy*. 2008;101:206-211.
270. Larenas-Linnemann D. Sublingual immunotherapy: Dosing in relation to clinical and immunological efficacy. *Allergy and Asthma Proceedings*. 2008;29(2):130-138.
271. Canonica W, Passalacqua G. Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. *World Allergy Organization Journal*. April 2008:70-72.
272. Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens J, Togias T, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2 LEN\* and AllerGen\*\*). *Allergy*. 2008;63(86):8-160.
273. Cox L. Sublingual Immunotherapy in Pediatric Allergic Rhinitis and Asthma: Efficacy, Safety, and Practical Considerations. *Pediatric Allergy and Immunology*. 2007;7:410-420.
274. Didier A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. *American Academy of Allergy, Asthma & Immunology*. October 2007:1-8.
275. Cox L, Li JT, Nelson HS, et al. Allergen Immunotherapy: a practice parameter second update. *Journal of Allergy & Clinical Immunology*. 2007 Sep;120(3Suppl):S25-85.
276. Pondrom S. Sublingual Immunotherapy (SLIT) Quality of Life Outcomes. *COSM 2007: American Rhinologic Society*. 2007;2(8):24-25.
277. Cox L. Sublingual immunotherapy, part 2: Safety and practical considerations. *The Journal of Respiratory Disease*. June 2007;6:237-243.
278. Tahamiler R, Gkioukixel S, Canakcioglu S. Long-Term Efficacy of Sublingual Immunotherapy in Patients With Perennial Rhinitis. *The Laryngoscope*. 2007;117:965-969.
279. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (Grazax) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. *Clinical and Experimental Allergy*. 2007;37:772-779.
280. Pham-Thi N, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. *Pediatric Allergy and Immunology*. 2007;18:47-57.

281. Bonds RS, et al. Allergic Disorders: When Should You Consider Immunotherapy? *Consultant*. 2007;47(4):405-412.
282. Cox L. Sublingual immunotherapy, part I: Review of Clinical Efficacy. *The Journal of Respiratory Diseases*. 2007;28(4):162-168.
283. Nelson HS. Allergen immunotherapy: Where is it now? *Journal of Allergy and Clinical Immunology*. 2007;119(4):769-779.
284. Durham S. Tradition and innovation: Finding the right balance. *Journal of Allergy and Clinical Immunology*. 2007;119(14):792-795.
285. Pajno G. Sublingual immunotherapy: The optimism and the issues. *Journal of Allergy and Clinical Immunology*. 2007;119(4):796-801.
286. Passalacqua G, et al. Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 2007;119(4):881-891.
287. Leatherman B, et al. Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature. *Otolaryngology-Head and Neck Surgery*. 2007;136:S1-S20.
288. Marogna M, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. *Annals of Allergy, Asthma & Immunology*. 2007;98:274-280.
289. Finegold I. Allergen immunotherapy; Present and future. *Asthma and Allergy Proceedings*. 2007;28(1):44-49.
290. Bellanti J, Settignano R. Sublingual immunotherapy: A procedure whose time has come? *Asthma and Allergy Proceedings*. 2007;28(1), pages 1-2, January-February 2007.
291. Marogna M, et al. Long-Lasting Effects of Sublingual Immunotherapy for House Dust Mites in Allergic Rhinitis with Bronchial Hyperreactivity: A Long-Term (13-Year) Retrospective Study in Real Life. *International Archives of Allergy & Immunology*. 2006;142(1):70-78.
292. Passalacqua G, Canonica GW. Sublingual immunotherapy:update 2006. *Current Opinion in Allergy and Clinical Immunology*. 2006;6:449-454.
293. Werner-Klein M. Sublingual immunotherapy of allergic diseases. *Expert Opinion in Drug Delivery*. 2006;3(5):599-612.
294. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. *Allergy*. 2006;61(10):1162-72.
295. Berto P, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. *Annals of Allergy, Asthma and Immunology*. 2006;97:615-621.
296. Passalacqua G, et al. New Insights in Sublingual Immunotherapy. *Current Allergy and Asthma Reports*. 2006;6:407-412.
297. McEldowney SJ, et al. Pollen Immunotherapy: Selection, Prevention, and Future Directions. *Current Allergy and Asthma Reports*. 2006;4:420-426.
298. Bousquet J. Sublingual Immunotherapy: Validated! *Allergy*. 2006;61(S81).
299. Burastero S. E. Sublingual immunotherapy for allergic rhinitis: an update. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2006;14:197-201.
300. Didier A. Future developments in sublingual immunotherapy. *Allergy*. 2006;61(Suppl. 81):29-31.
301. Malling HJ. Sublingual immunotherapy: efficacy – methodology and outcome of clinical trials. *Allergy*. 2006;61(Suppl. 81):24-28.
302. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. *Allergy*. 2006;61(Suppl. 81):15-19.
303. Passalacqua G, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. *Allergy*. 2006;61:849-854.

304. Canonica GW, Passalacqua G. Sublingual Immunotherapy in the Treatment of Adult Allergic Rhinitis Patients. *Allergy*. 2006;61:20.
305. Pham-Thi N, et al. Sublingual immunotherapy in the treatment of children. *Allergy*. 2006;61 (Suppl. 81):7-10.
306. Ortolani C, et al. Practice parameters for sublingual immunotherapy. *Monaldi Archives for Chest Disease*. 2006;65(1):44-6.
307. Guerra L, et al. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. *Allergologia et immunopathologia*. 2006;34(02):82-83.
308. Mascarell L, et al. Novel Ways for Immune Intervention in Immunotherapy: Mucosal Allergy Vaccines. *Immunology and Allergy Clinics of North America*. 2006;26:283-306.
309. Cox L, et al. Sublingual immunotherapy: A comprehensive review. *Journal of Allergy and Clinical Immunology*. 2006; 117(5):1021-1035.
310. Nelson H. Advances in upper airway diseases and allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 2006;117(5):1047-1053.
311. Durham S, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. *Journal of Allergy and Clinical Immunology*. 2006;117(4):802-809.
312. Passalacqua G, et al. Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. *Inflammation & Allergy – Drug Targets*. 2006;5:43-51.
313. Potter P. Update on sublingual immunotherapy. *Annals of Allergy, Asthma and Immunology*. 2006;96 (Suppl 1):S22-S25.
314. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. *Allergy*. 2006;61:149-150.
315. Dahl R, et al. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. *Allergy*. 2006;61:185-190.
316. Cingi C, et al. Efficacy of long-term sublingual-oral immunotherapy in allergic rhinitis. *ACTA Otorhinolaryngol Italica*. 2005;25:214-219.
317. Marogna M, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. *Journal of Allergy and Clinical Immunology*. 2005;115(6):1184-1188.
318. Gidaro GB, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. *Clinical & Experimental Allergy*. 2005;35:565-571.
319. Pajno G. Allergen immunotherapy in early childhood: between Scylla and Charybdis. *Clinical & Experimental Allergy*. 2005;35:551-553.
320. Courtney AU, et al. Childhood Asthma: Treatment Update. *American Family Physician*. 2005;71(10): 1959-1968.
321. Parks K. Advances in Immunotherapy: Current Considerations and Beyond. *The Allergy and Immunology Report*. 2005;1(2).
322. Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. *Allergy*. 2005;60:1-3.
323. Lambrecht BN. Dendritic cells in the pathogenesis of asthma. *Clinical and Experimental Allergy*. 2004;4: 123-128.
324. Passalacqua G, et al. Efficacy and safety of sublingual immunotherapy. *Annals of Allergy, Asthma, and Immunology*. 2004;93(1):3-12.
325. Portnoy J. Allergen Immunotherapy in the Prevention of Asthma. *Current Opinion Allergy Clinical Immunology*. 2004;4(2):131-136.
326. Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? *Allergy*. 2004;59:37-38.

327. Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. *Current Opinion in Allergy and Clinical Immunology*. 2004;4:539-542.
328. Mosages R. The role of hyposensitization: do we need to start rethinking? *Clinical Opinion in Allergy and Clinical Immunology*. 2004;4:155-157.
329. Norman P S. Immunotherapy: 1999-2004. *Journal of Allergy and Clinical Immunology*. 2004;113(6):1013-1023.
330. Passalacqua G, Lombardi C, Canonica GW. Sublingual Immunotherapy: An Update. *Current Opinion in Allergy and Clinical Immunology*. 2004;4(1).
331. Markert UR, Elsner P. Local Immunotherapy in Allergy. *Chemical Immunology and Allergy*. (Lead chapter by D. Morris, et al). 2003;Vol. 82, Karger, Basel, Switzerland.
332. Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis. (Cochrane Review), *The Cochrane Library*, Issue 2. 2003.
333. Canonica GW, Passalacqua G. Non-injection routes for immunotherapy. *Journal of Allergy and Clinical Immunology*. 2003;111(3):437-448.
334. Di Rienzo V, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10 year prospective study. *Clinical and Experimental Allergy*. 2003;33:206-210.
335. Bielory L, Heimall J. Review of complementary and alternative medicine in treatment of ocular allergies. *Current Opinion in Allergy and Clinical Immunology*. 2003; 3:395-399.
336. Passalacqua G, Baena-Cagnani C, Berardi M, Canonica GW. Oral and sublingual immunotherapy in pediatric patients. *Current Opinion in Allergy and Clinical Immunology*. 2003;3(2):139-145.
337. Li J, et al. Allergen immunotherapy: a practice parameter. *Journal of Allergy and Clinical Immunology*. 2003;90:27.
338. Kagi MK, Wuthrich B. Different methods of local allergen-specific immunotherapy. *Allergy*. 2002;57:379-388.
339. Reiber ME. Sublingual Administration of Allergen Desensitization. *Tennessee Medicine*. 2002:465-467.
340. Douglass J, O'Hehir R. Specific allergen immunotherapy: time for alternatives? *Clinical and Experimental Allergy*. 2002;32:1-3.
341. Bousquet J. The new ARIA guidelines: putting science into practice. *Clinical and Experimental Allergy Review*. 2002;2:38-43.
342. Volpe Della A, et al. Sublingual Allergen-Specific Immunotherapy in Allergic Rhinitis and Related Pathologies: Efficacy in a Pediatric Population. *International Journal of Immunopathology and Pharmacology*. 2002;15(1):35-40.
343. Malling H. Is Sublingual Immunotherapy Clinically Effective? *Current Opinion Allergy and Clinical Immunology*. 2002;2(6):523-532.
344. Allergic Rhinitis and its impact on Asthma (ARIA) Workshop Report. *Journal of Allergy and Clinical Immunology*. 2001;108(5).
345. Bousquet J. ARIA Workshop Group Guidelines. *Journal of Allergy and Clinical Immunology*. 2001:S242-S245.
346. Passalacqua G, Canonica GW. Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. *BioDrugs*. 2001;15(8):509-519.
347. Morris DL. Current use of sublingual-swallow immunotherapy. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2001;9(3):179-180.
348. Marogna M, et al. Clinical Practice Improvement Program for Immunotherapy of Respiratory Allergic Diseases. *International Journal of Immunopathology and Pharmacology*. 2001;14(2):93-101.
349. Theodoropoulos D, Lockey R. Allergen Immunotherapy: Guidelines, Update and Recommendations of the World Health Organization. *Allergy and Asthma Proceedings*. 2000;21(3):159-66.



350. Frew A, et al. Sublingual Immunotherapy. *Journal of Allergy Clinical Immunology*. 2001;441-444.
351. Brown JL, Frew AJ. The efficacy of oromucosal immunotherapy in respiratory allergy. *Clinical & Experimental Allergy*. 2001;21(1):8-10.
352. Rakoski J, Wessner D. A Short Assessment of Sublingual Immunotherapy. *International Archives of Allergy and Immunology*. 2001;126:185-187.
353. Pineda-Algorta J, et al. Study of the efficacy of sublingual immunotherapy in patients with grass pollen sensitization: Mini Symposium 3 Sublingual Immunotherapy. *Allergy*. 2000;63(55):24.
354. Ano-Garcia M, et al. Efficacy and safety of sublingual immunotherapy in patients with sensitization to *Dermatophagoides pteronyssinus*: Mini Symposium 3 Sublingual Immunotherapy. *Allergy*. 2000;55(63):24.
355. Khinchi MS, et al. Clinical efficacy of sublingual-swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen: Mini Symposium 3 Sublingual Immunotherapy. *Allergy*. 2000;63(55):24.
356. Donato RM. Patients with allergic rhinitis from Argentine treated with SLIT (sublingual immunotherapy) a non-injective route. Abstract presented October 2000 IACAI Conference.
357. Malling HJ. Allergen-specific immunotherapy. Present state and directions for the future. *Allergy*. 1999;54:30-33.
358. Passalacqua G, et al. Oral and Sublingual Immunotherapy: General Aspects and Critical Considerations. *WMW Themenheft: Hyposensibilisierung*. 1999;433-437.
359. Donahue JG, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. *Annals of Allergy, Asthma and Immunology*. 1999;82:339-347.
360. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. *World Health Organization Position Paper Allergy*. 1998;53(44):1-29.
361. Malling HJ. Sublingual Immunotherapy. *Clinical Experimental Allergy*. 1996; 26:1228-1231.
362. Passalacqua G, Canonica GW. Alternative routes for allergen-specific immunotherapy. *Journal of Investigational Allergology and Clinical Immunology*. 1996;6(2):81-87.
363. Creticos PS. A review of oral specific immunotherapy: Expressions on allergen specific immunotherapy. Stallergenes S.A. 1995;1. (US Based DBPC Study).

## 2) Studies/Abstracts

1. Aarestrup P, Aarestrup M, Aarestrup B, et al. Prophylaxis of Upper Airway Infections in a Patient with Partial IgA Deficiency: Concurrent Use of Sublingual Immunotherapy with Inactivated Whole-Cell Bacterial Extract and Der p1. *Case Reports in Otolaryngology*. 2020 August 24. doi: 10.1155/2020/6313176
2. Campisi L, Yong P, Kasternow B, et al. Illustrative Case Series and Narrative Review of Therapeutic Failure of Immunotherapy for Allergic Rhinitis. *Allergy and Rhinology*. 2020 August 28. doi: 10.1177/2152656720943822
3. Chen W, Shen X, Li Q, et al. Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up. *Immunotherapy*. 2020 July 21; 12(12). doi: 10.2217/imt-2020-0006
4. Dantzer J, Mudd K, Wood R. Long-term outcomes of peanut immunotherapy in children. *The Journal of Allergy and Clinical Immunology*. 2020 May; 8(5). doi: 10.1016/j.jaip.2019.12.036
5. Dubini M, Marraccini P, Brass D, et al. Occupational asthma and rhinitis due to wheat flour: sublingual specific immunotherapy treatment. *Med Lav*. 2020 June 26; 111(3). doi: 10.23749/mdl.v111i3.9446
6. Liu W, Zeng Q, He C, et al. Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis. *Pediatric Allergy and Immunology*. 2020 August 18. doi: 10.1111/pai.13332
7. Liu W, Zeng Q, Luo R. Predictors for Short-Term Efficacy of Allergen-Specific Sublingual Immunotherapy in Children with Allergic Rhinitis. *Mediators of Inflammation*. 2020 April 21. doi: 10.1155/2020/1847061

8. Lou H, Huang Y, Ouyang Y, et al. Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial. *European Journal of Allergy and Clinical Immunology*. 2020 February 7. doi: 10.1111/all.14218
9. Lou H, Wang X, Wei Q, et al. Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trial. *World Allergy Organization Journal*. 2020 September; 13(9). doi: 10.1016/j.waojou.2020.100458
10. Xian M, Zhang L. Artemisia annua- sublingual immunotherapy: first step to cross the chasm. *European Journal of Allergy and Clinical Immunology*. 2020 August 2. doi: 10.1111/all.14539
11. Xian M, Feng M, Dong Y, et al. Changes in CD4+CD25+FoxP3+ Regulatory T Cells and Serum Cytokines in Sublingual and Subcutaneous Immunotherapy in Allergic Rhinitis with or without Asthma. *International Archives of Allergy and Immunology*. 2019 Nov 13; 181(1). doi: 10.1159/000503143
12. Jung J, Kang T, Kang I, et al. Comparison of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites in Korea. *Ear, Nose & Throat Journal*. 2019 Nov 19. doi: 10.1177/0145561319882593
13. Gao Y, Lin X, Jin M, et al. Enhanced Efficacy of Dust Mite Sublingual Immunotherapy in Low-Response Allergic Rhinitis Patients After Dose Increment at 6 Months: A Prospective Study. *International Archives of Allergy and Immunology*. 2020 Feb 18. doi: 10.1159/000505746
14. Ellis A, Boursiquot J, Carr S, et al. Patient and Physician Perceptions of Seasonal Allergic Rhinitis and Allergen Immunotherapy: A Parallel Physician Patient Survey. *Allergy, Asthma & Clinical Immunology*. 2020 Feb 21; 16(15). doi: 10.1186/s13223-020-0412-8
15. Romantowski J, Specjalski K, Jakub K, et al. Smoking history is negatively associated with allergen specific immunotherapy efficacy: a retrospective analysis. *Advances in Dermatology and Allergology*. 2019 Dec 30; 36(6). doi: 10.5114/ada.2018.80654
16. Liu L, Chen J, Xu J, et al. Sublingual Immunotherapy of Atopic Dermatitis in Mite-Sensitized Patients: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study. *Artificial Cells, Nanomedicine, and Biotechnology*. Dec 2019; 47(1). doi: 10.1080/21691401.2019.1640709
17. Chan A, Luk W, Fung L, et al. The effectiveness of sublingual immunotherapy for house dust mite-induced allergic rhinitis and its co-morbid conditions. *Immunotherapy*. 2019 Oct 14; 11(16). doi: 10.2217/imt-2019-0093
18. Lee VS, Lin SY. Allergy and the Pediatric Otolaryngologist. *Otolaryngologic Clinics of North America*. 2019 Oct; 52(5). doi: 10.1016/j.otc.2019.05.005
19. Satyaraj, E, Wedner H, Bousquet J. Keep the cat, change the care pathway: A transformational approach to managing Fel d 1, the major cat allergen. *Allergy*. 2019 Oct; 74. doi: 10.1111/all.14013
20. Kim JY, Han DH, Won TB, et al. Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy. *The Laryngoscope*. 2018 Dec 13. doi: 10.1002/lary.27721
21. Orgel K, Burk C, Smeekens J, et al. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness. *Clinical & Experimental Allergy*. 2019 April; 49(4). doi: 10.1111/cea.13305
22. Pfaar O, Bachert C, Kuna P, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. *The Journal of Allergy and Clinical Immunology*. 2019 Mar; 143(3). doi: 10.1016/j.jaci.2018.11.018
23. Ponce M, Schroeder F, Bannert C, et al. Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre-school children. *European Journal of Allergy and Clinical Immunology*. 2018 Nov 5; 74(4). doi: 10.1111/all.13658
24. Remington BC, Krone T, Koppelman SJ. Quantitative risk reduction through peanut immunotherapy: Safety benefits of an increased threshold in Europe. *Pediatric Allergy and Immunology*. 2018 Nov; 29. doi: 10.1111/pai.12961

25. Wang J, Chang H, Wei M, et al. Effect of sublingual dust mite drops on single or multiple allergens allergic rhinitis in children. 2018 Nov; 32(21). doi: 10.13201/j.issn.1001-1781.2018.21.010
26. Wang Y, Li C, Xu Y, et al. Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis. *The Indian Journal of Pediatrics*. 2018 Oct; 85(10). doi: 10.1007/s12098-018-2703-3
27. Han M, Chen Y, Wang M. Sublingual immunotherapy for treating adult patients with allergic rhinitis induced by house dust mite among Chinese Han population: A retrospective study. *Medicine*. 2018 Jul 27; 97(30). doi: 10.1097/MD.00000000000011705.
28. Novakova S, Novakova P, Yakovliev P, et al. A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis. *American Journal of Rhinology and Allergy*. 2018 May; 32(3). doi: 10.1177/.
29. Ortiz A, McMains K, Laury A. Single vs multiallergen sublingual immunotherapy in the polysensitized patient: a pilot study. *International Forum of Allergy and Rhinology*. 2018 April; 8(4). doi: 10.1002/alr.22071.
30. Penagos M, Eifan A, Durham S, et al. Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. *Current Treatment Options in Allergy*. 2018 Aug 31; 5(3). doi: 10.1007/s40521-018-0176-2.
31. Zhong C, Yang W, Li Y, et al. Clinical evaluation for sublingual immunotherapy with *Dermatophagoides farinae* drops in adult patients with allergic asthma. *Irish Journal of Medical Science*. 2018 May; 187(2). doi: 10.1007/s11845-017-1685-x.
32. Zieglmayer P, Nolte H, Nelson H, et al. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. *Annals of Allergy, Asthma & Immunology*. 2016; 117. doi: <http://dx.doi.org/10.1016/j.anai.2016.10.015>.
33. Kiotseridis H, Arvidsson P, Backer V, et al. Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax – a real life study. *NPJ Primary Care Respiratory Medicine*. 2018 Feb 12; 28(1). doi: 10.1038/s41533-018-0072-z.
34. Hoseini R, Jabbari F, Rezaee A, et al. House dust mite sublingual-swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled Iranian study. *Journal of Biological Regulators and Homeostatic Agents*. 2018 Jan; 32(1).
35. Guo Y, Li Y, Wang D, et al. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis. *American Journal of Rhinology & Allergy*. 2017 Jul 1; 31(4):42-47. doi: 10.2500/ajra.2017.31.4447.
36. Lim JH, Kim JY, Han DH, et al. Sublingual immunotherapy (SLIT) for house dust mites does not prevent new allergen sensitization and bronchial hyper-responsiveness in allergic rhinitis children. *PLOS*. 2017 Aug 14; 12(8):e0182295. doi: 10.1371/journal.pone.0182295.
37. Seo MY, Kim DK, Jee HM, et al. A survey of Korean physicians' prescription patterns for allergic rhinitis. *Clinical and Experimental Otorhinolaryngology*. 2017 Dec; 10(4):332-337. doi: 10.21053/ceo.2017.00143.
38. Yonekura S, Okamoto Y, Sakurai D, et al. An analysis of factors related to the effect of sublingual immunotherapy on Japanese cedar pollen induced allergic rhinitis. *Allergology International*. 2017 Jul 28. doi: 10.1016/j.alit.2017.07.005.
39. Leger D, Bonnefoy B, Pigearias B, et al. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. *Allergy, Asthma & Clinical Immunology*. 2017 Aug 16; 13(36). doi: 10.1186/s13223-017-0208-7.
40. di Coste A, Occasi F, De Castro G, et al. Predictivity of clinical efficacy of sublingual immunotherapy (SLIT) based on sensitisation pattern to molecular allergens in children with allergic rhinoconjunctivitis. *Allergologia et Immunopathologia*. 2017 Sep - Oct; 45(5):452-456. doi: 10.1016/j.aller.2017.01.001.
41. Bozek A, Starczewska-Dymek L, Jarzab J. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients. *Annals of Allergy, Asthma & Immunology*. 2017 Jul; 119(1):77-82. doi: 10.1016/j.anai.2017.05.012.

42. Marogna M, Massolo A, Passalacqua G. Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period. *World Allergy Organization Journal*. 2017 Feb 14. doi: 10.1186/s40413-016-0132-1.
43. Lin X, Lin H, Wei X, et al. The efficacy and safety of sublingual immunotherapy in children and adult patients with allergic rhinitis. *Allergol Immunopathol (Madr)*. 2017 Feb 22. doi: 10.1016/j.aller.2016.10.016.
44. Yang Y, Zhou W, Chen A. Efficacy of sublingual immunotherapy for cedar pollinosis: A systematic review and meta-analysis. *Annals of Allergy, Asthma & Immunology*. 2016 Oct;117(4):348-353. doi: 10.1016/j.anai.2016.07.024.
45. Nolte H, Plunkett G, Grosch K, et al. Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions. *Annals of Allergy, Asthma & Immunology*. 2016 Sep;117(3):298-303. doi: 10.1016/j.anai.2016.07.004.
46. Nucera E, Aruanno A, Rizzi A, et al. Profilin desensitization: A case series. *International Journal of Immunopathology and Pharmacology*. 2016 Sep;29(3):529-36. doi: 10.1177/0394632015621926.
47. Sakurai D, Yonekura S, Iinuma T, et al. Sublingual immunotherapy for allergic rhinitis: Subjective versus objective tools to evaluate its success. *Rhinology*. 2016 Sep;54(3):221-30. doi: 10.4193/Rhin15.223.
48. Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. *Cellular & Molecular Immunology*. 2016 Apr 11. doi: 10.1038/cmi.2016.14.
49. Klimek L, Mosbech H, Ziegelmayer P, Rehm D, Stage BS, Demoly P. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. *Expert Review of Clinical Immunology*. 2016 Apr;12(4):369-377. doi: 10.1586/1744666X.2016.1144473. Epub 2016 Feb 11.
50. Larenas-Linnemann D. Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis. *Annals of Allergy, Asthma & Immunology*. 2016 Apr;116(4):274-286. doi: 10.1016/j.anai.2016.02.008.
51. Vesna, T., Denisa, D., Slavenka, J., Lidija, B., Aleksandra, B., Jasna, B., Vojislav, D., Aleksandra, P., Aleksandra, A., & Mirjana, B. (2016). Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. *Iranian Journal Of Allergy, Asthma And Immunology*. 15(2), 112-121.
52. Maloney J, Berman G, Gagnon R, et al. Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. *Journal of Allergy and Clinical Immunology: In Practice*. 2016 Mar-Apr;4(2):301-309.e2. doi: 10.1016/j.jaip.2015.11.004. Epub 2016 Jan 2.
53. Horn A, Zeuner H, Wolf H, et al. Health-related quality of life during routine treatment with the SQ-standardised grass allergy immunotherapy tablet: A non-interventional observational study. *Clinical Drug Investigation*. 2016 Mar 15. doi: 10.1007/s40261-016-0388-9.
54. Jerzynska, J, Stelmach W, Rychlik B, Lechanska, J, Podlecka D, Stelmach I. The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis. *Allergy and Asthma Proceedings*. 2016 Mar;37(2):105-114. doi: 10.2500/aap.2016.37.3921.
55. Soh JY, Thalayasingam M, Ong S, Loo EX, Shek LP, Chao SS. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period. *The Journal of Laryngology & Otology*. 2016 Mar;130(3):272-277. doi: 10.1017/S0022215116000025. Epub 2016 Jan 19.
56. Reisacher WR, Suurna MV, Rochlin K, Bremberg MG, Tropper G. Oral mucosal immunotherapy for allergic rhinitis: A pilot study. *Journal of Allergy & Rhinology*. 2016 Jan;7(1):21-28. doi: 10.2500/ar.2016.7.0150.
57. Demoly P, Passalacqua G, Calderon MA, Yalaoui T. Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose. *Clinical and Translational Allergy*. 2015 Dec 23;5:44. doi: 10.1186/s13601-015-0088-1. eCollection 2015.
58. Steveling EH, Lao-Araya M, Koulias C, et al. Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes. *Clinical and Translational Allergy*. 2015 Dec 17;5:43. doi: 10.1186/s13601-015-0087-2. eCollection 2015.

59. Chen Z, Qian Y, Liu S, et al. Onset time and efficacy of sublingual immunotherapy with *Dermatophagoides farinae* drops in children with allergic rhinitis. *Chinese Journal of Otorhinolaryngology Head and Neck Surgery*. 2015 Aug;50(8):622-6.
60. Chen S, Zeng X, Wang L, et al. Effects of house dust mite sublingual immunotherapy in children with allergic rhinitis and asthma. *Chinese Journal of Otorhinolaryngology Head and Neck Surgery*. 2015 Aug;50(8):627-631.
61. Leonardi S, Castro A, Lanzafame A, et al. Safety and efficacy of sublingual specific immunotherapy to house dust mite using a different dosage: A pilot study. *Journal of Biological Regulators & Homeostatic Agents*. 2015 Apr-Jun;29(2 Suppl 1):84-8.
62. Karakoc-Aydiner E, Eifan AO, Baris S, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: A 3-year prospective randomized controlled trial. *Journal of Investigational Allergology and Clinical Immunology*. 2015;25(5):334-42.
63. Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mösges R. Optimum treatment strategies for polyallergic patients — analysis of a large observational trial. *Current Medical Research and Opinion*. 2015 Dec;31(12):2249-59. doi: 10.1185/03007995.2015.1094653. Epub 2015 Oct 6.
64. Lin Z, Liu Q, Li T, Chen D, Chen D, Xu R. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. *International Forum of Allergy & Rhinology*. 2015 Nov 17. doi: 10.1002/alr.21657.
65. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation in allergen content in sublingual allergen immunotherapy with house dust mites. *Allergy*. 2015 Nov;70(11):1413-20. doi: 10.1111/all.12694. Epub 2015 Sep 11.
66. Nolte M, et al. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. *Annals of Allergy, Asthma & Immunology*. 2015 Oct 21. doi: 10.1016/j.anai.2015.09.018.
67. Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: A clinical trial. *Allergy*. 2015 Oct 14. doi: 10.1111/all.12791.
68. Katotomichelakis M, et al. Smoking effects on quality of life of allergic rhinitis patients after sublingual immunotherapy. *Rhinology*. 2015 Dec;53(4):325-31. doi: 10.4193/Rhin14.245.
69. Pfaar O, et al. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. *Allergy*. 2015 Sep 3. doi: 10.1111/all.12760.
70. Murakami D, et al. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study. *Auris Nasus Larynx*. 2015 Jul 18. pii: S0385-8146(15)00169-8. doi: 10.1016/j.anl.2015.06.011.
71. Barberi S, et al. Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. *Asia Pacific Allergy*. 2015 Jul;5(3):163-9. doi: 10.5415/apallergy.2015.5.3.163.
72. Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. *Clinical and Translational Allergy*. 2015 May 22;5:12. doi: 10.1186/s13601-015-0057-8. eCollection 2015.
73. Huang S, et al. Study on the efficacy and safety of sublingual immunotherapy with standardized *dermatophagoides farinae* drops for allergic rhinitis. *Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery*. 2015 Apr;29(7):618-21.
74. Hu X, et al. Efficacy of sublingual immunotherapy with *Dermatophagoides farinae* drops on patients with allergic rhinitis of different symptom severity. *Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery*. 2015 Feb;29(3):223-5.
75. Pfaar O, Richter HG, Klimek L, Sieber J, Hadler M, Karagiannis E. Sublingual immunotherapy with a five-grass pollen tablet in adult patients with allergic rhinitis: An open, prospective, noninterventional, multicenter study. *BioMed Research International*. 2015;2015:584291. doi: 10.1155/2015/584291.



76. Okamoto Y, et al. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. *International Archives of Allergy and Immunology*. 2015;166(3):177-88. doi: 10.1159/000381059.
77. Kruse K, Gerwin E, Eichel A, Shah-Hosseini K, Mosges R. Conjunctival provocation tests: A predictive factor for patients seasonal allergic rhinoconjunctivitis symptoms. *The Journal of Allergy and Clinical Immunology, in Practice*. 2015 May-Jun;3(3):381-6. doi: 10.1016/j.jaip.2014.10.015. Epub 2015 Jan 22.
78. Incorvaia C, Ridolo E. In the strategies to prevent asthma exacerbations, allergic asthma needs specific treatment. *Current Medical Research and Opinion*. 2015 Apr;31(4):821-3. doi: 10.1185/03007995.2015.1024215. Epub 2015 Mar 19.
79. Shamji MH, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. *Journal of Allergy & Immunology*. 2015 Apr;135(4):913-921.e9. doi: 10.1016/j.jaci.2014.09.049. Epub 2014 Nov 22.
80. Potter PC, Baker S, Fenemore B, Nurse B. Clinical and cytokine responses to house dust mite sublingual immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2015 Apr;114(4):327-34. doi: 10.1016/j.anai.2014.12.015. Epub 2015 Feb 3.
81. Liu L, et al. The efficacy of sublingual immunotherapy with *Dermatophagoides farinae* vaccine in a murine atopic dermatitis model. *Clinical and Experimental Allergy*. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417.
82. Mascarell L, et al. Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells. *Allergy*. 2015 Apr;70(4):408-19. doi: 10.1111/all.12576.
83. Park KH, et al. In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. *Allergy Asthma Immunology Research*. 2015 Mar;7(2):124-9. doi: 10.4168/aaair.2015.7.2.124. Epub 2014 Dec 18.
84. Maloney J, et al. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. *Allergy*. 2015 Mar;70(3):302-9. doi: 10.1111/all.12560. Epub 2015 Jan 14.
85. Ciprandi, G. A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy. *Journal of Asthma & Allergy*. 2015 Mar 6;8:25-7. doi: 10.2147/JAA.S82077. eCollection 2015.
86. Theodoropoulos DS, Morris MS, Morris DL. Sustained improvement of psoriatic lesions in the course of sublingual immunotherapy for airborne allergens; clinical evidence of cross-tolerance. *European Review for Medical and Pharmacological Sciences*. 2015;19(3):392-5.
87. Senti G, Kundig T. Intralymphatic immunotherapy. *World Allergy Organization Journal*. 2015 Mar 7;8(1):9. doi: 10.1186/s40413-014-0047-7. eCollection 2015.
88. De Rienzo V, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. *Annals of Allergy, Asthma & Immunology*. 2014 Dec;113(6):671-673. e1. doi: 10.1016/j.anai.2014.09.009. Epub 2014 Oct 7.
89. Nolte H, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. *Journal of Allergy and Clinical Immunology*. 2015 Jan 27. pii: S0091-6749(14)03711-7. doi: 10.1016/j.jaci.2014.12.1911.
90. Hou B, Murata M, Said AS, Sakaida H, Masuda S, Takahashi T, Zhang Z, Takeuchi K. Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. *Allergy & Rhinology (Providence, RI)*. 2015 Jan;6(1):33-8. doi: 10.2500/ar.2015.6.0107. Epub 2015 Feb 11.
91. Kei-ichi Y, et al. Immunological parameters in prophylactic sublingual immunotherapy in asymptomatic subjects sensitized to Japanese cedar pollen. *Allergology International*. 2015 Jan;64(1):54-9. doi: 10.1016/j.alit.2014.07.001. Epub 2014 Oct 20.

92. Eberle P, Brueck H, Gall R, Hadler M, Sieber J, Karagiannis E. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents. *Pediatric Allergy and Immunology*. 2014 Dec;25(8):760-6. doi: 10.1111/pai.12298. Epub 2014 Dec 29.
93. Ding LF, et al. Effects of sublingual immunotherapy on serum IL-17 and IL-35 levels in children with allergic rhinitis or asthma. *Zhongguo Dang Dai Er Ke Za Zhi*. 2014 Dec;16(12):1206-10.
94. Serrano E, Wahn HU, Didier A, Bachert C. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis. *American Journal of Rhinology & Allergy*. 2014 Nov-Dec;28(6):471-6. doi: 10.2500/ajra.2014.28.4112. Epub 2014 Oct 2
95. [The effect and the analysis of the influence factors of sublingual immunotherapy on patients with pharyngitis and allergy to house dust mite]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2014 Oct;28(19):1511-3.
96. Hébert J, et al. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. *Allergy, Asthma & Clinical Immunology*. 2014 Oct 30;10(1):53. doi: 10.1186/1710-1492-10-53. eCollection 2014.
97. Winterroth LC, Williams PV. Efficacy and Safety of Grass Sublingual Immunotherapy Tablet, MK-7243: a Large Randomized Controlled Trial. *Pediatrics*. 2014;134:S161 DOI: 10.1542/peds.2014-1817XX.
98. Gorelik M, Narisety SD, Guerrero AL, Chichester KL, Keet CA, Bieneman AP, Hamilton RG, Wood RA, Schroeder JT, Frischmeyer-Guerrero PA. Suppression of the immunologic response to peanut during immunotherapy is often transient. *Journal of Allergy & Clinical Immunology*. 2014 Dec 24. pii:S0091-6749(14)01646-7. doi: 10.1016/j.jaci.2014.11.010.
99. Franco F, et al. New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. *Biologics*. 2014 Sep 12;8:221-6. doi: 10.2147/BTT.S50951. eCollection 2014.
100. Mosbech H, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 2014 Sep;134(3):568-575.e7. doi: 10.1016/j.jaci.2014.03.019. Epub 2014 May 3.
101. Calderón MA, Berstein DI, Blaiss M, Anderssen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. *Clinical & Experimental Allergy*. 2014 Oct;44(10):1228-39. doi: 10.1111/cea.12331.
102. Irani C, Saleh RA, Jammal M, Haddad F. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. *International Forum of Allergy and Rhinology*. 2014 Oct;4(10):802-7. doi: 10.1002/alr.21375. Epub 2014 Sep 15.
103. Bozek A, Kolodziejczyk K, Warkocka-Szolysek B, Jarzab J. Grass pollen sublingual immunotherapy: A double-blind, placebo controlled study in elderly patients with seasonal allergic rhinitis. *American Journal of Rhinology and Allergy*. 2014 Sep-Oct;28(5):423-7. doi: 10.2500/ajra.2014.28.4091.
104. Liu, et al. The Efficacy of Sublingual Immunotherapy with *Dermatophagoides farinae* Vaccine in a Murine Atopic Dermatitis Model. *Clinical & Experimental Allergy*. 2014 Sep 25. doi: 10.1111/cea.12417.
105. Zhang C, Ohno T, Kang S, Takai T, Azuma M. Repeated antigen painting and sublingual immunotherapy in mice convert sublingual dendritic cell subsets. *Vaccine*. 2014 Sep 29;32(43):5669-76. doi:10.1016/j.vaccine.2014.08.013. Epub 2014 Aug 29.
106. Muñoz-Wolf N, Rial A, Saavedra JM, Chabalgoity JA. Sublingual immunotherapy as an alternative to induce protection against acute respiratory infections. *Journal of Visualized Experiments*. 2014 Aug 30;(90). doi:10.3791/52036.
107. de Blay F, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial. *Respiratory Medicine*. 2014 Aug 7. pii:S0954-6111(14)00276-5. doi:10.1016/j.rmed.2014.07.017.
108. Luo RI, et al. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy. *European Journal of Pediatrics*. 2014 Aug;173(8):1033-40. doi:10.1007/s00431-014-2287-5. Epub 2014 Mar 4.

109. Kralimarkova TZI, et al. Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial. *Annals of Allergy, Asthma & Immunology*. 2014 Jul;113(1):108-13. doi:10.1016/j.anai.2014.03.019. Epub 2014 Apr 16.
110. [No authors listed]. Sublingual immunotherapy for allergic rhinitis. *The Medical Letter on Drugs and Therapeutics*. 2014 Jun 9;56(1444):47-8.
111. Poole, CD, Bannister, CA, Norgaard Andreasen J, Strodl Andersen, J, Currie, CJ. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. *Health and Quality of Life Outcomes*. 2014 Jun 13;12:99. doi: 10.1186/1477-7525-12-99.
112. Quin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farina drops in patients with atopic dermatitis. *International Journal of Dermatology*. 2014 May;53(5):650-5. doi:10.1111/ijd.12302. Epub 2013 Aug 22.
113. Devillier P, Dreyfus JF, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. *BMC Medicine*. 2014 May 1;12:71. doi: 10.1186/1741-7015-12-71.
114. Durham SR, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. *Allergy*. 2014 May;69(5):617-23. doi:10.1111/all.12373. Epub 2014 Mar 10.
115. Trebuchon, F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. *Clinical and Translational Allergy*. 2014 Apr 29;4:15. doi: 10.1186/2045-7022-4-15. eCollection 2014.
116. Sato S, et al. Clinical studies in oral allergen-specific immunotherapy: differences among allergens. *International Archives of Allergy and Immunology*. 2014;164(1):1-9. doi:10.1159/000361025. Epub 2014 Apr 29.
117. Chen BY, Long ZXM, Huang YJ, Zeng JM. [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in monosensitized and polysensitized patients with allergic rhinitis] [Article in Chinese]. *Chinese Journal of Otorhinolaryngology Head and Neck Surgery*. 2013 Jul;48(7):549-554.
118. De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, Casatagna G, Giancane G, Duse M. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. *European Review for Medical and Pharmacological Sciences*. 2013 Aug;17(16):2225-2231.
119. Quin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides Farinae Drops in children with atopic dermatitis. *International Journal of Dermatology*. 2014 May;53(5):650-655.
120. Tian M, Lu YQ, Wang Y, Jiang YH, Zhao DY. Long-term efficacy of sublingual immunotherapy with Dermatophagoides Farinae Drops in children with allergic asthma sensitized to dust mites]. [Article in Chinese]. *Chinese Journal of Pediatrics*. 2013 Oct;51(10):741-744.
121. Chen S, Wang L, Liao F, Zeng X, Xing QB, Chen B, Lin XZ. [Efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in preschool and school-age children with allergic asthma and allergic rhinitis]. [Article in Chinese]. *Chinese Journal of Pediatrics*. 2014 Nov;51(11):831-835.
122. Queirós MG, Silva DA, Siman IL, Ynoue LH, Araújo NS, Pereira FL, Almeida KC, Miranda JS, Pena JD, Cunha-Junior JP, Taketomi EA. Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children. *Pediatric Allergy and Immunology*. 2013 Dec;24(8):752-761.
123. Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, Alexander M, Coyne TC. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. *Journal of Allergy and Clinical Immunology*. 2014 Mar;133(3):751-758.
124. Sikora JM, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. *Annals of Allergy, Asthma & Immunology*. 2013;110(3):194-197.

125. Baiardini I, Puggioni F, Menoni S, Boot JD, Diamant Z, Braido F, Canonica GW. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. *Respiratory Medicine*. 2013;107(3):361-7.
126. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. *Clinical Experimental Allergy*. 2013;43(2):242-8.
127. Wang DH, Chen L, Cheng L, Li KN, Yuan H, Lu JH, Li H. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial. *Laryngoscope*. 2013 Jun;123(6):1334-40. doi: 10.1002/lary.23935. Epub 2013 Apr 24.
128. Creticos PS, Maloney J, Bernstei, DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nekam K, Nolte H. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. *Journal of Allergy and Clinical Immunology*. 2013;131(5):1342-1349.
129. Marogna M, Braidì C, Bruno ME, Colombo C, Colombo F, Massolo A, Palumbo L, Compalati E. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: A real-life randomised trial. *Allergol Immunopathol (Madr)*. 2013 Jul-Aug;41(4):216-24. doi: 10.1016/j.aller.2012.07.004. Epub 2012 Nov 9.
130. Zheng BQ, Wang GL, Yang S. Efficacy of specific sublingual immunotherapy with dermatophagoides farinae drops in the treatment of cough variant asthma in children. *Zhongguo Dang Dai Er Ke Za Zhi*. 2012;14(8):585-8.
131. Nayak AS, Atiee GJ, Dige E, Maloney J, Nolte H. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. *Allergy and Asthma Proceedings*. 2012; 33(5):404-10.
132. Wessel F, Chartier A, Meunier, JP., Magnan, A. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons – the GRAAL trial. *Clinical Drug Investigation*. 2012;32(7):451-63.
133. Batard T, Zimmer A, Nony E, Bouley J, Airouche S, Luce S, Turfkruyer M, Tourdot S, Mascarell L, Moingeon P. Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation. *Vaccine*. 2012;30(38):5666-74.
134. Panjo GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T, Valenzise M, Passalacqua G. Adherence to sublingual immunotherapy in preschool children. *Pediatric Allergy and Immunology*. 2012;23(7):688-9.
135. Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, Eberle P, Bufe A. SLIT Study Group. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. *Journal of Allergy and Clinical Immunology*. 2012;130(4):886-93.
136. Han DH, Choi YS, Lee JE, Kim DY, Kim JW, Lee CH, Rhee CS. Clinical efficacy of sublingual immunotherapy in pediatric patients with allergic rhinitis sensitized to house dust mites: Comparison to adult patients. *Acta Oto-laryngologica*. 2012;132 Suppl 1:S88-93.
137. Bordas-Le Floch V, Bussieres L, Airouche S, Lautrette A, Bouley J, Berjont N, Horiot S, Huet A, Jain K, Limoine P, Chabre H, Batard T, Mascarell L, Baron-Bodo V, Tourdot S, Nony E, Moingeon P. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. *International Archives of Allergy and Immunology*. 2012;158(2):157-67.
138. Vanbervliet B, Tourdot S, Mascarell L, Rouzaire P, Vocanson M, Rozieres A, Benetiere J, Moingeon P, Nicolas JF, Hennino A. SLIT prevents the development of eczema in percutaneous allergen-sensitized mice. *Journal of Investigative Dermatology*. 2012;132(1):244-6.
139. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, Kundig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. *Journal of Allergy and Clinical Immunotherapy*. 2012;129(1):128-35.

140. Alesina R, Milani M, Pecora S. A multicenter, randomized, parallel-group trial assessing compliance, tolerability, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis. *Journal of Allergy (Cairo)*. 2012;2012:673502. doi: 10.1155/2012/673502.
141. Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'albani I, Puccinelli P. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. *Journal of Drug Design, Development and Therapy*. 2012;6:117-23.
142. Moussu H, Van Overtvelt L, Horiot S, Tourdot S, Airouche S, Zuercher A, Holvoet S, Prioult G, Nutten S, Mercenier A, Mascaraell L, Moingeon P. Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy. *International Archives of Allergy and Immunology*. 2011;158(1):35-42.
143. Panjo GB, Caminiti L, Crisafulli G, Vita D, Valenzise M, De Luca R, Passalacqua G. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. *Pediatric Allergy and Immunology*. 2011;22(8):803-07.
144. Tourdot S, Airouche S, Berjont N, Da Silveira A, Mascarell L, Jacquet A, Caplier L, Langelot M, Baron-Bodo V, Moingeon P. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation. *Clinical Experimental Allergy*. 2011;41(12):1784-92.
145. Stelmach I, Kaluzinska-Parazyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. *Allergy*. 2012 Mar;67(3):312-20. doi: 10.1111/j.1398-9995.2011.02758.x. Epub 2011 Dec 6.
146. Barberi S, Villa MP, Panjo GB, La Penna F, Barreto M, Cardelli P, Amodeo R, Tabacco F, Caminiti L, Ciprandi G. Immune response to sublingual immunotherapy in children allergic to mites. *Journal of Biological Regulators & Homeostatic Agents*. 2011;25(4):627-34.
147. Theodoropoulos DS, Katzenberger DR, Jones WM, Morris M, Her C, Cullen NA, Morris DL. Allergen-specific sublingual immunotherapy in the treatment of migraines: A prospective study. *European Review for Medical and Pharmacological Sciences*. 2011;15(10):1117-21.
148. Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I. A novel approach in allergen-specific immunotherapy: Combination of sublingual and subcutaneous routes. *Journal of Allergy and Clinical Immunology*. 2011;128(4):808-15.
149. Milani M, Pecora S. Clinical relevance of non-grass pollens respiratory allergies in Italy and effects of specific sublingual immunotherapy: The rainbow trial, a multicentre 3-year prospective observational study. *European Annals of Allergy and Clinical Immunotherapy*. 2011;43(4):111-6.
150. Kuna P, Samolinski B, Worm M, Pfaar O, Klimek L. Sustained clinical efficacy of sublingual immunotherapy with a high-dose grass pollen extract. *European Annals of Allergy and Clinical Immunology*. 2011;43(4):117-21.
151. Gastaminza G, Algorta J, Uriel O, Audicana MT, Fernandez E, Sanz ML, Munoz D. Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients. *Trials*. 2011;12:191.
152. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3 year efficacy in pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. *Journal of Allergy and Clinical Immunology*. 2011;128(3):559-66.
153. Lee J, Choi Y, Kim M, Han D, Rhee C, Lee C, et al. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. *Annals of Allergy, Asthma and Immunology*. 2011;107(1):79-84.
154. Panzner P, Petras M, Sykora T, Lesna JK, Liska M. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy. *Allergy and Asthma Proceedings*. 2011;32(2):142-50.
155. Panizo C, Cimarra M, Gonzalez-Mancebo W, Vega A, Senent C, Martin S. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets. *Journal of Investigational Allergology and Clinical Immunology*. 2010;20(6):454-62.



156. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. *Journal of Allergy and Clinical Immunology*. 2011;127(1):72-80.
157. Yuta A, Ogihara H, Miyamoto Y, Takeuchi K, Okubo K. The enhanced clinical efficacy by treated years and the sustained efficacy after treatment of sublingual immunotherapy for Japanese cedar pollinosis. *Alerugi*. 2010;9(11):1552-61.
158. Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to *Alternaria alternata*: a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial. *Current Medical Research and Opinion*. 2010;26(12):2801-6.
159. Cortellini G, Spadolini I, Patella V, Fabbri E, Santucci A, Severino M, et al. Sublingual immunotherapy for *Alternaria*-induced allergic rhinitis: a randomized placebo-controlled trial. *Annals of Allergy, Asthma & Immunology*. 2010;105(5):382-6.
160. Yonekura S, Okamoto Y, Sakurai D, Horiguchi S, Hanazawa T, Nakano A. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. *Allergology International*. 2010;59(4).
161. Incorvaia C, Rapetti A, Scurati S, Puccinelli P, Capece M, Frati F. Importance of patient's education in favoring compliance with sublingual immunotherapy. *Allergy*. 2010;65(10):1341-2.
162. Skoner D, Gentile D, Bush R, Fasano M, McLaughlin A, Esch R. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. *Journal of Allergy and Clinical Immunology*. 2010;125(3):660-6.
163. Durham S, Emminger W, Kapp A, Colombo G, de Monchy J, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. *Journal of Allergy and Clinical Immunology*. 2010;125:131.
164. Ariano R, Berto P, Incorvaia C, Di Cara G, Boccardo R, LaGrutta S, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic asthma. *Annals of Allergy, Asthma and Immunology*. 2009;103:254-259.
165. Reshamwala N, Song S, Yu GP, Swamy R, Berquist W, Nguyen T, et al. Study of Sublingual Immunotherapy in Subjects with *Dermatophagoides Farniae* and Timothy Grass Allergy. *Journal of Allergy and Clinical Immunology*. 2008;123(2).
166. Emminger W, Durham S, Riis B, Maloney J, Nolte H. The efficacy of Single-grass-allergen-immunotherapy-tablet Treatment in Mono- and Multi-sensitized Allergic Rhinitis Patients: Findings from a Post Hoc Analysis. *Journal of Allergy and Clinical Immunology*. 2008;123(2).
167. Seidenberg J, Wahn U, Emeryk A, Lheritier-Barrand M, Gall M. Evaluation of a Five Grass-pollen Sublingual Immunotherapy Tablets (SLIT) in a Pediatric Population at Peak Pollen Season and Immunological Outcomes. *Journal of Allergy and Clinical Immunology*. 2008;123(2).
168. Bufe A, Henmar H, Gronager P, Durham S. Sublingual Immunotherapy with Fast-Dissolving Grass Tablets Induces Comparable IgF4 Antibody and IgE-blocking Responses in Children and Adults. *Journal of Allergy and Clinical Immunology*. 2009;123(2).
169. Marogna M, Spadolini I, Massolo A, Berra D, Zanon, Chiodini E, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. *Annals of Allergy, Asthma & Immunology*. 2009;102:69-75.
170. Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. *European Annals of Allergy and Clinical Immunology*. 2007;39(5):148-156.
171. Alvarez-Cuesta E, Berges-Gimeno P, Mancebo EG, Fernandez-Caldas E, Cuesta-Herranz J, Casnovas M. Sublingual immunotherapy with a standardized cat dander extract: Evaluation of efficacy in a double blind placebo controlled study. *Allergy: European Journal of Allergy and Clinical Immunology*. 2007;62(7):810-817.
172. Esch RE. Sublingual immunotherapy. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2008 Jun;16(3):260-4. doi: 10.1097/MOO.0b013e3282fc706f.

173. Esch R, Bush R, Peden D, Lockey R. Sublingual-oral administration of standardized allergenic extracts: Phase one safety and dosing results. *Annals of Allergy, Asthma and Immunology*. 2008;100(5):475-481.
174. Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunni N, et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. *International Archives of Allergy & Immunology*. 2008;146:76-84.
175. Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: Results from the SIMAP database study. *Current Medical Research and Opinion*. 2008;24(1):261-266.
176. Jacobsen L, Valovirta E. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma. *Current Opinion in Allergy & Clinical Immunology*. 2007;7(6):556-560.
177. Nuhoglu Y, Ozumut SS, Ozdemir C, Ozdemir M, Nuhoglu C, Erguven M. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: A retrospective analysis of clinical course over a 3-year follow-up period. *Journal of Investigational Allergology and Clinical Immunology*. 2007;17(6):375-378.
178. De Blay F, Barnig C., Kanny G, et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. *Annals of Allergy, Asthma, and Immunology*. 2007;99:453-461.
179. Penagos M, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest*. 2008 Mar;133(3):599-609. Epub 2007 Oct 20.
180. Cadario G. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. *Current Medical Research and Opinion*. 2007;23(100):2503-6.
181. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. *Allergy*. 2007;62(8):954-7.
182. Grier T, et al. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. *Annals of Allergy, Asthma, and Immunology*. 2007;99:151-160.
183. Ozdemir C, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. *Pediatric Allergy and Immunology*. 2007;18:508-515.
184. Roder E, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. *Journal of Allergy and Clinical Immunology*. 2007;119(4):892-898.
185. Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau M, Massabie-Bouchat Y, Aferiat-Derome A, André C. Safety and efficacy of juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: A double-blind, placebo-controlled study. *International Archives of Allergy and Immunology*. 2007;142:239-246.
186. Di Rienzo V, Pucci S, D'Alo S, Di Cara G, Incorvaia C., Frati F, Romano A. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: A placebo-controlled study. *Clinical and Experimental Allergy Reviews*. 2006;6:67-70.
187. Kinaciyan T, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v I homolog Mal d I. *Journal of Allergy and Clinical Immunology*. 2007;119(4):937-943.
188. Penagos M, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: A meta-analysis of randomized, placebo-controlled, double-blind trials. *Annals of Allergy Asthma and Immunology*. 2006;97(2):141-8.
189. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. *Annals of Allergy, Asthma & Immunology*. 2006;97:158-163.
190. Dahl R, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. *Journal of Allergy and Clinical Immunology*. 2006;118(2):434-440.
191. Valovirta E, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. *Allergy*. 2006;61:1177-1183.

192. Bernardini R, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double blind, placebo-controlled study. *Current Medical Research and Opinions*. 2006;22(8):1515-1522.
193. Olaguibel J, Alvarez Puebla M. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. *Journal of Investigational Allergology and Clinical Immunology*. 2005;15(1):9-16.
194. Fiocchi A, et al. A prospective study on safety of sublingual immunotherapy in children aged 3 to 6 years. *Journal of Allergy and Clinical Immunology*. 2005;115(2):S265.
195. Tesse R, et al. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome. *Journal of Allergy and Clinical Immunology*. 2005;115(2):S266.
196. Bahceciler N, et al. Impact of sublingual immunotherapy on specific antibody levels in children allergic to house dust mites. *International Archives of Allergy and Immunology*. 2005;136(3):287-294.
197. Wilson D, et al. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. *Allergy*. 2005 Jan;60(1):4-12.
198. Marogna M, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: Clinical efficacy and more. *Allergy*. 2004;59(11):1205-1210.
199. Novembre E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. *Journal Allergy and Clinical Immunology*. 2004;114(4):851-857.
200. Smith H, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat allergic rhinitis. *Journal Allergy and Clinical Immunology*. 2004;114(4):831-837.
201. Savi E, et al. A latex-containing hepatitis-B vaccine administered in a severely latex allergic paediatric patient after specific sublingual immunotherapy: A case report. *Allergy*. 2004;59(9):1014-1015.
202. Drachenberg K, et al. Sublingual specific immunotherapy for adults and children: A post marketing surveillance study. *Journal of Investigational Allergology and Clinical Immunology*. 2004;32(2):76-81.
203. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. *American Journal of Clinical Dermatology*. 2004;5(5):281-294.
204. Cistero B, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. *Journal of Investigational Allergology and Clinical Immunology*. 2004;14(1):17-25.
205. Tonnel A, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. *Allergy*. 2004;59:491-197.
206. Bufe A, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: A double-blind placebo-controlled study. *Allergy*. 2004;59(5):498-504.
207. Pajno G, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: A randomized controlled trial dagger. *Allergy*. 2004;59(8):883-887.
208. Pajno G, et al. Comparisons between injection and sublingual immunotherapy for rhinitis and asthma in allergic children to house dust mite or parietaria pollen. A case controlled study. *Journal of Allergy and Clinical Immunology*. 2004;113(2):(abs.).
209. Niu C, et al. Efficacy and safety of sublingual immunotherapy with high dose house dust mite extract in asthmatic children – a multicenter randomized double-blind, and placebo-controlled study. *Journal of Investigational Allergology and Clinical Immunology*. 2004;113(2):(abs.).
210. Mauro M., et al. Efficacy and safety of subcutaneous and sublingual immunotherapy in birch pollinosis. *Journal of Allergy and Clinical Immunology*. 2004;113(2).
211. Melranci C, Matteoli M. Efficacy of allergoid sublingual immunotherapy in children with asthma and/or allergic rhinoconjunctivitis: Comparison study with drugs. *Journal of Allergy and Clinical Immunology*. 2004;113(2):(abs.).
212. Bassi M, et al. High dose sublingual immunotherapy: Economic evaluation from an Italian observational data base study. *Journal of Allergy and Clinical Immunology*. 2004;113(2):(abs.).

213. Pajno G. Efficacy of sublingual immunotherapy in asthma and eczema. *Chemical Immunology and Allergy*. 2003;82:77-88.
214. Wuthrich B, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. *Journal of Investigational Allergology and Clinical Immunology*. 2003;13(3):145-148.
215. Andre C, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. *International Archives of Allergy and Immunology*. 2003;131:111-118.
216. Ippoliti F, et al. Immunomodulation during sublingual therapy in allergic children. *Pediatric Allergy and Immunology*. 2003;14:216-221.
217. Pajno G, et al. Parietaria pollen sublingual immunotherapy for asthmatic children: Seasonal behavior in methacholine PC20. *Journal of Allergy and Clinical Immunology*. 2003:(abs).
218. Mortemousque B, et al. House-dust mite sublingual — swallow immunotherapy in perennial conjunctivitis: A double-blind, placebo-controlled study. *Clinical and Experimental Allergy*. 2003;33:464-469.
219. Gonzalez E, et al. Efficacy and safety of a standardized sublingual therapeutic vaccine of cat epithelia extract. *Journal of Allergy and Clinical Immunology*. 2003: S200(abs).
220. Cirila A, et al. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two year controlled study. *Allergologia et Immunopathologia*. 2003;31(1):31-43.
221. Madonini F, et al. Long-term and preventive effects of sublingual allergen specific immunotherapy: A retrospective, multicentric study. *International Journal of Immunopathology and Pharmacology*. 2003;16(1):73-79.
222. Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. *Journal of Investigative Allergology and Clinical Immunology*. 2003;13(3):170-176.
223. Torres Lima M, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: A randomized controlled trial. *Clinical and Experimental Allergy*. 2002;32:507-514.
224. Silvestri M, et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity in asthmatic children sensitized to house dust mites following sublingual immunotherapy. *Journal of Investigative Allergology and Clinical Immunology*. 2002;12(1):6-7 (abs).
225. Velarde-Domiquez T, et al. Clinical effectiveness and security of sublingual immunotherapy as a treatment for allergy asthma secondary to *Dermaphgoides* in pediatric population. *Revista de Sanidad Militar*. 2002;56(1):10-14 (abs).
226. Criado Molina A, et al. [Immunotherapy with an oral *Alternaria* extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and invitro parameters]. *Allergologia et Immunopathologia*. 2002;30(6):319-330.
227. Olaguibel J, et al. Adherence to and safety of a high dose sublingual immunotherapy regimen with a standardized grass pollen extract. *Journal of Allergy and Clinical Immunology*. 2002;109(1):S201.
228. Pajno G, et al. Impact of sublingual immunotherapy on seasonal asthma of allergic children to parietaria pollen treated with inhaled fluticasone propionate. *Journal of Allergy and Clinical Immunology*. 2002;109(1):S200.
229. Ariano R, et al. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of *Cupressus arizonica*. A double blind study. *Allergologia et Immunopathologia*. 2001; 29(6):238-244.
230. Bahceciler N, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double-blind, placebo-controlled study. *Pediatric Pulmonology*. 2001;32:49-55.
231. Caffarelli C, et al. Preseasonal local allergoid immunotherapy to grass pollen in children. *Allergy*. 2000;55:1142-1147.
232. Valle C, et al. Effects of sublingual immunotherapy in patients sensitized to *Ambrosia*. An open controlled study. *Allergologia et Immunopathologia*. 2000;28(6):311-317.

233. Mastrandrea F, et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. *Allergologia et Immunopathologia*. 2000;28(2):54-62.
234. Pajno G, et al. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind placebo controlled study. *Allergy*. 2000;55:842-849.
235. Guez S, et al. House dust mite SLIT in perennial rhinitis: A double blind placebo controlled study. *Allergy*. 2000;55:369-375.
236. Pradalier A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. *Allergy*. 1999;54:819-828.
237. Bousquet J., et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double blind, placebo-controlled study. *Allergy*. 1999;54(3):249-260.
238. Purello-D'Ambrosio F, et al. Sublingual immunotherapy: A double blind placebo controlled trial with *Parietaria judaica* extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. *Allergy*. 1999;54:968-973.
239. La Rosa M, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized *Parietaria judaica* extract in children with allergic rhinoconjunctivitis. *Journal of Allergy and Clinical Immunology*. 1999:425-432.
240. Passalacqua G, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to *Parietaria* species: A double-blind, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 1999:964-968.
241. Di Rienzo V, et al. Grass pollen specific sublingual/swallow immunotherapy in children: Open-controlled comparison among different treatment protocols. *Allergologia et Immunopathologia*. 1999;27(3):145-151.
242. Yourdas D, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. *Allergy*. 1998;53:662-672.
243. Clavel R, Bousquet J, et al. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of standardized five-grass-pollen extract in rhinitis. *Allergy*. 1998;53:493-498.
244. Horak F, et al. Immunotherapy with sublingual birch pollen extract. A short-term double blind placebo study. *Journal of Investigative Allergology and Clinical Immunology*. 1998;8(3):165-171.
245. Hordijk G, et al. Sublingual immunotherapy with a standardised grass pollen extract: A double-blind placebo-controlled study. *Allergologia et Immunopathologia*. 26(5):234-240.
246. Passalacqua G, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. *The Lancet*. 1998;351:629-632.
247. Luwema R, et al. Sublingual immunotherapy with a standardized grass pollen extract (Oralgen); A placebo controlled study. *The Journal of Allergy and Clinical Immunology*. 1997;99(1):Part 2 (abs 282).
248. Passalacqua G, et al. Clinical and immunological effects of a long-term sublingual-oral immunotherapy to mite: A double blind study. *The Journal of Allergy and Clinical Immunology*. 1997;99(1):Part 2 (abs 1630).
249. Van Deusen M, et al. Efficacy and safety of oral immunotherapy with short ragweed. *Annals of Allergy, Asthma & Immunology*. 1997;78:573-580.
250. Gozalo F, et al. Clinical efficacy and tolerance of two year *Lolium perenne* sublingual immunotherapy *Allergologia et Immunopathologia*. 1997;25(5):219-227.
251. Passalacqua G. Sublingual immunotherapy: Accumulated experience. *Journal of Investigative Allergology and Clinical Immunology*. 1997;7(5):364-366.
252. Hirsh T, et al. Double blind placebo controlled study of sublingual immunotherapy with house dust mites extracts in children. *Pediatric Allergy & Immunology*. 1997;8:21-27.
253. Purello-D'Ambrosio F, et al. Rush sublingual immunotherapy in *parietaria* allergic patients. *Allergologia et Immunopathologia*. 1996;21(4):146-151.



254. Troise C, et al. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: A double-blind study. *Journal of Investigational Allergology and Clinical Immunology*. 1995;5(1):25-30.
255. Clavel R, et al. Reduction of corticosteroid therapy by sublingual immunotherapy. Double blind study against placebo of Standardized 5 Grass Pollen Extract in Rhinitis. *Allergy*. 1995; 50(26):279.
256. Giovane A, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: Evidence of safety and efficacy in pediatric patients. *Clinical and Experimental Allergy*. 1994;24:53-59.
257. Sabbah A, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen. *Allergy*. 1994;49:309-313.
258. Casanovas M, et al. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of *Olea europaea* pollen administered sublingually. *Journal of Investigational Allergology and Clinical Immunology*. 1994;4(6):305-314.
259. Tari M., et al. Immunologic evaluation of 24 month course of sublingual immunotherapy. *Allergologia et Immunopathologia*. 1994;22(5):209-216.
260. Tari M, et al. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite-A double blind study. *Allergologia et Immunopathologia*. 1990; 18(5):277-284.
261. Leng X, et al. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. *Annals of Allergy, Asthma & Immunology*. 1990;64:27-31.
262. Taudorf E, et al. Oral immunotherapy in birch pollen hay fever. *Journal of Allergy and Clinical Immunology*. 1987;80(2):153-161.
263. Van Nierkerk C, De Wet J. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever; A double blind study. *Clinical and Experimental Allergy*. 1987;17:507-513.
264. Scadding G., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. *Clinical and Experimental Allergy*. 1986;16:483-491.
265. Morris D. Treatment of respiratory disease with ultra-small doses of antigens. *Annals of Allergy, Asthma & Immunology*. 1970;28(10):494-500.

### 3) Comparison Studies of Sublingual, Subcutaneous and Other Allergen Therapies

1. Aggarwal P, Senthilkumaran S. Dust Mite Allergy. *Stat Pearls Publishing*. 2020 August 16.
2. Bilancia M, Pasculli G, Bona D. A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy. *PLOS One*. 2020 May 14; 15(5). doi: 10.1371/journal.pone.0232753
3. Borg M, Lokke A, Hilberg O. Compliance in subcutaneous and sublingual allergen immunotherapy: A nationwide study. *Respiratory Medicine*. 2020 August 1; 170. doi: 10.1016/j.rmed.2020.106039
4. Devillier P, Demoly P, Molimard M. Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies? *Expert Review of Respiratory Medicine*. 2020 March 4; 5. doi: 10.1080/17476348.2020.1733417
5. Di Bona D, Bilancia M, Albanesi M, et al. Cost-effectiveness of grass pollen allergen immunotherapy in adults. *European Journal of Allergy and Clinical Immunology*. 2020 September; 75(9). doi: 10.1111/all.14246
6. Klimek K, Pfaar O, Worm M, et al. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. *Allergologie Select*. 2020 May 28. doi: 10.5414/ALX02147E
7. Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. *European Journal of Allergy and Clinical Immunology*. 2020 July; 75(7). doi: org/10.1111/all.14336

8. Marcucci F, Isidori C, Argentiero A, et al. Therapeutic perspectives in food allergy. *Journal of Translational Medicine*. 2020 August 5; 18(1). doi: 10.1186/s12967-020-02466-x
9. Pfaar O, Angier E, Muraro A, et al. Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. *European Journal of Allergy and Clinical Immunology*. 2020 September. doi: 10.1111/all.14270
10. Pfaar O, Ziegelmayer P. Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. *Clinical and Translational Allergy*. 2020 July 29; 10(33). doi: 10.1186/s13601-020-00336-9
11. Protcor T, Morrrough E, Fenske O, et al. Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis. *Clinical and Translational Allergy*. 2020 April 20; 10(10). doi: 10.1186/s13601-020-00315-0
12. Dupuis P, Prokopich C, Hynes A, et al. A contemporary look at allergic conjunctivitis. *Allergy, Asthma & Clinical Immunology*. 2020 Jan 21; 16(5). doi: 10.1186/s13223-020-0403-9
13. Incorvaia C, Makri E, Ridolo E, et al. Advances in allergen immunotherapy as a treatment of asthma. *Expert Review of Respiratory Medicine*. 2019 Oct 18; 13(12). doi: 10.1080/17476348.2019.1676153
14. Nelson H. Allergy immunotherapy for inhalant allergens: Strategies to minimize adverse reactions. *Allergy and Asthma Proceedings*. Jan 1 2020; 41(1). doi: 10.2500/aap.2020.41.190014
15. Gray C. Current Controversies and Future Prospects for Peanut Allergy Prevention, Diagnosis and Therapies. *Journal of Asthma and Allergy*. 2020 Jan 16. doi: 10.2147/JAA.S196268
16. Kim E, Patel C, Burks A. Immunotherapy approaches for peanut allergy. *Expert Review of Clinical Immunology*. 2019 Dec 19; 16(2). doi: 10.1080/1744666X.2019.1708192
17. van de Veen W, Akdis M. Tolerance mechanisms of AIT. *European Journal of Allergy and Clinical Immunology*. 2019 Nov 23. doi: 10.1111/all.14126
18. Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. *European Journal of Allergy and Clinical Immunology*. 2019 May 16; 74(5). doi: 10.1111/all.13749
19. Bjermer L, Westman M, Holmstrom M, et al. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. *Allergy, Asthma & Clinical Immunology*. 2019 April 16; 15(24). doi: 10.1186/s13223-018-0314-1
20. Bielory L, Schoenberg D. Ocular allergy: update on clinical trials. *Current Opinion in Allergy and Clinical Immunology*. 2019 Oct; 19(5). doi: 10.1097/ACI.0000000000000564
21. Chaaban MR, Mansi A, Tripple JW, et al. SCIT Versus SLIT: Which One Do You Recommend, Doc? *The American Journal of Medical Sciences*. 2019 May; 357(5). doi: 10.1016/j.amjms.2019.02.004
22. Domdey A, Njue A, Nuabor W, et al. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. *European Annals of Allergy and Clinical Immunology*. 2019 June 12; 51(4). doi: 10.23822/EurAnnACI.1764-1489.100
23. Feng M, Zeng X, Li J. House dust mite subcutaneous immunotherapy in Chinese patients with allergic asthma and rhinitis. *Journal of Thoracic Disease*. 2019 June 12; 11(8). doi: 10.21037/jtd.2019.06.35
24. Giallongo A, Parisi GF, Licari A, et al. Novel therapeutic targets for allergic airway disease in children. *Drugs in Context*. 2019 July 9; 8. doi: 10.7573/dic.212590
25. Guan K, Liu B, Wang M, Li Z, et al. Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA. *Clinical Reviews in Allergy & Immunology*. 2019 Aug; 57(1). doi: 10.1007/s12016-019-08751-y
26. Incorvaia C, Barberi S, Pastorello E, et al. The growing importance of real-life studies in allergen immunotherapy. *European Annals of Allergy and Clinical Immunology*. 2019 May 13; 51(3). doi: 10.23822/EurAnnACI.1764-1489.84
27. Matsuoka T, Igarashi S, Kuroda Y, et al. Dual sublingual immunotherapy with Japanese Cedar Pollen droplets and House Dust Mite tablets. *Allergology International*. 2019 Apr 5. doi: 10.1016/j.alit.2019.03.005

28. Abramowicz M, Kruszewski J, Chcialowski A. Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. *Advances in Dermatology and Allergology*. 2018 Dec; 35(6). doi: 10.5114/ada.2018.77614
29. Anvari S, Miller J, Yeh CY, et al. IgE-Mediated Food Allergy. *Clinical Reviews in Allergy & Immunology*. 2018 Oct 29. doi: 10.1007/s12016-018-8710-3
30. Cook Q, Kim E. Update on peanut allergy: Prevention and immunotherapy. *Allergy & Asthma Proceedings*. 2019 Jan; 40(1): 14-20. doi: 10.2500/aap.2019.40.4190
31. Larsen JM, Bogh KL. Animal models of allergen-specific immunotherapy in food allergy: Overview and opportunities. *Clinical & Experimental Allergy*. 2018 June 19; 48(10). doi: 10.1111/cea.13212
32. Mahler V, Esch R, Kleine-Tebbe J, et al. Understanding differences in allergen immunotherapy products and practices in North America and Europe. *The Journal of Allergy and Clinical Immunology*. 2019 Mar; 143(3). doi: 10.1016/j.jaci.2019.01.024
33. Boudreau-Romano S, Qamar N. Peanut Allergy: Changes in Dogma and Past, Present, and Future Directions. *Pediatric Annals*. 2018 Jul 1; 47(7). doi: 10.3928/19382359-20180621-02.
34. Gunawardana N, Durham S. New approaches to allergen immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2018 July 10; 121(3). doi: 10.1016/j.anai.2018.07.014.
35. Hoyte F, Nelson H. Microarray-Based Multivariate Analysis of the Effectiveness of Sublingual Immunotherapy for Cedar Pollinosis. *F1000 Research*. 2018 Aug 23. doi: 10.12688/f1000research.15367.1.
36. Larsen J, Bogh K. Animal models of allergen-specific immunotherapy in food allergy: Overview and opportunities. *Clinical and Experimental Allergy*. 2018 Oct; 48(10). doi: 10.1111/cea.13212.
37. Mueller R, Jensen-Jarolim E, Roth-Walter F, et al. Allergen immunotherapy in people, dogs, cats and horses – differences, similarities and research needs. *European Journal of Allergy and Clinical Immunology*. 2018 April 19; 1(11). doi: 10.1111/all.13464.
38. Parrish C, Kim H. Food-Induced Anaphylaxis: an Update. *Current Allergy and Asthma Reports*. 2018 Jun 14; 18(8). doi: 10.1007/s11882-018-0795-5.
39. Richards J, Stumpf J. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. *The Annals of Pharmacotherapy*. 2018 Oct; 52(10). doi: 10.1177/1060028018769443.
40. Romantsik O, Tosca M, Zappettini S, et al. Oral and sublingual immunotherapy for egg allergy. *The Cochrane Database of Systematic Reviews*. 2018 April 20; 4. doi: 10.1002/14651858.CD010638.pub3.
41. Scurlock A. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. *Clinical Reviews in Allergy & Immunology*. 2018 Oct; 55(2). doi: 10.1007/s12016-018-8677-0.
42. Wasserman S, Begin P, Watson W. IgE-mediated food allergy. *Allergy, Asthma & Clinical Immunology*. 2018 Sept 12; 14. doi: 10.1186/s13223-018-0284-3.
43. El-Sayed Z, El-Farghali O. Allergen-specific immunotherapy in children. *Egypt Journal of Allergy Immunology*. 2012; 10(2).
44. Wang Z, Shi H. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. *Journal of Huazhong University of Science and Technology*. 2017 June 6; 37(3). doi: 10.1007/s11596-017-1748-2.
45. Rice J, Diette G, Suarez-Cuervo C, et al. Allergen-specific immunotherapy in the treatment of pediatric asthma: A systematic review. *Pediatrics*. 2018 Mar 23. doi: 10.1542/peds.2017-3833.
46. Wells R, Fox A, Furman M. Recurrence of eosinophilic oesophagitis with subcutaneous grass pollen immunotherapy. *BMJ Case Reports*. 2018 Mar 15. doi: 10.1136/bcr-2017-223465.
47. Tabatabaian F, Casale T. Allergic rhinitis management: What's next? *Expert Review of Clinical Immunology*. 2018 Mar; 14(3). doi: 10.1080/1744666X.2018.
48. Parrish C, Har D, Bird A. Current status of potential therapies for IgE-mediated food allergy. *Current Allergy and Asthma Reports*. 2018 Feb 22; 18(3). doi: 10.1007/s11882-018-0772-z.

49. Pelaia C, Vatrella A, Lombardo N. Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children. *Expert Opinion on Biological Therapy*. 2018 Feb; 18(2). doi: 10.1080/14712598.2018.1402003.
50. Mims J. Advancements and dilemmas in the management of allergy. *Otolaryngologic Clinics of North America*. 2017 Dec; 50(6). doi: 10.1016/j.otc.2017.08.001.
51. Franzese C. Advances in food allergy. *Otolaryngologic Clinics of North America*. 2017 Dec; 50(6). doi: 10.1016/j.otc.2017.08.008.
52. Pacharn P, Vichyanond P. Immunotherapy for IgE-mediated wheat allergy. *Human Vaccines & Immunotherapeutics*. 2017 Oct 3; 13(10). doi: 10.1080/21645515.2017.1356499.
53. Davila I, Dominguez-Ortega J, Navarro-Pulido A, et al. Consensus document on dog and cat allergy. *European Journal of Allergy and Clinical Immunology*. 2018 Jan 10. doi: 10.1111/all.13391.
54. Rajakulasingam R, Farah N, Huber P, et al. Practive and safety of allergen-specific immunotherapy for allergic rhinitis in the UK National Health Service: A report of “real world” clinical practice. *Clinical and Experimental Allergy*. 2018 Jan; 48(1). doi: 10.1111/cea.13052.
55. Sitton C, Temples H. Practice Guidelines for Peanut Allergies. *Journal of Pediatric Health Care*. 2018 Jan; 32(1). doi: 10.1016/j.pedhc.2017.09.013.
56. Nurmatov U, Dhama S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. *Clinical and Translational Allergy*. 2017 Aug 8;7(24). doi: 10.1186/s13601-017-0159-6.
57. Hur GY, Lee JH, Park HS. Allergen immunotherapy for the treatment of respiratory allergies in the elderly. *Current Opinion in Allergy and Clinical Immunology*. 2017 Aug;17(4):304-308. doi: 10.1097/ACI.0000000000000370.
58. Roxbury CR, Lin SY. Efficacy and Safety of Subcutaneous and Sublingual Immunotherapy for Allergic Rhinoconjunctivitis and Asthma. *Otolaryngologic Clinics of North America*. 2017 Dec;50(6):1111-1119. doi: 10.1016/j.otc.2017.08.011.
59. Hamad A, Burks WA. Emerging approaches to food desensitization in children. *Current Allergy and Asthma Reports*. 2017 May;17(5):32. doi: 10.1007/s11882-017-0700-7.
60. Asaria M, Dhama S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. *European Journal of Allergy and Clinical Immunology*. 2017 Jul 18. doi: 10.1111/all.13254.
61. Schwanke T, Carragee E, Bremberg M, et al. Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. *American Journal of Rhinology & Allergy*. 2017 Sep 1;31(5):310-316. doi: 10.2500/ajra.2017.31.4465.
62. Dominquez-Ortega J, Delgado J, Blanco C, et al. Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence. *Journal of Investigational Allergology and Clinical Immunology*. 2017 Jun 27. doi: 10.18176/jiaci.0149.
63. Tsabouri S, Mavroudi A, Feketea G, et al. Subcutaneous and sublingual immunotherapy in allergic asthma in children. *Frontiers in Pediatrics*. 2017 April 21; 5(82). doi: 10.3389/fped.2017.00082.
64. Chen M, Land M. The current state of food allergy therapeutics. *Human Vaccines & Immunotherapeutics*. 2017 Oct 3;13(10):2434-2444. doi: 10.1080/21645515.2017.1359363.
65. Anderson HM, Wood RA, Busse WW. Dust mite-induced perennial allergic rhinitis in pediatric patients and sublingual immunotherapy. *American Academy of Allergy, Asthma & Immunology: Grand Rounds Review*. 2016 Sept 21. doi: 10.1016/j.jaip.2016.07.013.
66. Nelson HS, Durham SR. Allergen immunotherapy for a teenager with seasonal allergic rhinitis due to grass pollen: Subcutaneous or sublingual route? *American Academy of Allergy, Asthma and Immunology: Pro/Con Review*. 2016 Oct 26. doi: 10.1016/j.jaip.2016.10.012.

67. Manzotti G, Riario-Sforza GG, Dimatteo M, et al. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment. *European Annals of Allergy and Clinical Immunology*. 2016 Nov; 48(6): 224-227.
68. Damm K, Volk J, Horn A, et al. Patient preferences in allergy immunotherapy (AIT) in Germany – a discrete-choice-experiment. *Health Economics Review*. 2016 Aug 2. doi: 10.1186/s13561-016-0110-x.
69. Passalacqua G, Canonica GW, Bagnasco D. Benefit of SLIT and SCIT for allergic rhinitis and asthma. *Current Asthma and Allergy Reports*. 2016 Nov; 16(12): 88.
70. Scadding GW, Calderon MA, Shamji MH, et al. Effect of Two Years of Treatment with Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at Three Years among Patients with Moderate to Severe Seasonal Allergic Rhinitis: A Randomized Clinical Trial: The GRASS Randomized Clinical Trial. *JAMA*. 2017;317(6):615-625. doi:10.1001/jama.2016.21040.
71. Lemberg ML, Berk T, Shah-Hosseini K, et al. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center. *Patient Preference and Adherence*. 2017;11: 63-70. doi: 10.2147/PPA.S122948.
72. Reinhold T, Bruggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. *Allergo Journal International*. 2016 Nov 21. doi: 10.1007/s40629-016-0002-y.
73. Bjorstad A, Cardell LO, Hahn-Pederson J, et al. A cost minimisation analysis comparing sublingual immunotherapy to subcutaneous for the treatment of house dust mite allergy in a Swedish setting. *Clinical Drug Investigation*. 2017 Mar 22. doi: 10.1007/s40261-0717-0516-1.
74. Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. *Journal of Allergy and Clinical Immunology*. 2016 Oct;138(4):1081-1088. doi: 10.1016/j.jaci.2016.04.061.
75. Durham SR, Creticos PS, Nelson HS, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. *Cellular and Molecular Immunology*. 2016 Apr 11. doi: 10.1038/cmi.2016.14.
76. Luo X, Hong H, Tang J, et al. Increased expression of miR-146a in children with allergic rhinitis after allergen-specific immunotherapy. *Allergy, Asthma & Immunology Research*. 2016 Mar;8(2):132-140. doi: 10.4168/aaair.2016.8.2.132. Epub 2015 Oct 22.
77. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? *Journal of Allergy and Clinical Immunology*. 2016 Feb;137(2):339-349.e10. doi: 10.1016/j.jaci.2015.12.1298.
78. Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. *Allergy and Asthma Proceedings*. 2016 Jan;37(1):50-56. doi: 10.2500/aap.2016.37.3907.
79. Miao Q, et al. A comparison of the effects of subcutaneous and sublingual immunotherapy on immunological responses in children with asthma. *The Chinese Journal of Contemporary Pediatrics*. 2015 Nov;17(11):1210-6.
80. Schulten V, et al. Distinct modulation of allergic T cell responses by subcutaneous versus sublingual allergen-specific immunotherapy. *Clinical & Experimental Allergy*. 2015 Oct 5. doi: 10.1111/cea.12653.
81. French C, Seiberling K. Comparative costs of subcutaneous and sublingual immunotherapy. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2015 Jun;23(3):226-9. doi: 10.1097/MOO.000000000000159.
82. Nelson H, Cartier S, Allen-Ramey 3, Lawton S, Calderon MA. Network meta-analysis show commercialized subcutaneous and sublingual grass products have comparable efficacy. *Journal of Allergy and Clinical Immunology. In Practice*. 2015 Mar-Apr;3(2):256-266.e3. doi: 10.1016/j.jaip.2014.09.018. Epub 2014 Nov 20.
83. Tabatabaian F, Casale TB. Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). *Allergy and Asthma Proceedings*. 2015 Mar-Apr;36(2):100-4. doi: 10.2500/aap.2015.36.3830.



84. Verheggen BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. *Clinical and Translational Allergy*. 2015 Jan 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015.
85. Satya ND, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. *Journal of Allergy and Clinical Immunology*. DOI:10.1016/j.jaci.2014.11.005.
86. Lierl MB. New developments in the treatment of pediatric allergic rhinitis and conjunctivitis. *Pediatric Annals*. 2014 Aug;43(8):e192-200. doi:10.3928/00904481-20140723-09.
87. Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis: current update. *Current Opinion Otolaryngology & Head and Neck Surgery*. 2014 Jun;22(3):211-5. doi:10.1097/MOO.0000000000000045.
88. Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? *Current Opinion in Allergy and Clinical Immunology*. 2014 Aug;14(4):363-70. doi:10.1097/ACI.0000000000000084.
89. Larenas Linnemann DE, S Blaiss M. Selection of patients for sublingual versus subcutaneous immunotherapy. *Immunotherapy*. 2014 Jul;6(7):871-84. doi:10.2217/imt.14.55.
90. Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. *Journal of Evaluation in Clinical Practice*. 2014 Jun;20(3):225-38. doi:10.1111/jep.12112. Epub 2014 Jan 21.
91. Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, Hershey G, Liu AH, O'Connor GT, Pongratic JA, Zoratti E, Little F, Granada M, Kennedy S, Durham SR, Shamji MH, Busse WW. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. *Journal of Allergy and Clinical Immunology*. 2014 Mar;133(3):846-852.
92. Paino GB, Caminiti L, Passalacqua G. Changing the route of immunotherapy administration: an 18-year survey in pediatric patients with allergic rhinitis and asthma. *Allergy and Asthma Proceedings*. 2013 Nov-Dec;34(6):523-526.
93. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. *Clinical and Transitional Allergy*. 2013 Dec 21;3(1):42.
94. Nelson, H. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? *Journal of Allergy and Clinical Immunology: In Practice*. 2014 Mar-Apr;2(2):144-149.
95. Frati F, Dell'Albani I, Incorvaia C. Why are direct comparisons of subcutaneous and sublingual immunotherapy so rare? *Journal of Allergy and Clinical Immunology*. 2014 Mar;133(3):936.
96. Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. *Current Allergy and Asthma Reports*. 2013;13(2):178-95.
97. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. *Journal of Allergy and Clinical Immunology*. 2012;130(5):1097-1107.
98. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? *Current Opinions on Allergy and Clinical Immunology*. 2012;12(6):640-7.
99. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *International Archives of Allergy and Immunology*. 2012;157(3):288-98.
100. Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. *International Forum of Allergy and Rhinology*. 2012 Jul-Aug;2(4):280-4. doi: 10.1002/alr.21037. Epub 2012 Mar 20.
101. Calderón MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. *Current Opinions in Allergy and Clinical Immunology*. 2012;12(3):249-56.

102. Saporta D. Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients. *Journal of Environmental and Public Health*. 2012;2012:492405. doi: 10.1155/2012/492405. Epub 2012 Feb 20.
103. La Rosa M, Lionetti E, Leonardi S, Salpietro A, Bianchi L, Salpietro C, Miraglia Del Giudice M, Ciprandi G, Marseglia GL. Specific immunotherapy in children: The evidence. *International Journal of Immunopathology and Pharmacology*. 2011;24(Suppl. 4):69-78.
104. Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. *Pediatric Pulmonology*. 2011;3(6):747-56.
105. Sieber J, Shah-Hosseini K, Mosages R. Specific immunotherapy for allergic rhinitis to grass and tree pollens in daily medical practice-symptom load with sublingual immunotherapy compared to subcutaneous immunotherapy. *Annals of Medicine*. 2011;43(6):418-24.
106. Cochard M, Eigenmann P. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. *Journal of Allergy and Clinical Immunology*. 2009 Aug;124(2):378-9. doi: 10.1016/j.jaci.2009.04.040. Epub 2009 Jul 9.
107. Larenas-Linnemann D. Subcutaneous and Sublingual Immunotherapy in Children: Complete Update on Controversies, Dosing and Efficacy. *Current Allergy and Asthma Reports*. 2008;8:465-474.
108. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs. subcutaneous allergen immunotherapy. *Annals of Allergy, Asthma and Immunology*. 2008;100(5):482-489.
109. Townley, R. Is Sublingual Immunotherapy “Ready for Prime Time”? *Chest*. 2008;133:589-590.
110. Saporta D, McDaniel A. Efficacy comparison of multiple-antigen subcutaneous injection immunotherapy and multiple-antigen sublingual immunotherapy. *Ear, Nose & Throat Journal*. 2007;86(8):493-497.
111. Mauroa M, Russelloa M, Incorvaia C, Gazzolaa G, Di Carac G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: A randomized study. *European Annals of Allergy and Clinical Immunology*. 2007;39:119-122.
112. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebo-controlled, double-blind, double-dummy study. *Allergy*. 2004;59:45-53.
113. Mungan D, et al. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma a placebo controlled study. *Annals of Allergy, Asthma, and Immunology*. 1999; 82:485-490.
114. Quirino T, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. *Clinical and Experimental Allergy*. 1996;26:1253-1261.
115. Bernardis P, et al. Injective versus sublingual immunotherapy in *Alternaria tenuis* allergic patients. *Journal of Investigational Allergology and Clinical Immunology*. 1996;6(1):55-62.

#### 4) Mechanisms of Sublingual Immunotherapy

1. Alvaro-Lozano M, Akdis C, Akdis M, et al. EAACI Allergen Immunotherapy User’s Guide. *Pediatric Allergy and Immunology*. 2020 May; 31(25). doi: 10.1111/pai.13189
2. Barker-Tejeda T, Bazire R, Obeso D, et al. Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics. *European Journal of Allergy and Clinical Immunology*. 2020 August 19. doi: 10.1111/all.14565
3. Boonpiyathad T, Sozener Z, Akdis M, et al. The role of Treg cell subsets in allergic disease. *Asian Pacific Journal of Allergy and Immunology*. 2020 September; 38(3). doi: 10.12932/AP-030220-0754
4. Delgado M, Rizzo G, Fossati C, et al. Sublingual Omp16-driven redirection of the allergic intestinal response in a pre-clinical model of food allergy. *Clinical and Experimental Allergy*. 2020 June 5. doi: 10.1111/cea.13676

5. Hesse L, Petersen A, Elberink J, et al. 1,25(OH)<sub>2</sub> VitD<sub>3</sub> supplementation enhances suppression of grass pollen-induced allergic asthma by subcutaneous and sublingual immunotherapy in a mouse model. *Scientific Reports*. 2020 June 2. doi: 10.1038/s41598-020-65946-6
6. Hoof I, Schulten V, Layhadi J, et al. Allergen-specific IgG + memory B cells are temporally linked to IgE memory responses. *The Journal of Allergy and Clinical Immunology*. 2020 July 1; 146(1). doi: 10.1016/j.jaci.2019.11.046
7. Hoshino M, Akitsu K, Kubota K, et al. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma. *Clinical and Experimental Allergy*. 2020 June 17; 50(9). doi: 10.1111/cea.13686
8. Joubert A, Geppert M, Johnson L, et al. Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease. *Frontiers in Immunology*. 2020 June 30. doi: 10.3389/fimmu.2020.01334
9. Nomura Y, Okubo K, Nakamura T, et al. Long-term treatment of Japanese cedar pollinosis with Japanese cedar pollen SLIT drops and persistence of treatment effect: A post-marketing clinical trial. *Allergology International*. 2020 July 8. doi: 10.1016/j.alit.2020.05.008
10. Otsuka K, Otsuka H, Matsune S, et al. Decreased numbers of metachromatic cells in nasal swabs in Japanese cedar pollinosis following sublingual immunotherapy. *Immunity, Inflammation and Disease*. 2020 May 28; 8(3). doi: 10.1002/iid3.314
11. Pechsrichuang P, Jacquet A. Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation? *Clinical and Experimental Allergy*. 2020 February 15. doi: 10.1111/cea.13588
12. Pelst M, Hobart C, Wallaey C, et al. Adjuvanting Allergen Extracts for Sublingual Immunotherapy: Calcitriol Downregulates CXCL8 Production in Primary Sublingual Epithelial Cells. *Frontiers in Immunology*. 2020 June 9. doi: 10.3389/fimmu.2020.01033
13. Sadeghi M, Koushki K, Mashayekhi K, et al. DC-targeted gold nanoparticles as an efficient and biocompatible carrier for modulating allergic responses in sublingual immunotherapy. *International Immunopharmacology*. 2020 September; 86. doi: 10.1016/j.intimp.2020.106690
14. Sanchez Acosta G, Kinaciyani T, Kitzmuller C, et al. IgE-blocking antibodies following SLIT with recombinant Mal d I accord with improved apple allergy. *The Journal of Allergy and Clinical Immunology*. 2020 April 4. doi: 10.1016/j.jaci.2020.03.015
15. Schiavi L, Brindisi G, De Castro G, et al. Nasal reactivity evaluation in children with allergic rhinitis receiving grass pollen sublingual immunotherapy. *Allergy and Asthma Proceedings*. 2020 September 1; 41(5). doi: 10.2500/aap.2020.41.200063
16. Shahbaz S, Varasteh A, Koushki K, et al. Sublingual dendritic cells targeting by aptamer: Possible approach for improvement of sublingual immunotherapy efficacy. *International Immunopharmacology*. 2020 August 20; 85. doi: 10.1016/j.intimp.2020.106603
17. Shahgordi S, Sankian M, Yazdani Y, et al. Immune responses modulation by curcumin and allergen encapsulated into PLGA nanoparticles in mice model of rhinitis allergic through sublingual immunotherapy. *International Immunopharmacology*. 2020 July; 84. doi: 10.1016/j.intimp.2020.106525
18. Yan Lam H, Tergaonkar V, Seok Ahn K. Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies. *Bioscience Reports*. 2020 April 30; 40(4). doi: 10.1042/BSR20200256
19. Zissler U, Schmidt-Weber C. Predicting Success of Allergen-Specific Immunotherapy. *Frontiers in Immunology*. 2020 August 25. doi: 10.3389/fimmu.2020.01826
20. Tosca M, Olcese R, Licari A, et al. Allergen Immunotherapy and Asthma. *Pediatric Allergy and Immunology*. 2020 Feb 3; 31(24). doi: 10.1111/pai.13161
21. Sampath V, Sindher S, Pinzon A, et al. Can food allergy be cured? What are the future prospects? *European Journal of Allergy and Clinical Immunology*. 2019 Nov 16. doi.org/10.1111/all.14116
22. Heeringa J, McKenzie C, Varsee N, et al. Induction of IgG<sub>2</sub> and IgG<sub>4</sub> B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. *European Journal of Allergy and Clinical Immunology*. 2019 Oct 6. doi: 10.1111/all.14073

23. Pfaar O, Agache I, Blay F. Perspectives in allergen immunotherapy: 2019 and beyond. *European Journal of Allergy and Clinical Immunology*. 2019 Dec 24; 74(108). doi: 10.1111/all.14077
24. Takahara E, Matsune S, Ishida M, et al. Preliminary Clinical Trial to Explore Predictive Biomarkers of Response to Sublingual Immunotherapy for Japanese Cedar Pollinosis. *Journal of Nippon Medical School*. 2020 Feb 20. doi: 10.1272/jnms.JNMS.2020\_87-506
25. Yang Y, Nagai S, Kang S, et al. Tolerogenic Properties of CD206+ Macrophages Appeared in the Sublingual Mucosa After Repeated Antigen-Painting. 2020 Mar 4. doi: 10.1093/intimm/dxaa014
26. Hajavi J, Hashemi M, Sankian M. Evaluation of size and dose effects of rChe a 3 allergen loaded PLGA nanoparticles on modulation of Th2 immune responses by sublingual immunotherapy in mouse model of rhinitis allergic. *International Journal of Pharmaceutics*. 2019 May 30; 563. doi: 10.1016/j.ijpharm.2019.03.040.
27. Hoshino M, Akitsu K, Kubota K. Effect of Sublingual Immunotherapy on Airway Inflammation and Airway Wall Thickness in Allergic Asthma. *The Journal of Allergy and Clinical Immunology: In Practice*. 2019 Jun 20. doi: 10.1016/j.jaip.2019.06.003
28. Jacquet A. Perspectives in Allergen-Specific Immunotherapy: Molecular Evolution of Peptide- and Protein-Based Strategies. *Current Protein & Peptide Science*. 2019 Jul 18. doi: 10.2174/1389203720666190718152534
29. Kaminuma O, Kitamura N, Gotoh M, et al. Thrombospondin 1-mediated suppression of mast cell degranulation is involved in the efficacy of sublingual immunotherapy. *Allergology International: Official Journal of the Japanese Society of Allergology*. 2019 Sep; 68. doi: 10.1016/j.alit.2019.03.007
30. Kitzmüller C, Jahn-Schmid B, Kinaciyan T, et al. Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response. *Allergy*. 2019 Aug; 74(8). doi: 10.1111/all.13779
31. Li H, Wen Y, Wu S, et al. Epigenetic Modification of Enhancer of Zeste Homolog 2 Modulates the Activation of Dendritic Cells in Allergen Immunotherapy. *International Archives of Allergy and Immunology*. 2019; 180(2). doi: 10.1159/000500882
32. Maina E, Devriendt B, Cox E. Food allergen-specific sublingual immunotherapy modulates peripheral T cell responses of dogs with adverse food reactions. *Veterinary Immunology and Immunopathology*. 2019 Jun; 212. doi: 10.1016/j.vetimm.2019.05.003
33. Moura AL, Pereira C, Regateiro F, et al. Pru p 3 sublingual immunotherapy ultra-rush protocol is safe and clinically effective. *European Annals of Allergy and Clinical Immunology*. 2019 Sep 16; 51(5). doi: 10.23822/EurAnnACI.1764-1489.99
34. Nowak-Węgrzyn A, Sato S, Fiocchi A, et al. Oral and sublingual immunotherapy for food allergy. *Current Opinion in Allergy and Clinical Immunology*. 2019 Sep 12. doi: 10.1097/ACI.0000000000000587
35. Qu Y, Yamada T, Aoi N, et al. Sublingual Immunotherapy Attenuates Nasal Symptoms Upon Allergen Exposure in Murine Allergic Rhinitis Model via an Induction of IL-10 producing T cells in Submandibular Lymph Node. *The Annals of Otolaryngology, Rhinology, and Laryngology*. 2019 Jun; 128(6). doi: 10.1177/0003489419835848
36. Tanaka Y, Fukumoto S, Sugawara S. Mechanisms underlying the induction of regulatory T cells by sublingual immunotherapy. *Journal of Oral Biosciences*. 2019 Jun; 61 (2). doi: 10.1016/j.job.2019.02.001
37. Bacher P, Scheffold A. The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. *The Journal of Allergy and Clinical Immunology*. 2018 Dec; 142(6). doi: 10.1016/j.jaci.2018.10.016
38. Elewa YHA, Mizoguchi T, Ichii O, et al. Morphofunctional analysis of antigen uptake mechanisms following sublingual immunotherapy with beads in mice. *PLoS One*. 2018 Dec 20; 13(12). doi: 10.1371/journal.pone.0201330
39. Huoman J, Papapavlou G, Pap A, et al. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children. *Pediatric Allergy and Immunology*. 2019 Feb 25. doi: 10.1111/pai.13047

40. Rodriguez M, Ramos-Soriano J, Perkins J, et al. Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model. *Scientific Reports*. 2019 Mar 11; 9(1). doi: 10.1038/s41598-019-40114-7
41. Sampath V, Nadeau KC. Newly identified T cell subsets in mechanistic studies of food immunotherapy. *The Journal of Clinical Investigation*. 2019 April; 129(4). doi: 10.1172/JCI124605
42. Suzuki S, Sakurai D, Sakurai T, et al. Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis. *Allergology International*. 2019 Feb 22. doi: 10.1016/j.alit.2019.02.003
43. Wang YT, Liu HC, Chen HC, et al. Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma. *Allergy, Asthma and Clinical Immunology*. 2018 Oct 16; 14(43). doi: 10.1186/s13223-018-0269-2
44. Wen Y, Zhou L, Li Y, et al. Role of leptin in allergic rhinitis during sublingual immunotherapy. *European Archives of Otorhinolaryngology*. 2018 Nov; 275(11). doi: 10.1007/s00405-018-5123-0
45. Xie ZJ, Guan K, Yin J. Advances in the clinical and mechanism research of pollen induced seasonal allergic asthma. *American Journal of Clinical and Experimental Immunology*. 2019 Feb 15; 8(1).
46. Yin Z, Mi Y, Zhia X. Sublingual immunotherapy of *Dermatophagoides farinae* drops in nasal cavity local allergy. 2019 Jan; 33(1). doi: 10.13201/j.issn.1001-1781.2019.01.016
47. Caruso M, Cibella F, Emma R, et al. Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. *International Immunopharmacology*. 2018 Jul; 60. doi: 10.1016/j.intimp.2018.04.034.
48. Ghasemi Z, Varasteh A, Moghadam M, et al. Sublingual Immunotherapy with Sal kI Expressing *Lactococcus lactis* Down-regulates Th2 Immune Responses in Balb/c Mice. *Iranian Journal of Allergy, Asthma and Immunology*. 2018 Jun; 17(3).
49. Globinska A, Boonpiyathad T, Satitsuksanoa P, et al. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. *Annals of Allergy, Asthma and Immunotherapy*. 2018 Sep; 121(3). doi: 10.1016/j.anai.2018.06.026.
50. Gotoh M, Kaminuma O, Hiroi T, et al. Microarray-Based Multivariate Analysis of the Effectiveness of Sublingual Immunotherapy for Cedar Pollinosis. *Allergy, Asthma & Immunology Research*. 2018 Sep; 10(5). doi: 10.4168/aaair.2018.10.5.562.
51. Haruna T, Kariya S, Fujiwara T, et al. Role of whole saliva in the efficacy of sublingual immunotherapy in seasonal allergic rhinitis. *Allergology International*. 2018 Aug 27. doi: 10.1016/j.alit.2018.07.008.
52. Hesse L, Brouwer U, Petersen A, et al. Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyper responsiveness in grass pollen mouse models for allergic asthma. *Experimental Models of Allergic Disease*. 2018 Aug; 48. doi: 10.1111/cea.13169.
53. Jat K, Kumar A. Sublingual Immunotherapy in Allergic Rhinitis: Search for a Suitable Biomarker Continues! *Indian Journal of Pediatrics*. 2018 Oct; 85(10). doi: 10.1007/s12098-018-2773-2.
54. Kother J, Mandl A, Allekotte S, et al. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy. *Clinical and Translational Allergy*. 2018 July 4; 8(28). doi: 10.1186/s13601-018-0214-y.
55. Shamji M, Layhadi J, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy. *The Journal of Allergy and Clinical Immunology*. 2018 July 25. doi: 10.1016/j.jaci.2018.06.041.
56. Smaldini P, Trejo F, Cohen J, et al. Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells. *Allergy*. 2018 April; 73(4). doi: 10.1111/all.13402.
57. Tofukuji S, Katayama K, Nakano Y, et al. Allergen-specific sublingual immunotherapy is dose and duration dependent in a murine allergic rhinitis model. *Journal of Allergy and Clinical Immunology*. 2018 Aug 10. doi: 10.1016/j.jaci.2018.08.002.



58. Wang Y, Li C, Xu Y, et al. Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis. *Indian Journal of Pediatrics*. 2018 Oct; 85(10). doi: 10.1007/s12098-018-2703-3.
59. Xu K, Deng Z, Li D, et al. Efficacy of add-on sublingual immunotherapy for adults with asthma: A meta-analysis and systematic review. *Annals of Allergy, Asthma and Immunology*. 2018 Aug; 121(2). doi: 10.1016/j.anai.2018.05.019.
60. Hovav, A. Dendritic cells of the oral mucosa. *Mucosa Immunology*. 2014 Jan; 7(1). doi: 10.1038/mi.2013.42.
61. Ihara F, Sakurai D, Yonekura S, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. *Experimental Allergy and Immunology*. 2018 Mar 8. doi: 10.1111/all.13436.
62. Gotoh M, Kaminuma O, Nakaya A, et al. Involvement of taste receptors in the effectiveness of sublingual immunotherapy. *Allergology International: Official Journal of the Japanese Society of Allergology*. 2018 Mar 6. doi: 10.1016/j.alit.2018.02.003.
63. Palomares F, Gomez F, Bogas G. Immunological changes induced in peach allergy patients with systemic reactions by Pru p 3 sublingual immunotherapy. *Molecular Nutrition & Food Research*. 2018 Feb; 62(3). doi: 10.1002/mnfr.201700669.
64. Soria I, Lopez-Relano J, Vinuela M, et al. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. *European Journal of Allergy and Clinical Immunology*. 2018 Jan 10. doi: 10.1111/all.13396.
65. Aliu H, Rask C, Brimnes J, et al. Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen. *International Journal of Nanomedicine*. 2017 Nov 22. doi: 10.2147/IJN.S137033.
66. Wambre E, Jeong D. Oral Tolerance Development and Maintenance. *Immunology and Allergy Clinics of North America*. 2018 Feb; 38(1). doi: 10.1016/j.jiac.2017.09.003.
67. Gamazo C, D'Amelio C, Gastaminza G, et al. Adjuvants for allergy immunotherapeutics. *Human Vaccines & Immunotherapeutics*. 2017 Oct 3; 13(10). doi: 10.1080/21645515.2017.1348447.
68. Damask C. Immunotherapy: Treating with fewer allergens? *Otolaryngologic Clinics of North America*. 2017 Dec; 50(6). doi: 10.1016/j.otc.2017.08.012.
69. Thirion-Delalande C, Gervais F, Fisch C, et al. Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products. *PLOS*. 2017 Sep 8. doi: 10.1371/journal.pone.0183398.
70. Moingeon P, Mascarell L. Differences and similarities between sublingual immunotherapy of allergy and oral tolerance. *Seminars in Immunology*. 2017 Apr. doi: 10.1016/j.smim.2017.07.003.
71. Salari F, Vahedi F, Varasteh AR, et al. Enhanced sublingual immunotherapy by TAT-fused recombinant allergen in a murine rhinitis model. *International Immunopharmacology*. 2017 Jul;48:118-125. doi: 10.1016/j.intimp.2017.04.011.
72. Gotoh M, Kaminuma O, Nakaya A, et al. Identification of biomarker sets for predicting the efficacy of sublingual immunotherapy against pollen-induced allergic rhinitis. *International Immunology*. 2017 Jun 1;29(6):291-300. doi: 10.1093/intimm/dxx034.
73. Nowak-Wegrzyn A, Chatchatee P. Mechanisms of tolerance induction. *Annals of Nutrition & Metabolism*. 2017. doi: 10.1159/000457915.
74. Jensen-Jarolim E, Pali-Scholl I, Roth-Walter F. Outstanding animal studies in allergy II. From atopic barrier and microbiome to allergen-specific immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2017 Jun;17(3):180-187. doi: 10.1097/ACI.0000000000000364.
75. Rodriguez MJ, Mascaraque A, Ramos-Soriano J, et al. Pru p 3-Epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy. *Molecular Nutrition & Food Research*. 2017 Oct;61(10). doi: 10.1002/mnfr.201700110.
76. Caillot N, Bouley J, Jain K, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. *The Journal of Allergy and Clinical Immunology*. 2017 Sep;140(3):759-770. doi: 10.1016/j.jaci.2016.10.036.

77. Moingeon P, Lombardi V, Baron-Bodo V, et al. Enhancing allergen-presentation platforms for sublingual immunotherapy. *American Academy of Allergy, Asthma & Immunology: Clinical Commentary Review*. 2016 July 25. doi: 10.1016/j.jaip.2016.07.020.
78. Alvaro M, Sancha J, Larramona H, et al. Allergen-specific immunotherapy: Update on immunological mechanisms. *Allergologia et immunopathologia*. 2012 July 22. doi: 10.1016/j.aller.2012.07.018.
79. Meng Q, Liu X, Li P, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. *International Forum of Allergy & Rhinology*. 2016 Aug;6(8):862-70. doi: 10.1002/alr.21743.
80. Tanaka Y, Nagashima H, Bando K, et al. Oral CD103-CD11b+ classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes. *Mucosal Immunology*. 2016 May 11. doi: 10.1038/mi.2016.46.
81. Nomura T, Suzuki M, Yokota M, et al. Effect of Japanese cedar-specific sublingual immunotherapy on allergen-specific TH2 cell counts in blood. *Annals of Allergy, Asthma & Immunology*. 2016 Jul;117(1):72-78. doi: 10.1016/j.anai.2016.04.003.
82. Hagner S, Rask C, Brimnes J, et al. House Dust Mite-Specific Sublingual Immunotherapy Prevents the Development of Allergic Inflammation in a Mouse Model of Experimental Asthma. *International Archives of Allergy and Immunology*. 2016 Jun;170(1):22-34. doi: 10.1159/000446155.
83. Shima K, Koya T, Tsukioka K, et al. Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. *Allergology International*. 2016 Jul 8. pii: S1323-8930(16)30083-1. doi: 10.1016/j.alit.2016.05.012.
84. Jerzynska J, Stelmach W, Balcerak J, et al. Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy. *Allergy & Asthma Proceedings*. 2016 Jul;37(4):324-34. doi: 10.2500/aap.2016.37.3958.
85. Larenas Linnemann DE, Singh J, Rosario N, et al. Similar biological activity in skin prick test for Oralair® (8200 BAU) and Grazax® (6200 BAU) reinforces effective SLIT dosing level. *Allergy*. 2016 Aug 3. doi: 10.1111/all.12998.
86. Hüser C, Dieterich P, Singh J, et al. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite allergic patients. *Allergy*. 2016 Apr 12. doi: 10.1111/all.12913.
87. Würtzen PA, Gupta S, Brand S, Andersen PS. Grass pollen immunotherapy: Where are we now. *Immunotherapy*. 2016 Apr;8(4):399-411. doi: 10.2217/imt.16.1.
88. Chester JG, Bremberg MG, Reisacher WR. Patient preferences for route of allergy immunotherapy: A comparison of four delivery methods. *International Forum of Allergy & Rhinology*. 2016 Feb 2. doi: 10.1002/alr.21707.
89. Pishdadian A, Varasteh A, Gholamin M, et al. Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy. *Iranian Journal of Basic Medical Sciences*. 2016 Jan;19(1):64-71.
90. Creticos PS. Allergen immunotherapy: Vaccine modification. *Immunology And Allergy Clinics of North America*. 2016 Feb;36(1):103-24. doi: 10.1016/j.iac.2015.08.010.
91. Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of aeroallergen immunotherapy: Subcutaneous immunotherapy and sublingual immunotherapy. *Immunology and Allergy Clinics of North America*. 2016 Feb;36(1):71-86. doi: 10.1016/j.iac.2015.08.003.
92. Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: Comparative efficacy, current and potential indications, and warnings-United States versus Europe. *Immunology and Allergy Clinics of North America*. 2016 Feb;36(1):13-24. doi: 10.1016/j.iac.2015.08.005.
93. Salari F, Varasteh AR, Vahedi F, Hashemi M, Sankian M. Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice. *International Immunopharmacology*. 2015 Dec;29(2):672-8. doi: 10.1016/j.intimp.2015.09.011. Epub 2015 Sep 26.

94. Li H, Xu E, He M. Cytokine Responses to specific immunotherapy in house dust mite-induced allergic rhinitis patients. *Inflammation*. 2015 Dec;38(6):2216-23. doi: 10.1007/s10753-015-0204-3.
95. Gorelik M, Frischmeyer-Guerrero PA. Innate and adaptive dendritic cell responses to immunotherapy. *Current Opinion in Allergy & Clinical Immunology*. 2015 Dec;15(6):575-80. doi: 10.1097/ACI.0000000000000213.
96. Larenas-Linnemann, D. Allergen immunotherapy: an update on protocols of administration. *Current Opinion in Allergy and Clinical Immunology*. 2015 Dec;15(6):556-567. doi:10.1097/ACI.0000000000000220.
97. Mauro M, Boni E, Makri E, Incorvaia C. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. *Expert Opinion on Drug Metabolism & Toxicology*. 2015 Nov 13:1-7. doi:10.1517/17425255.2015.1113255.
98. Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 2015 Oct 29. doi: 10.1016/j.jaci.2015.09.015.
99. Sakashita M, et al. Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a. *Cytokine*. 2015 Sep;75(1):181-5. doi: 10.1016/j.cyt.2015.03.019. Epub 2015 Apr 28.
100. Vacher G, Sublet E, Gurny R, Borchard G. Establishment and first characterization of a sublingual epithelial and immune cell co-culture model. *Allergy and Asthma Proceedings*. 2015 Mar-Apr;36(2):100-4. doi: 10.2500/aap.2015.36.3830.
101. Nagai Y, et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice. *Clinical and Experimental Allergy*. 2015 Mar;45(3):677-86. doi: 10.1111/cea.12329.
102. Kim SH, Mun SJ, Han DH, Kim JW, Kim DY, Rhee CS. Three-year follow-up results of sublingual immunotherapy in patients with allergic rhinitis sensitized to house dust mites. *Allergy, Asthma & Immunology Research*. 2015 Mar;7(2):118-23. doi: 10.4168/aair.2015.7.2.118. Epub 2014 Oct 30.
103. Allam JP, Novak N. Immunological mechanisms of sublingual immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2014 Dec;14(6):564-9. doi: 10.1097/ACI.0000000000000118.
104. Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. *Current Allergy and Asthma Reports*. 2014 Nov;14(11):473. doi: 10.1007/s11882-014-0473-1.
105. Frischmeyer-Guerrero PA, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy. *Clinical Immunology*. 2014 Nov;155(1):47-59. doi: 10.1016/j.clim.2014.08.006. Epub 2014 Aug 27.
106. Nestor CE, et al. Sublingual immunotherapy alters expressions of IL-4 and its soluble and membrane-bound receptors. *Allergy*. 2014 Nov;69(11):1564-6. doi: 10.1111/all.12505. Epub 2014 Sep 13.
107. Rael E, Lockey RF. Optimal duration of allergen immunotherapy. *Journal of Clinical Immunology*. 2014 Nov;134(5):1218-9.e2. doi: 10.1016/j.jaci.2014.08.046. Epub 2014 Nov 5.
108. Toskala E. Immunology. *International Forum of Allergy & Rhinology*. 2014 Sep;4 Suppl 2:S21-7. doi:10.1002/air.21380.
109. Cuppari C, et al. Allergen immunotherapy, routes of administration and cytokine networks: an update. *Immunotherapy*. 2014 June;6(6):775-86. doi:10.2217/imt.14.47.
110. Tian M, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for *Dermatophagoides farinae* on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. *International Forum of Allergy & Rhinology*. 2014 May;4(5):371-375.
111. Shim BS, Choi Y, Cheon IS, Song MK. Sublingual delivery of vaccines for the induction of mucosal immunity. *Immune Network*. 2013 Jun;13(3):81-85.
112. Compalati E, Braido F, Walter Canonica G. Sublingual immunotherapy: recent advances. *Allergology International*. 2013 Dec;62(4):415-523.

113. Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. *Allergy and Asthma Proceedings*. 2014 Jan-Feb;35(1):34-42.
114. Ciepiela O, Zawadzka-Krajewska A, Kotuła I, van Overveld F, Kulus M, Demkow U. Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation. *Pediatric Allergy, Immunology, and Pulmonology*. 2014 Mar 1;27(1):17-23.
115. Casale TB, Stokes JR. Immunotherapy: what lies beyond. *Annals of Allergy, Asthma & Immunology*. 2014 Mar;133(3):612-619.
116. Steinke JW, Lawrence MG. T-cell biology in immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2014 Mar;112(3):195-199.
117. Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, de Frutos C, Blanco C, Carrera AC, Barber D, Varona R. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. *The Journal of Allergy and Clinical Immunology*. 2014 Jan;133(1):133-138.
118. Ciepiela O, Zawadzka-Krajewska A, Kotula I, Pyrzak B, Demkow U. Influence of sublingual immunotherapy on the expression of Mac-1 integrin in neutrophils from asthmatic children. *Advances in Experimental Medicine and Biology*. 2013;756:73-80.
119. Rolland JM, Prickett S, Gardner LM, O'Hehir RE. T cell targeted strategies for improved efficacy and safety of specific immunotherapy for allergic disease. *Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry*. 2013;12(3):201-22.
120. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, Hwang PH, Hoyte EG, Garcia MA, Nadeau KC. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. *Journal of Allergy and Clinical Immunology*. 2012;130(1):215-24.
121. Guida G, Boita M, Scirelli T, Bommarito L, Heffler E, Badiu I, Bellone G, Mietta S, Mistrello G, Rolla G. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy. *Allergy and Asthma Proceedings*. 2012;33(5):411-5.
122. Baron-Bodo V, Batard T, Nguyen H, Frereux M, Horiot S, Harwanegg C, Bergmann KC, de Beaumont O, Moingeon P. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. *Clinical and Experimental Allergy*. 2012;42(10):1510-8.
123. Di Gioacchino M, Cavallucci E, Ballone E, et al. Dose-dependent clinical and immunological efficacy of sublingual immunotherapy with mite monomeric allergoid. *International Journal of Immunopathology and Pharmacology*. 2012;25(3):671-9.
124. Yamada T, Tongu M, Goda K, Aoi N, Morikura I, Fuchiwaki T, Kawauchi H. Sublingual immunotherapy induces regulatory function of IL-10-Expressing CD4(+)CD25(+)Foxp3(+) T cells of cervical lymph nodes in murine allergic rhinitis model. *Journal of Allergy (Cairo)*. 2012;2012:490905. doi: 10.1155/2012/490905. Epub 2012 Oct 17.
125. Bonvalet M, Moussu H, Wambre E, et al. Allergen-specific CD4(+) T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy. *Clinical and Experimental Allergy*. 2012;42(12):1745-55.
126. Marcucci F, Sensi L, Incorvaia C, Dell'albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. *Clinical Molecular Allergy*. 2012 Jun 13;10(1):7. doi: 10.1186/1476-7961-10-7.
127. Zimmer A, Bouley J, Le Mignon M, Pliquet E, Horiot S, Turfkruyer M, Baron-Bodo V, Horak F, Nony E, Louise A, Moussu H, Mascarell L, Moingeon P. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. *Journal of Allergy and Clinical Immunology*. 2012;129(4):1020-30.
128. Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2012;12(1):1-6.

129. Allam JP, Novak N. Local immunotherapy mechanisms of sublingual immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2011;11(6):571-8.
130. Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: Mechanisms and applications. *Clinical and Developmental Immunology*. 2012;2012:623474. doi: 10.1155/2012/623474. Epub 2011 Nov 10.
131. Szczawinska-Poplonyk A. Development of mucosal immunity in children: A rationale for sublingual immunotherapy. *Journal of Allergy*. 2012;2012:492761. doi: 10.1155/2012/492761. Epub 2011 Oct 27.
132. Van Overtvelt L, Baron-Bodo V, Horiot S, Moussu H, Ricarte C, Horak F, et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. *Allergy*. 2011 Dec;66(12):1530-7. doi: 10.1111/j.1398-9995.2011.02696.x. Epub 2011 Aug 29.
133. Shamji, MH, Durham, SR. Mechanisms of immunotherapy to aeroallergens. *Clinical and Experimental Allergy*. 2011;41(9):1235-46.
134. Novak N, Allam P. Mucosal dendritic cells in allergy and immunotherapy. *Allergy*. 2011;95:22-4.
135. Wang Z, Li W, Chen H, Zhang W. Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma. *Journal of Huazhong University of Science and Technology Medical Science*. June 2011;31(3):376-8.
136. Ciprandi G, De Amici M, Marseglia GL. Serum IL-9 levels and sublingual immunotherapy: preliminary report. *Journal of Biological Regulators and Homeostatic Agents*. 2011;25(2):295-7.
137. Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. *Immunology and Allergy Clinics of North America*. 2011;31(2):191-209.
138. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. *Allergy*. 2011;66(6):733-9.
139. Angelini F, Pacciani V, Corrente S, Silenzi R, Di Pede A, Polito A, et al. Dendritic cells modification during sublingual immunotherapy in children with allergic symptoms to house dust mites. *World Journal of Pediatrics*. 2011;7(1):24-30.
140. Piconi S, Trabattoni D, Rainone V, Borgonovo L, Passerini S, Rizzardini G, et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. *Journal of Immunology*. 2010;185(12):7723-30.
141. Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance. *Clinical and Experimental Allergy*. 2010;40(6):922-32.
142. Dahl R, Kapp A, Colombo G, de Monchy J, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. *Journal of Allergy and Clinical Immunology*. 2008;121(2):512-518.
143. Incorvaia C, Frati F, Puccinelli P, Marcucci F, Di Cara G, Sensi L, et al. Effects of sublingual immunotherapy on allergic inflammation. *Inflammation & Allergy Drug Targets*. 2008; 7:167-172.
144. Burastero, et al. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. *Annals of Allergy, Asthma & Immunology*. 2008;100:343-349.
145. Bohle B, Kinaciyan T, Gersymayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. *Journal of Allergy and Clinical Immunology*. 2007;120:707-713.
146. Ciprandi G, Cirillo I, Tosca M, Marseglia G, Fenoglio D. Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: Preliminary results. *Allergy and Asthma Proceedings*. 2007;28(5):574-577.
147. Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual Immunotherapy in sensitized Mice. *Annals of Allergy, Asthma & Immunology*. 2007 Apr;98(4):3266-72.
148. Akdis M, Akdis C. Mechanisms of allergen-specific immunotherapy. *Journal of Allergy and Clinical Immunology*. 2007;119(4):780-791.



149. Bahceciler N, et al. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. *Current Medical Chemistry*. 2007;14:265-269.
150. Ciprandi G, et al. Sublingual immunotherapy: An update on immunologica and functional effects. *Allergy and Asthma Proceedings*. 2007;28(1):40-43.
151. Frati F, et al. Mucosal immunization application to allergic disease: Sublingual immunotherapy. *Allergy and Asthma Proceedings*. 2007;28(1):35-39.
152. Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. *Vaccine*. 2007;25(5):957-964.
153. Savolainen J, et al. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. *Allergy*. 2006;61:1184-1190.
154. Akdis C, et al. Immunological mechanisms of sublingual immunotherapy. *Allergy*. 2006;61:11.
155. Ciprandi G, et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: Preliminary reports. *International Immunopharmacology*. 2006;6:1370-1373.
156. Jutel M, et al. Mechanisms of allergen specific immunotherapy – T-cell tolerance and more. *Allergy*. 2006;61:796-807.
157. Malling H, et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. *Journal of Investigative Allergology and Clinical Immunology*. 2006;16(3):162-168.
158. Cosmi L, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- $\gamma$ -and interleukin-10-production. *Clinical and Experimental Allergy*. 2006;36:261-272.
159. Ciprandi G, et al. Allergen-specific immunotherapy: An update on immunological mechanisms of action. *Monaldi Archives for Chest Disease*. 2006;65(1):34-37.
160. Ciprandi G, et al. Sublingual immunotherapy and regulatory T-cells. *Allergy*. 2006;61:511-513.
161. Dehlink E, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. *Clinical and Experimental Allergy*. 2006;36:32-39.
162. Moingeon P, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. *Allergy*. 2006;61:151-165.
163. Omata N, et al. Ovalbumin-specific IgE modulates ovalbumin-specific T-cell response after repetitive oral antigen administration. *Journal of Allergy and Clinical Immunology*. 2005 Apr;116(4):822-7.
164. Ciprandi G., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: A preliminary report. *Annals of Allergy, Asthma & Immunology*. 2005;95(1):38-44.
165. Jan de Heer H, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. *Journal of Experimental Medicine*. 2004;200(1):89-98.
166. Arikian C, et al. BCG-induced IL-12 did not improve parameters in asthmatic children treated w/sublingual immunotherapy. *Clinical and Experimental Allergy*. 2004;34:398-405.
167. Reich M, et al. Nonspecific plasma proteins during sublingual immunotherapy. Local Immunotherapy in Allergy. *Chemical Immunology*. 2003;82:99-108.
168. Bagnasco M, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. *Clinical and Experimental Allergy*. 2001;31:54-60.
169. Marcucci F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): Safety and immunologic implications. *Allergy*. 2001;56:1091-1095.
170. Markert, U.R. Preliminary analysis of clinical parameters, plasma proteins and T cell functions of allergic patients after up to 3 years sublingual immunotherapy. Abstract presented October 2000 IACAI conference.

171. Fanta C, et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. *International Archives of Allergy and Immunology*. 1999;120:218-224.
172. Yuksel H, et al. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. *Journal of Investigative Allergology and Clinical Immunology*. 1999;9(5):305-313.
173. Bagnasco M, et al. Absorption and distribution kinetics of the major Parietaria allergen administered by noninjectable routes to healthy human beings. *Journal of Allergy and Clinical Immunology*. 1997Jul;100:13-18.
174. Giannarini L. Decrease of allergen-specific T cell response induced by local nasal immunotherapy. *Clinical and Experimental Allergy*. 1998;28:547-551.

## 5) Safety, Quality-of-Life and Adherence Related Studies

1. Arasi S, Pajno G, Panasiti I, et al. Allergen immunotherapy in children with respiratory allergic diseases. *Minerva Pediatrica*. 2020 July 29. doi: 10.23736/S0026-4946.20.05959-9
2. Blome C, Hadler M, Karagiannis E, et al. Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study. *Advances in Therapy*. 2020 April 28; 37(6). doi: 10.1007/s12325-020-01345-7
3. Chen H, Chen Y, Lin B, et al. Efficacy and adherence of sublingual immunotherapy in patients aged 60 to 75 years old with house dust mite-induced allergic rhinitis. *American Journal of Otolaryngology*. 2020 August; 41(4). doi: 10.1016/j.amjoto.2020.102538
4. Giudice M, Licari A, Brambilla I, et al. Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View. *Children*. 2020 June 2; 7(6). doi: 10.3390/children7060058
5. Janssens N, Ouwerkerk L, Wijk R, et al. Acute systemic reactions to sublingual immunotherapy for house dust mite. *European Journal of Allergy and Clinical Immunology*. 2020 May 25. doi: 10.1111/all.14417
6. Jin M, Zhang L, Zhou G, et al. The effect of the standard length of the first prescription on the adherence to sublingual immunotherapy for patients with allergic rhinitis. *International Forum of Allergy and Rhinology*. 2020 June; 10(6). doi: 10.1002/alr.22553
7. Kim J, Rhee C, Cho S, et al. House Dust Mite Sublingual Immunotherapy in Children Versus Adults With Allergic Rhinitis. *American Journal of Rhinology and Allergy*. 2020 June 13. doi: 10.1177/1945892420931713
8. Kim J, Rhee C, Mun S, et al. Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy. *The Laryngoscope*. 2020 June 20. doi: 10.1002/lary.28762
9. Liu W, Zeng Q, Yan S, et al. Risk Factors for Safety of Allergen-Specific Sublingual Immunotherapy in Children with Allergic Rhinitis. *International Archives of Allergy and Immunology*. 2020 September 16. doi: 10.1159/000508523
10. Mahler V, Mentzer D, Bonertz A, et al. Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation - summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019. *Clinical and Translational Allergy*. 2020 June 29; 10(28). doi: 10.1186/s13601-020-00327-w
11. Novakova S. Determinants and Factors of Satisfaction with Sublingual Immunotherapy in Patients with Allergic Rhinitis. *Folia Medica*. 2020 June 30; 62(2). doi: 10.3897/folmed.62.e47000
12. Smith D, Coop C, Freeman T. B-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile? *Current Opinion in Allergy and Clinical Immunology*. 2020 August; 20(4). doi: 10.1097/ACI.0000000000000657
13. Vogelberg C, Bruggenjurgen B, Richter H, et al. Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma. *Patient Preference and Adherence*. 2020 May 13. doi: 10.2147/PPA.S242957
14. Carlo C, Jessica C, Carla M, et al. Allergen-specific immunotherapy for inhalant allergens in children. *Current Pediatric Reviews*. 2019 Oct 20. doi: 10.2174/1573396315666191021104003

15. Cox L. Approach to Patients with Allergic Rhinitis: Testing and Treatment. *Medical Clinics of North America*. 2020 January; 104(1). doi: 10.1016/j.mcna.2019.09.001
16. Huang Y, Wang C, Lin X, et al. Association between component-resolved diagnosis of house dust mite and efficacy of allergen immunotherapy in allergic rhinitis patients. *Clinical and Translational Allergy*. 2019 Dec 19; 9(64). doi: 10.1186/s13601-019-0305-4
17. Knol E, de Jong N, Ulfman L, et al. Management of Cow's Milk Allergy from an Immunological Perspective: What Are the Options? *Nutrients*. 2019 Oct 22; 11(11). doi: 10.3390/nu11112734
18. Bernstein D, Epstein T. Safety of Allergen Immunotherapy in North America From 2008-2017: Lessons Learned From the ACAAI/AAAAI National Surveillance Study of Adverse Reactions to Allergen Immunotherapy. *Allergy and Asthma Proceedings*. 2020 Mar 1; 41(2). doi: 10.2500/aap.2020.41.200001
19. Jim M, Zhang L, Zhou G, et al. The effect of the standard length of the first prescription on the adherence to sublingual immunotherapy for patients with allergic rhinitis. *International Forum of Allergy & Rhinology*. 2020 Mar 29. doi: 10.1002/alr.22553
20. Compalati E, Incorvaia C, Urbano S, et al. The Safety of Carbamylated Monomeric Allergoids for Sublingual Immunotherapy. Data From a Pharmacovigilance Study. *Immunotherapy*. 2020 Feb; 12(3). doi: 10.2217/imt-2019-0095
21. Cafone J, Capucilli P, Hill DA, et al. Eosinophilic esophagitis during sublingual and oral allergen immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2019 Aug; 19(4). doi: 10.1097/ACI.0000000000000537
22. Cuesta-Herranz J, Laguna JJ, Mielgo R, et al. Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA). *European Annals of Allergy and Clinical Immunology*. 2019 Sep 16; 51(5). doi: 10.23822/EurAnnACI.1764-1489.104
23. Imanaka T, Sato I, Kawasaki Y, et al. An analysis of factors associated with compliance and dropout of sublingual immunotherapy on Japanese cedar pollinosis patients. *International Forum of Allergy & Rhinology*. 2019 Jun; 9(6). doi: 10.1002/alr.22308
24. Kikkawa S, Kamijo A, Nakagome K, et al. Predictors of adherence to sublingual immunotherapy for Japanese cedar pollinosis: a prospective analysis. *Asian Pacific Journal of Allergy and Immunology*. 2019 Jul 16. doi: 10.12932/AP-200219-0499
25. Kikkawa S, Nakagome K, Kobayashi T, et al. Sublingual Immunotherapy for Japanese Cedar Pollinosis Attenuates Asthma Exacerbation. *Asthma, Allergy & Immunology Research*. 2019 May; 11(3). doi: 10.4168/air.2019.11.3.438
26. Penagos M, Durham SR. Duration of allergen immunotherapy for inhalant allergy. *Current Opinion in Allergy and Clinical Immunology*. 2019 Aug 28. doi: 10.1097/ACI.0000000000000585
27. Pitsios C, Tsoumani M, Bilò MB, et al. Contraindications to immunotherapy: a global approach. *Clinical and Translational Allergy*. 2019 Sep 11; 9(45). doi: 10.1186/s13601-019-0285-4
28. Raskopf E, Allekotte S, Compalati E, et al. Dose escalation using carbamylated monomeric tree pollen drops is well tolerated in patients with allergic rhinoconjunctivitis and points towards clinical effects. *Allergy*. 2019 May 20. doi: 10.1111/all.13872
29. Zhang YZq, Luo J, Wang ZH, et al. Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. *American Journal of Otolaryngology*. 2019 Sep; 40(5). doi: 10.1016/j.amjoto.2019.07.010
30. Salem L, Dao VA, Shah-Hosseini K, et al. Impaired sports performance of athletes suffering from pollen-induced allergic rhinitis: a cross-sectional, observational survey in German athletes. *The Journal of Sports Medicine and Physical Fitness*. 2019 April; 59(4). doi: 10.23736/S0022-4707.18.08556-0
31. Stone B, Charap E, Black H. Understanding Patient Experiences with Allergen Immunotherapy: "Living with Allergies Study." *Annals of Allergy, Asthma & Immunology*. 2019 Mar 20. doi: 10.1016/j.anai.2019.03.009

32. Yu W, Mao L, Pan Q, et al. Efficacy of Sublingual Administration of Dermatophagoides Farinae Drops for Treatment of Pediatric Allergic Rhinitis Accompanied by Adenoid Hypertrophy and Improvement of Immune Function. *Medical Science Monitor*. 2019 Jan 1; 25. doi: 10.12659/MSM.911982
33. Ashkanani F, Nader Al Duhirat EE, Al Tamimi Z, et al. Quality of life improvement after sublingual immunotherapy for allergy rhinitis. *Journal of Otolaryngology – ENT Research*. 2017; 9(2). doi: 10.15406/joentr.2017.09.00281.
34. Ferrando M, Racca F, Madeira L, et al. A critical appraisal on AIT in childhood asthma. *Clinical and Molecular Allergy*. 2018 Mar 6; 16(6). doi: 10.1186/s12948-018-0085-8.
35. Molnar V, Nagy A, Tamasi L, et al. From genomes to diaries: a 3-year prospective, real-life study of ragweed-specific sublingual immunotherapy. *Immunotherapy*. 2017 Nov; 9(15). doi: 10.2217/imt-2017-0093.
36. Kiykim A, Mumcu G, Ogulur I, et al. Could sublingual immunotherapy affect oral health in children with asthma and/or allergic rhinitis sensitized to house dust mite? *International Archives of Allergy and Immunology*. 2017;174(1):52-56. doi: 10.1159/000480082.
37. Wang T, Li Y, Wang F, et al. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. *International Forum of Allergy & Rhinology*. 2017 Apr;7(4):389-392. doi: 10.1002/alr.21909.
38. Novakova SM, Staevska MT, Novakova PI, et al. Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life. *Health and Quality of Life Outcomes*. 2017 Sep 29;15(1):189. doi: 10.1186/s12955-017-0764-z.
39. Juel J. Tinnitus after administration of sublingual immunotherapy. *SAGE Open Medical Case Reports*. 2017 Feb 20. doi: 10.1177/2050313X17713150.
40. Malet A, Azpeitia A, Gutierrez D, et al. Comprehensive study of patients' compliance with sublingual immunotherapy in house dust mite perennial allergic rhinitis. *Advances in Therapy*. 2016 June 16. doi: 10.1007/s12325-016-0347-0.
41. Portnoy J, Cox LS. Is the benefit from prescribing epinephrine autoinjectors for sublingual immunotherapy worth the cost? Lessons learned from clinical trials. *American Academy of Allergy, Asthma & Immunology: Editorial*. 2016 Nov 13. doi: 10.1016/j.jaip.2016.11.008.
42. Passalacqua G, Nowak-Wegrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. *J Allergy Clin Immunol Pract*. 2017 Jan - Feb;5(1):13-21. doi: 10.1016/j.jaip.2016.06.020. Epub 2016 Aug 12.
43. Epstein TG, Calabria C, Cox LS, et al. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. *Clinical Commentary Review*. 2016 Nov 1. doi: 10.1016/j.jaip.2016.09.017.
44. Rodriguez Del Rio P, Vidal C, Just J, et al. The European survey on adverse systematic reactions in allergen immunotherapy (EASSI): A paediatric assessment. *Pediatric Allergy and Immunology*. 2017 Feb; 28(1): 60-70. doi: 10.1111/pai.12660.
45. Berstein DI, Bardelas JA Jr., Svanholm Fogh B, et al. A practical guide to the sublingual immunotherapy tablet adverse event profile: Implications for clinical practice. *Postgraduate Medicine*. 2017 Mar 22: 1-8. doi: 10.1080/00325481.2017.1302306.
46. Tam HH, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. *Allergy*. 2016 Sep;71(9):1345-56. doi: 10.1111/all.12932.
47. Moral A, Moreno V, Girón F, et al. Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy. *Journal of Asthma and Allergy*. 2016 Jun 29;9:129-33. doi: 10.2147/JAA.S107830.
48. Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults with Allergic Asthma: A Randomized Clinical Trial. *JAMA*. 2016 Apr 26;315(16):1715-25. doi: 10.1001/jama.2016.3964.
49. Roux M, Devillier P, Yang WH, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. *Journal of Allergy and Clinical Immunology*. 2016 Aug;138(2):451-458. doi: 10.1016/j.jaci.2016.03.039.

50. Maina E, Cox E. A double blind, randomized, placebo controlled trial of the efficacy, quality of life and safety of food allergen-specific sublingual immunotherapy in client owned dogs with adverse food reactions: a small pilot study. *Veterinary Dermatology*. 2016 Oct;27(5):361-e91. doi: 10.1111/vde.12358.
51. Lemberg ML, Eberle P, Shah-Hosseini K. Importance of Quality of Life for Adherence to Sublingual Immunotherapy. *BioMed Research International*. 2016;5186765. doi: 10.1155/2016/5186765.
52. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 2016 Aug 10. pii: S0091-6749(16)30783-7. doi: 10.1016/j.jaci.2016.06.044.
53. Scholz FM, Burrows AK, Muse R. First report of angio-oedema subsequent to the administration of allergen specific sublingual immunotherapy for the management of equine hypersensitivity dermatitis. *Veterinary Dermatology*. 2016 Oct;27(5):439-e115. doi: 10.1111/vde.12349.
54. Béné J, Ley D, Roboubi R, Gottrand F, Gautier S. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. *Annals of Allergy, Asthma & Immunology*. 2016 Apr 5. pii: S1081-1206(16)30055-2. doi: 10.1016/j.ana.2016.03.017.
55. Chirumbolo S. Commentary: Sublingual allergen immunotherapy in HIV-positive patients. *Frontiers in Immunology*. 2016 Mar 31;7:132. doi: 10.3389/fimmu.2016.00132. eCollection 2016.
56. Wang C, Wang K, Liu S, Qin X, Chen K, Zhang T. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. *International Journal of Pediatric Otorhinolaryngology*. 2016 Feb;81:15-20. doi: 10.1016/j.ijporl.2015.12.001. Epub 2015 Dec 13.
57. Incorvaia C, Mauro M, Leo G, Ridolo E. Adherence to sublingual immunotherapy. *Current Allergy and Asthma Reports*. 2016 Jan;16(2):12. doi: 10.1007/s11882-015-0586-1.
58. Henmar H, Frisenette SM, Grosch K, et al. Fractionation of source materials leads to a high reproducibility of the SQ house dust mite SLIT-tablets. *International Archives of Allergy and Immunology*. 2016;169(1):23-32. doi: 10.1159/000444016. Epub 2016 Mar 9.
59. Leader BA, Rotella M, Stillman L, DelGaudio JM, Patel ZM, Wise SK. Immunotherapy compliance: Comparison of subcutaneous versus sublingual immunotherapy. *International Forum of Allergy & Rhinology*. 2015 Dec 31. doi: 10.1002/alr.21699.
60. Yuta, A, Ogawa Y, Suzuki Y, et al. Clinical efficacy of sublingual immunotherapy for Japanese cedar pollinosis in the first follow-up year. *Japanese Journal of Allergology*. 2015 Dec;64(10):1323-1333. doi: 10.15036/areru.64.1323.
61. Sahadevan A, Cusack R, Lane SJ. Safety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthma. *Irish Medical Journal*. 2015 Nov-Dec;108(10):304-7.
62. Oykman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy. *Allergy, Asthma & Clinical Immunology*. 2015 Nov 10;11:31. doi: 10.1186/s13223-015-0096-7. eCollection 2015.
63. Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen-induced allergic rhinitis - Differences between subcutaneous and sublingual treatment. *Basic & Clinical Pharmacology & Toxicology*. 2015 Aug;117(2):73-84. doi: 10.1111/bcpt.12416. Epub 2015 Jun 3.
64. Iemoli E, et al. Sublingual allergen immunotherapy in HIV positive patients. *Allergy*. 2015 Jul 30. doi: 10.1111/all.12713.
65. Landi M, Meglio P, Praitano E, Lombardi C, Passalacqua G, Canonica GW. The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. *Clinical and Molecular Allergy*. 2015 Jul 24;13(1):15. doi: 10.1186/s12948-015-0021-0. eCollection 2015.
66. Makatsori M, et al. Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. *Clinical Translational Allergy*. 2015 Apr 27;5:17. doi: 10.1186/s13601-015-0060-0. eCollection 2015.
67. Bender BG. Motivating patient adherence to allergic rhinitis treatments. *Current Allergy and Asthma Reports*. 2015 Mar;15(3):10. doi: 10.1007/s11882-014-0507-8.
68. Sandrini A, Rolland JM, O'Hehir RE. Current developments for improving efficacy of allergy vaccines. *Expert Review of Vaccines*. 2015;14(8):1073-87. doi: 10.1586/14760584.2015.1050385. Epub 2015 May 26.



69. Katotomichelakis M, et al. Predictors of quality of life improvement in allergic rhinitis patients after sublingual immunotherapy. *Annals of Otolaryngology, Rhinology and Laryngology*. 2015 Jun;124(6):430-6. doi: 10.1177/0003489414565001. Epub 2014 Dec 23.
70. Occasi F, De Castro G, Zicari AM, Indinnimeo L, Tancredi G, Duse M. Sublingual immunotherapy in children and its potential beneficial collateral effect on respiratory tract infections. *Current Medical Research and Opinion*. 2015 May;31(5):939-41. doi: 10.1185/03007995.2015.1027182. Epub 2015 Mar 31.
71. Burks AW, et al. Sublingual immunotherapy for peanut allergy: Long-term follow-up of randomized multicenter trial. *Journal of Allergy and Clinical Immunology*. 2015 May;135(5):1240-1248.e3. doi: 10.1016/j.jaci.2014.12.1917. Epub 2015 Feb 3.
72. Özdemir Ö. The local and system reactions due to sublingual immunotherapy: is anaphylaxis associated with therapy? *Iranian Journal of Allergy, Asthma and Immunology*. 2015 Apr;14(2):228-230.
73. Mitobe Y, Yokomoto Y, Ohashi-Doi K. Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy. *Regulatory Toxicology and Pharmacology*. 2015 Apr;71(3):529-40. doi: 10.1016/j.yrtph.2015.02.009. Epub 2015 Feb 17.
74. Hsiao KC, Smart J. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. *Pediatric Allergy and Immunology*. 2015 Feb;26(1):92. doi: 10.1111/pai.12329.
75. Albin S, Nowak-Wegrzyn A. Potential treatments for food allergy. *Immunology and Allergy Clinics of North America*. 2015 Feb;35(1):77-100. doi: 10.1016/j.iac.2014.09.011. Epub 2014 Nov 21.
76. McGowan EC, Wood RA. Sublingual (SLIT) versus oral immunotherapy (OIT) for food allergy. *Current Allergy and Asthma Reports*. 2014 Dec;14(12):486. doi: 10.1007/s11882-014-0486-9.
77. Lucendo AJ, Arias Á, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. *Annals of Allergy, Asthma & Immunology*. 2014 Dec;113(6):624-9. doi: 10.1016/j.anai.2014.08.004. Epub 2014 Sep 10.
78. Le UH, Burks AW. Oral and sublingual immunotherapy for food allergy. *The World Allergy Organization Journal*. 2014 Dec 8;7(1):35. doi: 10.1186/1939-4551-7-35. eCollection 2014.
79. Hsieh FH. Oral food immunotherapy and iatrogenic eosinophilic esophagitis: an acceptable level of risk? *Annals of Allergy, Asthma & Immunology*. 2014 Dec;113(6):581-2. doi: 10.1016/j.anai.2014.09.008.
80. Szépfalusi Z, et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and protolerogenic effects. *Pediatric Allergy and Immunology*. 2014 Dec;25(8):788-95. doi: 10.1111/pai.12310.
81. Romantsik O, Bruschetti M, Tosca MA, Zappettini S, Della Casa Alberighi O, Calevo MG. Oral and sublingual immunotherapy for egg allergy. *The Cochrane Database of Systematic Reviews*. 2014 Nov 18;11:CD010638. doi: 10.1002/14651858.CD010638.pub2
82. Vazquez-Ortiz M, Alvaro M, Piquer M, Giner MT, Dominguez O, Lozano J, Jiménez-Feijoo R, Cambra FJ, Plaza AM. Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers. *Annals of Allergy, Asthma & Immunology*. 2014 Oct;113(4):482-4. doi: 10.1016/j.anai.2014.07.010. Epub 2014 Aug 19.
83. Li P, Li Q, Huang Z, Chen W., Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. *International Forum of Allergy & Rhinology*. 2014 Oct;4(10):796-801. doi:10.1002/air.21397. Epub 2014 Aug 21.
84. Makatsori M, Calderón MA. Anaphylaxis: still a ghost behind allergen immunotherapy. *Current Opinion Allergy & Clinical Immunology*. 2014 Aug;14(4):316-22. Doi:10.1097/ACU.0000000000000075.
85. Calderón MA, et al. An EAACI “European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)”: the methodology. *Clinical and Translational Allergy*. 2014 Jul 21;4:22. Doi:10.1186/2045-7022. eCollection 2014.
86. Sánchez J. Adherence to allergen immunotherapy improves when patients choose the route of administration: Subcutaneous or sublingual. *Allergologia et Immunopathologia*. 2014 Sep 5. pii:S0301-0546(14)00128-1. doi:10.1016/j.aller.2014.04.011.

87. Goh A, et al. Gum pigmentation: an unusual adverse effect of sublingual immunotherapy. *Asia Pacific Allergy*. 2014 Jul;4(3):177-9. doi:10.5415/apallergy.2014.4.2.177. Epub 2014 Jul 29.
88. Nolte H, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. *Annals of Allergy, Asthma & Immunology*. 2014 Jul;113(1):93-100.e3. doi:10.1016/j.anai.2014.04.018. Epub 2014 May 14.
89. Frati F, et al. Safety of sublingual immunotherapy in children. *Expert Opinion on Drug Safety*. 2014 Jul;13(7):947-53. Doi:10.1517/14740338.2014.918949. Epub 2014 May 12.
90. Antico A. Long-Term-Adherence to Sublingual Therapy: Literature Review and Suggestions for Management Strategies Based On Patients' Needs and Preferences. *Clinical & Experimental Allergy*. 2014 Jun 28. doi:10.1111/cea.12362.
91. Bergmann KC, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. *Journal of Allergy & Clinical Immunology*. 2014 Jun;133(6):1608-14.e6. doi:10.1016/j.jaci.2014.11.012. Epub 2013 Dec 31.
92. Makatsori M, et al. Dropouts in sublingual allergen immunotherapy trials – systematic review. *Allergy*. 2014 May;69(5):571-80. Doi:10.1111/all.12385. Epub 2014 Mar 27.
93. Scalla G, Ciccarelli A, Calabró C. Adverse reaction to sublingual Parietaria vaccine following an ultra-rush induction. *European Annals of Allergy and Clinical Immunology*. 2014 May;46(3):116-8.
94. Klimek L, et al. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. *Clinical and Translational Allergy*. 2014, 4:23.
95. Laury AM, Schlosser RJ, Wise SK. Sublingual immunotherapy and quality of life. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2013 Jun;21(3):252-255.
96. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? *Expert Review of Clinical Immunology*. 2013 Oct;9(10):937-947.
97. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. *Current Opinion in Allergy and Clinical Immunology*. 2013 Dec;13(6):656-662.
98. Ravi A, Rank MA. Reducing and managing systemic reactions to immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2013 Dec;13(6):651-655.
99. Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. *Annals of Allergy, Asthma & Immunology*. 2014 Feb;112(2):146-153.
100. Shao J, Cui YX, Zheng YF, Peng HF, Zheng ZL, Chen JY, Li Q, Cao LF. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. *American Journal of Rhinology & Allergy*. 2014 Mar;28(2):131-139.
101. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 2013 Aug;132(2):353-560.
102. Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. *The Journal of Allergy and Clinical Immunology: In Practice*. 2014 March – April;2(2):152-155.
103. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. *Allergy*. 2013 Sep;68(9):1193-5.
104. Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Soulie S, Zeldin RK. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. *Clinical Experimental Allergy*. 2013;43(5):568-77.
105. Vovlolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. *Allergologia et Immunopathologia*. 2013 Jul-Aug;41(4):279-81. doi: 10.1016/j.aller.2012.05.012. Epub 2012 Dec 17.

106. Mailhol C, Didier A. Allergen-specific immunotherapy in the treatment of pollen allergy. *Revue des Maladies Respiratoires*. 2013;30(2):142-51.
107. Mun SJ, Shin JM, Han DH, Kim JW, Kim DY, Lee CH, Min YG, Rhee CS. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis. *International Forum of Allergy & Rhinology*. 2013;3(3):177-83.
108. Koberlein J, Mosges R. Oralair®: a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. *Immunotherapy*. 2013;5(1):13-21.
109. Balaji R, Parasuramalu BG, Chandregowda BV, Gangaboraiah. Safety, tolerability, and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis. *Allergologia et Immunopathologia*. 2014 May-Jun;42(3):216-23. doi: 10.1016/j.aller.2012.12.005. Epub 2013 Mar 5.
110. Liu LL, Guo DD, Liang QX, Ding S, Chen JY, Wu B, Li Q. Sublingual immunotherapy for experimental allergic conjunctivitis in a murine model induced by dermatophagoides farinae allergen. *International Archives of Allergy and Immunology*. 2013;161(3):205-12. doi: 10.1159/000346335. Epub 2013 Mar 15.
111. Tourdot S, Airouche S, Berjont N, Moussu H, Betbeder D, Nony E, Bordas-Le Floch V, Baron-Bodo V, Mascarell L, Moingeon P. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. *Vaccine*. 2013 May 28;31(23):2628-37. doi: 10.1016/j.vaccine.2013.03.041.
112. Cui L, Wang ZN, Xu ZQ, Xia ZF. Efficacy and safety of sublingual immunotherapy of allergic rhinitis in children between 4 and 5 years age group and 11 and 12 years age group. *Zhonghua Er Bi Yan Hou Tou Jing wai Ke Za Zhi*. 2013;48(1):17-21.
113. Chiriac AM, Demoly P. Respiratory allergies. *La Presse Médicale*. 2013 Apr;42(4 Pt 1):395-404. doi: 10.1016/j.lpm.2012.06.005. Epub 2012 Aug 9.
114. Park IH, Hong SM, Lee HM. Efficacy and safety of sublingual immunotherapy in Asian children. *International Journal of Pediatric Otorhinolaryngology*. 2012;76(12):1761-6.
115. Sieber J, Neis M, Brehler R, Folster-Holst R, Kapp A, Klimek L, Merk H. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. *Expert Opinions on Drug Safety*. 2012;11(1):7-13.
116. Calderón MA, Simons FE, Malling H, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. *Allergy*. 2012;67(3):302-11.
117. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. *Journal of Allergy and Clinical Immunology*. 2012;129(3):717-725.
118. Scheinmann P, Pham Thi N, Karila C, de Blic J. Allergic march in children, from rhinitis to asthma; management, indication of immunotherapy. *Archives of Pediatrics*. 2012;19(3):330-4.
119. Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, efficacy, and mode of action. *Immunotherapy*. 2012;4(2):201-12.
120. Vichyanond P, Pensrichon R, Kurasirikul S. Progress in the management of childhood asthma. *Asia Pacific Allergy*. 2012;2(1):15-25.
121. Shaikh WA, Shaika SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. *Allergy*. 2012;67(6):741-3.
122. Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy; a retrospective, observational study. *International Journal of Immunopathology and Pharmacology*. 2012;25(1):193-206.
123. Woody J, Wise SK, Koeppe S, Schlosser RJ. Clinical improvement after escalation for sublingual immunotherapy (SLIT). *Ear, Nose and Throat Journal*. 2011;90(9):16-22.
124. Ciprandi G, Marseglia GL. Safety of sublingual immunotherapy. *Journal of Biological Regulators and Homeostatic Agents*. 2011;25(1):1-6.

125. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. *Clinical and Experimental Allergy*. 2011 Sep;41(9):1247-55.
126. Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M, et al. Sublingual Immunotherapy in Polysensitized Patients: Effect on Quality of Life. *Journal of Investigational Allergology and Clinical Immunology*. 2010;20(4):274-279.
127. Wise S, Woody J., Koepp S, Schlosser R. Quality of life outcomes with sublingual immunotherapy. *American Journal of Otolaryngology*. 2009;30:305-311.
128. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. *Journal of Allergy and Clinical Immunology*. 2009;12 (1):167-173.
129. Windom H., Lockey R. An update on the safety of specific immunotherapy. *Current Opinion in Allergy and Clinical Immunology*. 2008;8:571-576.
130. Rodriguez-Perez N, Ambriz-Moreno MJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. *Annals of Allergy, Asthma, & Immunology*. 2008;101:304-310.
131. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. *Allergy*. 2008 Mar;63(3):374. Epub 2007 Dec 8.
132. Moreno-Ancillo A, Moreno C, Ojeda P, Dominguez C, Barasona MJ, Garcia-Cubillana A, Martin, S. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without up dosing. *Journal of Investigational Allergology & Clinical Immunology*. 2007;17:399-405.
133. Dunsky E, et al. Anaphylaxis to sublingual immunotherapy. *Allergy*. 2006;61:1235-1244.
134. Antico A, et al. Anaphylaxis by latex sublingual immunotherapy. *Allergy*. 2006;61:1236-1237.
135. Larsen T, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy – a phase-I study. *Allergy*. 2006;61:1173-1176.
136. Frati F, et al. Dose dependence of efficacy but not of safety in sublingual immunotherapy. *Monaldi Archives of Chest Disease*. 2006;65(1):38-40.
137. Kleine-Tebbe J, et al. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: A randomized, placebo-controlled trial. *Allergy*. 2006;61:181-184.
138. Tripodi S, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. *International Archives of Allergy and Immunology*. 2006;139:149-152.
139. Di Rienzo V, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. *Clinical and Experimental Allergy*. 2005;35:560-564.
140. Scolozzi R. Tolerability of the allergoid sublingual immunotherapy with a monomeric allergoid in patients with allergic rhinitis and/or asthma. *Journal of Allergy and Clinical Immunology*. 2004;113(2):(abs).
141. Silvestris A. Tolerability of sublingual immunotherapy with monomeric allergoid in allergic sensitizations to house dust mite, Parietaria and grass. *Journal of Allergy and Clinical Immunology*. 2004;114(2):(abs).
142. Grosclaude M, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. *International Archives of Allergy and Immunology*. 2003;129(3):248-253.
143. Hasan H, et al. Short report – evaluation of immunotherapy for seasonal and perennial allergic rhinitis using quality of life questionnaires. *Current Allergy & Clinical Immunology*. 2003; 16(1).
144. Lombardi C, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. *Allergy*. 2001;56:989-992.
145. Lombardi C, et al. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. *Allergy*. 2000;55:677-78.
146. Andre C, et al. Safety of sublingual immunotherapy in children and adults. *International Archives of Allergy and Immunology*. 2000;121:229-234.

147. Madonini E, et al. Safety and efficacy evaluation of sublingual allergen-specific immunotherapy – a retrospective, multicenter study. *International Journal of Immunopathology and Pharmacology*. 2000;13(2):77-81.
148. Di Rienzo V, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. *Allergy*. Vol. 54, pgs. 1110-1113, 1999.
149. Ariano R, et al. Efficacy and safety of oral immunotherapy in respiratory allergy to *Parietaria judaica* pollen. A double-blind study. *Journal of Investigative Allergology and Clinical Immunology*. 1998;8(3):155-160.
150. Feliziani V, et al. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. *Allergologia et Immunopathologia*. 1995;23(5):224-230.

## 6) Other Indications for Treatment (Foods and Chemicals)

1. Bumbacea R, Corcea S, Ali S, et al. Mite allergy and atopic dermatitis: Is there a clear link? (Review). *Experimental and Therapeutic Medicine*. 2020 October; 20(4). doi: 10.3892/etm.2020.9120
2. De Corso E, Lucidi D, Cantone E, et al. Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: a Systematic Review. *Current Allergy and Asthma Reports*. 2020 September 5; 20(11). doi: 10.1007/s11882-020-00967-9
3. Dona D, Suphioglu C. Egg Allergy: Diagnosis and Immunotherapy. *International Journal of Molecular Sciences*. 2020 July 16; 21(14). doi: 10.3390/ijms21145010
4. Giovannini M, Mori F, Barni S, et al. Tailored Sublingual Immunotherapy in a Monosensitized Child with Natural Rubber Latex Allergy. *Pharmacology*. 2020 September 7. doi: 10.1159/000508140
5. Incorvaia C, Pucciarini F, Makri E, et al. Allergen immunotherapy for respiratory allergy: to what extent can the risk of systemic reactions be reduced? *Expert Opinion on Drug Safety*. 2020 May 21; 19(7). doi: 10.1080/14740338.2020.1773788
6. Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. *Drugs and Aging*. 2020 Feb 21; 37(3). doi: 10.1007/s40266-020-00750-5
7. Hardy L, Smeekens J, Kulis M. Biomarkers in Food Allergy Immunotherapy. *Current Allergy and Asthma Reports*. 2019 Dec 4; 19(61). doi: 10.1007/s11882-019-0894-y
8. Baker M, Wang J. Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies. *Current Allergy and Asthma Reports*. 2019 Nov 25. doi: 10.1007/s11882-019-0885-z
9. Tang R. House Dust Mite-Specific Immunotherapy Alters the Natural Course of Atopic March. *Journal of the Chinese Medical Association*. Feb 2020; 83(2). doi: 10.1097/JCMA.0000000000000231
10. Smith D, Freeman T. Sublingual Immunotherapy for Other Indications: Venom Large Local, Latex, Atopic Dermatitis, and Food. *Immunology and Allergy Clinics of North America*. Feb 2020; 40(1). doi: 10.1016/j.iac.2019.09.011
11. Costa C, Coimbra A, Vitor A, et al. Food allergy - from food avoidance to active treatment. *Scandinavian Journal of Immunology*. 2019 Sep 4. doi: 10.1111/sji.12824
12. Duca B, Patel N, Turner P. GRADE-ing the Benefit/Risk Equation in Food Immunotherapy. *Current Allergy and Asthma Reports*. 2019 April 25; 19(30). <https://doi.org/10.1007/s11882-019-0862-6>
13. Guttman-Yassky E, Zhou L, Krueger JG. The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions. *The Journal of Allergy and Clinical Immunology*. 2019 Aug; 144(2). doi: 10.1016/j.jaci.2019.03.021
14. Konstantinou GN, Kaitalidou E, Skoulikaris N. Sublingual immunotherapy and omalizumab cured allergic chronic rhinosinusitis and asthma: coincidence or synergistic effect? *Annals of Allergy, Asthma & Immunology*. 2019 Aug 21. doi: 10.1016/j.ana.2019.08.010
15. Linhart B, Freidl R, Elisyutina O, et al. Molecular Approaches for Diagnosis, Therapy and Prevention of Cow's Milk Allergy. *Nutrients*. 2019 June 29; 11(7). doi: 10.3390/nu11071492



16. Licari A, Manti S, Marseglia A, et al. Food Allergies: Current and Future Treatments. *Medicina*. 2019 May 1; 55(5). doi: 10.3390/medicina55050120
17. Sayed KM, Kamel AG, Ali AH. One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2019 Sep; 257(9). doi: 10.1007/s00417-019-04389-w
18. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: An update. *Experimental and Therapeutic Medicine*. 2019 Feb; 17(2).
19. Li JH, Yang LH, Chen Y, et al. Acupuncture as an add-on therapy to sublingual allergen-specific immunotherapy for patients with allergic rhinitis. *Medicine (Baltimore)*. 2019 Jan; 98(1). doi: 10.1097/MD.0000000000001394
20. Maciag MC, Phipatanakul W. Preventing the development of asthma: stopping the allergic march. *Current Opinion in Allergy and Clinical Immunology*. 2019 April; 19(2). doi: 10.1097/ACI.0000000000000501
21. Pitsios C, Dietis N. Ways to increase adherence to allergen immunotherapy. *Current Medical Research and Opinion*. 2018 Sept 20. doi: 10.1080/03007995.2018.1552044
22. Yang J, Zhang L, Zhao Z, et al. Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. *International Forum of Allergy and Rhinology*. 2018 May 21. doi: 10.1002/alr.22149.
23. Theodoropoulos D, Michalopoulou A, Cullen N, et al. Neuromodulation in the management of allergic chronic vaginitis. *Reproductive System & Sexual Disorders: Current Research*. 2016; 5(4). doi: 10.4172/2161-038X.1000197.
24. Scurlock A, Jones S. Advances in the approach to the patient with food allergy. *The Journal of Allergy and Clinical Immunology*. 2018 Mar 7. doi: 10.1016/j.jaci.2017.12.1008.
25. Parrish C, Kim E, Bird J. Interventional therapies for the treatment of food allergy. *Immunology and Allergy Clinics of North America*. 2018 Feb; 38(1). doi: 10.1016/j.iac.2017.09.006.
26. Burks A, Sampson H, Plaut M, et al. Treatment for food allergy. *The Journal of Allergy and Clinical Immunology*. 2018 Jan; 141(1). doi: 10.1016/j.jaci.2017.11.004.
27. Incorvaia C, Ridolo E, Mauro M, et al. Allergen immunotherapy for birch-apple syndrome: What do we know? *Immunotherapy*. 2017 Nov; 9(15). doi: 10.2217/imt-2017-0040.
28. Sridharan K, Sivaramakrishnan G. Sublingual immunotherapy in patients with latex allergy: a systematic review and meta-analysis of randomized controlled trials. *The Journal of Dermatological Treatment*. 2017 Nov; 28(7). doi: 10.1080/09546634.2017.1303567.
29. Rachid R, Keet C. Current status and unanswered questions for food allergy treatments. *The Journal of Allergy and Clinical Immunology*. 2018 Mar; 6(2). doi: 10.1016/j.jaip.2017.10.023.
30. El-Qutob D. Shrimp allergy: Beyond avoidance diet. *European Annals of Allergy and Clinical Immunology*. 2017 Nov; 49(6). doi: 10.23822/EurAnnACI.1764-1489.16.
31. Vanitha S, Sayantani B, Wenming Z, et al. New treatment directions in food allergy. *Annals of Allergy, Asthma & Immunology*. 2018 Mar; 120(3). doi: <https://doi.org/10.1016/j.anai.2018.01.004>.
32. Anvari S, Anagnostou K. The nuts and bolts of food immunotherapy: The future of food allergy. *Journal of Pediatrics*. 2018 Apr 4; 5(7). doi: 10.3390/children5040047.
33. Hamad A, Kim E, Burks W, et al. A novel assessment of sustained unresponsiveness (SU) after long term sublingual immunotherapy (SLIT) in peanut allergic children: Results of a 4 year phase II clinical trial. *The Journal of Allergy and Clinical Immunology*. 2018 Feb; 141(2).
34. Luanna Y, Steele P, Hamilton D, et al. Sustained unresponsiveness after sublingual immunotherapy for peanut-allergic children. *The Journal of Allergy and Clinical Immunology*. 2017 Feb; 139(2).
35. Kinaciyan T, Nagl B, Faustmann S, et al. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d I and Bet v I in patients with birch pollen-related apple allergy. *The Journal of Allergy and Clinical Immunology*. 2017 Sep 1. doi: 10.1016/j.jaci.2017.07.036.

36. Andorf S, Borres MP, Block W, et al. Association of clinical reactivity with sensitization to allergen components in multifeed-allergic children. *Journal of Allergy and Clinical Immunology*. 2017 Mar 25. doi: 10.1016/j.jaip.2017.01.016.
37. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. *Allergy*. 2017 Jan 6. doi: 10.1111/all.13124.
38. Hyang-Suk Y, Min-Young Y, Gun-Wook K, et al. Effectiveness of specific sublingual immunotherapy in Korean patients with atopic dermatitis. *Annals of Dermatology*. 2017 Feb 3. doi: 10.5021/ad.2017.29.1.1.
39. Theodoropoulos DS, Stockdale CK, Duquette DR, Morris MS. Inhalant allergy compounding the chronic vaginitis syndrome: Characterization of sensitization patterns, comorbidities and responses to sublingual immunotherapy. *Archives of Gynecology and Obstetrics*. 2016 Sep;294(3):541-8. doi: 10.1007/s00404-016-4081-2. Epub 2016 Apr 4.
40. DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). *Veterinary Dermatology*. 2016 Apr;27(2):82-e24. doi: 10.1111/vde.12284. Epub 2016 Jan 8.
41. Dahl R, Roberts G, de Blic J, et al. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. *Allergy and Asthma Proceedings*. 2016 Mar;37(2):92-104. doi: 10.2500/aap.2016.37.3937. Epub 2016 Jan 21.
42. Moingeon P, Cox L. Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America. *Expert Review of Clinical Immunology*. 2016 Feb 19:1-7. doi:10.1586/1744666X.2016.1147349.
43. Sindher S, Fleischer DM, Spergel JM. Advances in the treatment of food allergy: Sublingual and epicutaneous immunotherapy. *Immunology and Allergy Clinics of North America*. 2016 Feb;36(1):39-54. doi: 10.1016/j.iac.2015.08.008.
44. Barberi S, et al. Allergen immunotherapy and respiratory infections in children: an encouraging experience. *Minerva Pediatrica*. 2018 Feb;70(1):1-4. doi: 10.23736/S0026-4946.16.04394-2. Epub 2015 Nov 25.
45. Vazquez-Ortiz M, Turner PJ. Improving the safety of oral immunotherapy for food allergy. *Pediatric Allergy and Immunology*. 2015 Nov 23. doi: 10.1111/pai.12510.
46. Ras L, de Groot H, Stengs CH, van Weissenbruch R. Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study. *Annals of Allergy, Asthma & Immunology*. 2016 Jan;116(1):52-58.e2. doi: 10.1016/j.anai.2015.10.018. Epub 2015 Nov 17.
47. Melzer JM, Driskill BR, Clenney TL, Gessler EM. Sublingual immunotherapy for allergic fungal sinusitis. *Annals of Otolaryngology, Rhinology & Laryngology*. 2015 Oct;124(10):782-7. doi: 10.1177/0003489415583686. Epub 2015 Apr 22.
48. Burk CM, Kulis M, Leung N, Kim EH, Burks AW, Vickery BP. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy. *Clinical & Experimental Allergy*. 2015 Sep 12. doi: 10.1111/cea.12635.
49. Chhiba KD, Singh AM, Bryce PJ. New developments in immunotherapies for food allergy. *Immunotherapy*. 2015 Aug 7;7(8):913-22. doi: 10.2217/IMT.15.55. Epub 2015 Aug 13.
50. Ludman SW, Boyle RJ. Stinging insect allergy: current perspectives on venom immunotherapy. *Journal of Asthma and Allergy*. 2015 Jul 23;8:75-86. doi: 10.2147/JAA.S62288. eCollection 2015.
51. Chiang D, Berin MC. An examination of clinical and immunologic outcomes in food allergen immunotherapy by route of administration. *Current Allergy and Asthma Reports*. 2015 Jun;15(6):35. doi: 10.1007/s11882-015-0536-y.
52. Meglio P, et al. The oral food desensitization in the Italian allergy centres. *European Annals of Allergy and Clinical Immunology*. 2015 May;47(3):68-76.
53. Fernández-Rivas M. Fruit and vegetable allergy. *Chemical Immunology and Allergy*. 2015;101:162-70. doi: 10.1159/000375469. Epub 2015 May 21.

54. Sato S, Yanagida N, Ebisawa M. Oral immunotherapy and potential treatment. *Chemical Immunology and Allergy*. 2015;101:106-13. doi: 10.1159/000371697. Epub 2015 May 21.
55. Robison RG. Food allergy: Diagnosis, management, & emerging therapies. *Indian Journal of Medical Research*. 2014 Jun;139(6):805-13.
56. Kim EH, Burks W. Oral and sublingual immunotherapy. *Current Treatment Options in Allergy*. 2014 Mar 1;1(1):48-57. doi: 10.1007/s40521-013-0004-7.
57. Gorelik M, et al. Suppression of the immunologic response to peanut during immunotherapy is often transient. *Journal of Allergy and Clinical Immunology*. 2015 May;135(5):1283-92. doi: 10.1016/j.jaci.2014.11.010. Epub 2014 Dec 24.
58. Narisety SD, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. *Journal of Allergy and Clinical Immunology*. 2015 May;135(5):1275-1282.e6. doi: 10.1016/j.jaci.2014.11.005. Epub 2014 Dec 18.
59. Liu M, Burks AW, Green TD. Tree nut allergy: risk factors for development, Mitigation of reaction risk and current efforts in desensitization. *Expert Review of Clinical Immunology*. 2015 May;11(5):673-9. doi: 10.1586/1744666X.2015.1032258. Epub 2015 Mar 31.
60. Kulis M, Wright BL, Jones SM, Burks AW4 Diagnosis, management, and investigational therapies for food allergies. *Gastroenterology*. 2015 May;148(6):1132-42. doi: 10.1053/j.gastro.2015.01.034. Epub 2015 Jan 26.
61. Praticò AD, Leonardi S. Immunotherapy for food allergies: a myth or a reality? *Immunotherapy*. 2015;7(2):147-61. doi: 10.2217/imt.14.115.
62. Greenhawt MJ, Vickery PB. Allergist-reported trends in the practice of food allergen oral immunotherapy. *Journal of Allergy and Clinical Immunology: In Practice*. 2015 Jan-Feb;3(1):33-8. doi: 10.1016/j.jaip.2014.06.023.
63. Bublin M, Breiteneder H. Developing therapies for peanut allergy. *International Archives of Allergy and Immunology*. 2014;165(3):179-94. doi: 10.1159/000369340. Epub 2014 Dec 20.
64. Nowak-Węgrzyn A, Albin S. Oral Immunotherapy for food allergy: mechanisms and role in management. *Clinical & Experimental Allergy*. 2014 Jul 31. doi:10.1111/cea.12382.
65. Arkwright PD, Stafford JC, Sharma V. Atopic dermatitis in children. *Journal of Allergy and Clinical Immunology: In Practice*. 2014 Jul-Aug;2(4):388-95. Doi:10.1016/j.jaip.2014.01.016. Epub 2014 Apr 18.
66. Van Winkle RC, Chang C. The biochemical basis and clinical evidence of food allergy due to lipid transfer proteins: a comprehensive review. *Clinical Reviews in Allergy & Immunology*. 2014 Jun;46(3):211-24. doi:10.1007/s12016-012-8338-7.
67. Berin MC. Future Therapies for IgE-Mediated Food Allergy. *Current Pediatric Reports*. 2014 Jun 1;2(2):119-126.
68. Anagnostou K, Clark A. Peanut immunotherapy. *Clinical and Translational Allergy*. 2014 Sep 25;4:30. doi: 10.1186/2045-7022-4-30. eCollection 2014.
69. Keet CA, Wood RA. Emerging therapies for food allergy. *Journal of Clinical Investigation*. 2014 May 1;124(5):1880-6. doi:10.1172/JCI72061. Epub 2014 May 1.
70. Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Tavassoli M, Hoyte E, O'Riordan G, Blakemore A, Seki S, Hamilton RG, Nadeau KC. Phase I results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. *Journal of Allergy and Asthma Clinical Immunology*. 2014 Feb 20;10(1):7.
71. Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. *Journal of Allergy and Clinical Immunology*. 2014 Feb;133(2):468-75.
72. Greenhawt MJ. Oral and sublingual peanut immunotherapy is not ready for general use. *Allergy and Asthma Proceedings*. 2013 May-Jun;34(3):197-204.
73. Chin SJ, Vickery BP, Kulis MD, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. *Journal of Allergy and Clinical Immunology*. 2013 Aug;132(2):476-47.
74. Wang J, Sampson HA. Oral and sublingual immunotherapy for food allergy. *Asian Pacific Journal of Allergy and Immunology*. 2013 Sep;31(3):198-209.

75. Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow's milk allergy. *Journal of Allergy and Clinical Immunology*. 2013 Sep;132(3):737-739.
76. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. *Journal of Allergy and Clinical Immunology*. 2013 Dec;132(6):1368-74.
77. Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. *Current Opinion in Immunology*. 2013 Dec;25(6):781-787.
78. Nurmatov U, Devereux G, Worth A, Healy L, Sheikh A. Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis. *British Journal of Nutrition*. 2014 Jan 14;111(1):12-22.
79. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: Oral, sublingual and epicutaneous. *Journal of Allergy and Clinical Immunology: In Practice*. 2014 Feb;133(2):318-323.
80. Fleischer DM, Burks AW, Vickery BP, et al. Consortium of Food Allergy Research. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. *Journal of Allergy and Clinical Immunology*. 2013;131(1):119-27.
81. Yang YH, Chiang BL. Novel approaches to food allergy. *Clinical Reviews in Allergy & Immunology*. 2014 Jun;46(3):250-7. doi: 10.1007/s12016-013-8354-2.
82. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink JN. Venom immunotherapy for preventing allergic reactions for insect stings. *Cochrane Database of Systematic Reviews*. 2012;10.
83. Virkud YV, Vickery BP. Advances in immunotherapy for food allergy. *Discover Medical*. 2012;14(76):159-65.
84. Narisety SD, Keet CA. Sublingual vs. oral immunotherapy for food allergy: Identifying the right approach. *Drugs*. 2012;72(15):1977-89.
85. Sánchez-García S, Rodríguez Del Río P, Escudero C, Martínez-Gómez MJ, Ibáñez MD. Possible eosinophilic esophagitis induced by milk oral immunotherapy. *Journal of Allergy and Clinical Immunology*. 2012 Apr;129(4):1155-7.
86. Nettis E, Delle Donne P, Di Leo E, Fantini P, Passalacqua G, Bernardini R, Canonica GW, Ferrannini A, Vacca A. Latex immunotherapy: state of the art. *Annals in Allergy, Asthma, and Immunology*. 2012;109(3):160-5.
87. McWilliams L, Moussallem T, Burks W. Future therapies for food allergy. *Human Vaccines and Immunotherapeutics*. 2012 Oct;8(10):1479-84. doi: 10.4161/hv.20868. Epub 2012 Aug 16.
88. Mousallem T, Burks AW. Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. *Clinical Experimental Immunology*. 2012; 167(1):26-31.
89. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis and hypersensitivity reactions to foods, drugs, and insects in 2011. *Journal of Allergy and Clinical Immunology*. 2012;129(1):76-85.
90. Beyer K. A European perspective on immunotherapy for food allergies. *Journal of Allergy and Clinical Immunology*. 2012;129(5):1179-84.
91. Keet CA, Frischmeyer-Guerrero PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. *Journal of Allergy and Clinical Immunology*. 2012;129(2):448-55.
92. Burks AW, Jones SM, Wood RA, et al. Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. *New England Journal of Medicine*. 2012 Jul 19;367(3):233-43.
93. Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, Staats H, Burks AW. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. *Journal of Allergy and Clinical Immunology*. 2012;129(4):1159-62.
94. Kari O, Saari KM. Treatment of eye allergies. *Duodecim*. 2012;128(3):291-7.



95. Lasa Luaces EM, Tabar Purroy AI, Gargia Figueroa BE, Anda Apinaniz M, Sanz Laruga ML, Raulf-Heimsoth M, Barber Hernandez D. Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children. *Annals of Allergy, Asthma, and Immunology*. 2012;108(5):367-72.
96. Crisafulli G, Caminiti L, Pajno GB. Oral desensitization for immunoglobulin E-mediated milk and egg allergies. *Israel Medical Association Journal*. 2012;14(1):53-6.
97. Otsu K, Fleischer DM. Therapeutics in food allergy: The current state of the art. *Current Allergy and Asthma Reports*. 2012;12(1):48-54.
98. Cortellini G, Spadolini I, Santucci A, Cova V, Conti C, Corvetta A, Passalacqua G. Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: A case report. *European Annals of Allergy and Clinical Immunology*. 2011;43(5):162-4.
99. Vickery BP, Scurlock AM, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Perry TT, Jones SM, et al. Early and persistent gastrointestinal side effects predict withdrawal from Peanut oral immunotherapy (OIT). *Journal of Allergy and Clinical Immunology*. February 2011;127(2)AB26.
100. Mauro M, Russello M, Invorvaia C, Gazzola G, Frati F, Moingeon P, et al. Birch-Apple syndrome treated with birch pollen immunotherapy. *International Archives of Allergy and Immunology*. 2011;156(4):416-422.
101. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. *Journal of Allergy and Clinical Immunology*. 2011 Mar;127(3):654-60.
102. Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. *Journal of Allergy and Clinical Immunology*. 2011 Mar;127(3):640-6.
103. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: other indications. *Immunology and Allergy Clinics of North America*. 2011;31(2):279-87.
104. Kulis M, Vickery BP, Burks AW. Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. *Immunological Research*. 2011;49(1-3):216-26.
105. Garcia BE, Gonzalez-Mancebo E, Barber D, Martin S, Tabar AI, Diaz de Durana AM, et al. Sublingual immunotherapy in peach allergy: monitoring molecular sensitizations and reactivity to apple fruit and Platanus pollen. *Journal of Investigational Allergology and Clinical Immunology*. 2010;20(6):514-20.
106. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *Journal of Allergy and Clinical Immunology*. 2010 Jun;125(6):1322-6.
107. Buyukozturk S, Gelincik A, Ozseker F, Colakoglu B, Dal M. Latex Sublingual Immunotherapy: Can its safety be predicted? *Annals of Allergy, Asthma & Immunology*. 2010 April;104(4):330-42.
108. Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, Perry TT, Jones SM, Burks AW. Adverse reactions during peanut oral immunotherapy home dosing. *Journal of Allergy and Clinical Immunology*. 2009 Dec;124(6):1351-2.
109. Pereira C, Bartolome B, Asturian J, Ibarrola I, Tavares B, Loureiro G, et al. Specific sublingual immunotherapy with peach LTP (Pru p 3). One year treatment: a case report. *Cases Journal*. 2009;2:6553.
110. Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, Decinti M, et al. Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy. *Journal of Allergy and Clinical Immunology*. 2009 Aug;124(2):385.
111. Skripak J, Wood R. Mammalian milk allergy: avoidance strategies and oral desensitization. *Current Opinion in Allergy and Clinical Immunology*. 2009 Jun;9(3):259-64. doi: 10.1097/ACI.0b013e32832b2218.
112. Branum AM, Lukacs SL. Food allergy among children in the United States. *Pediatrics*. 2009 Dec;124(6):1549-55. doi: 10.1542/peds.2009-1210.
113. Fernández-Rivas M, Garrido Fernández S, Nadal JA, Díaz de Durana MD, García BE, González-Mancebo E, Martín S, Barber D, Rico P, Tabar A. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. *Allergy*. 2009 Jun;64(6):876-83. doi: 10.1111/j.1398-9995.2008.01921.x. Epub 2009 Jan 21.



114. Atkins D. Food allergy: diagnosis and management. *Primary Care*. 2008 Mar;35(1):119-40, vii. doi: 10.1016/j.pop.2007.09.003.
115. Beyer K, Wahn U. Oral immunotherapy for food allergy in children. *Current Opinion in Allergy and Clinical Immunology*. 2008;8:553-556.
116. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. *Journal of Allergy and Clinical Immunology*. 2008 Dec;122(6):1154-60. Epub 2008 Oct 25.
117. Nucera E, Schiavino D, Buomomo A, Pollastrini E, Altomonte G, Pecora V. et al. Sublingual-Oral Rush Desensitization to Mixed Cow and Sheep Milk: A Case Report. *Journal of Investigational Allergology and Clinical Immunology*. 2008;18(3):219-222.
118. Burks W, Laubach S, Jones S. Oral tolerance, food allergy, and immunotherapy: Implications for future treatment (Update Review). *Journal of Allergy and Clinical Immunology*. 2008 June;121(6):1344-50.
119. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchi D, Spadolini I, Canonica WG, Passalacqua, G.. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. *Journal of Allergy and Clinical Immunology*. 2008 Jul;122(1):44-8.
120. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. *Journal of Allergy and Clinical Immunology*. 2008 Feb;121(2):343-7. Epub 2007 Dec 26.
121. Skripak JM, Matsui EC, Mudd K, et al. The natural history of IgE-mediated cow's milk allergy. *Journal of Allergy and Clinical Immunology*. 2007;120(5):1172-7.
122. Munoz-Lopez F. Food allergy: oral tolerance or immunotherapy. *Allergologia et Immunopathologia*. 2007;35(5):165-168.
123. Nettis E, Colanardi MC, Soccio AL, Marcandrea M, Pinto L, Ferrannini A, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. *British Journal of Dermatology*. 2007; 156:674-681.
124. Pajno G, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized double-blind, placebo-controlled study. *Journal of Allergy and Clinical Immunology*. 2007;120:164-170.
125. Patriarca G. et al. Oral specific desensitization in food-allergic children. *Digestive Diseases Sciences*. 2007;52(7):1662-72.
126. Passalacqua G, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A Novel SLIT formulation during a Year). *Pediatric Allergy and Immunology*. 2007;18:58-62.
127. Buchanan A. et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. *Journal of Allergy and Clinical Immunology*. 2007;119(1):199-205.
128. Patriarca G, et al. Oral Rush Desensitization in Peanut Allergy: A Case Report. *Digestive Diseases and Sciences*. 2006;51(3):471-473.
129. Sun J-B, et al. Sublingual Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Induces Fox p3+CD25+CD4+ Regulatory T Cells and Suppresses Delayed-Type Hypersensitivity Reactions. *Scandinavian Journal of Immunology*. 2006;64:251-259.
130. de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. *Allergy*. 2006;61:1238-1239.
131. Kerzl R, et al. Life-threatening anaphylaxis to kiwi fruit: Protective sublingual allergen immunotherapy effect persists even after discontinuation. *Journal of Allergy and Clinical Immunology*. 2007 Feb;119(2):507-8.
132. Scurlock A, Lee L, Burks AW. Food Allergy in Children. *Immunology and Allergy Clinics of North America*. 2005 May;25(2):369-388.

133. Enrique E. et al. Sublingual immunotherapy for hazelnut food allergy: A randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. *Journal of Allergy and Clinical Immunology*. 2005; 116(5):1073-1079.
134. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. *Allergy*. 2004 Sep;59(9):980-7.
135. Cistero Bahima A, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. *Journal of Investigational Allergology and Clinical Immunology*. 2004;14(1):17-25.
136. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. *Journal of Allergy and Clinical Immunology*. 2003 June;111(6):1406-09.
137. Patriarca G. et al. Oral desensitizing treatment in food allergy: clinical and immunologic results. *Alimentary Pharmacology Therapy*. 2003 May;17(9):459-465.
138. Patriarca G. Sublingual Desensitization: A New Approach to Latex Allergy Problem. *Anesthesia & Analgesia*. 2002;95:956-960.
139. Sicherer SH. Clinical implications of cross-reactive food allergens. *Journal of Allergy and Clinical Immunology*. 2001 Dec;108(6):881-90.
140. Skolnick HS, Conover-Walker MK, Koerner CB, et al. The natural history of peanut allergy. *Journal of Allergy and Clinical Immunology*. 2001;107 (2):367-74.
141. Nucera E. Immunological Aspects of Oral Desensitization in Food Allergy. *Digestive Diseases and Sciences*. 2000;45(3):637-641.
142. Sampson HA. Food allergy. Part I: Immunopathogenesis and clinical disorders. *Journal of Allergy and Clinical Immunology*. March 1999 March;103(5):717-28.
143. Patriarca G, et al. Food allergy in children: results of a standardized protocol for oral desensitization. *Hepato-gastroenterology*. 1998;45(19):52-58.
144. Morris DL. Intradermal Testing and Sublingual Desensitization for Nickel. *Cutis*. 1998;61(3):129-132.
145. Panzani RC, et al. Oral hyposensitization to nickel allergy: preliminary clinical results. *International Archives of Allergy and Immunology*. 1995;107(1-3):251-254.
146. Morris D. Use of sublingual antigen in diagnosis and treatment of food allergy. *Annals of Allergy, Asthma & Immunology*. 1969;27(6):289-94

## 7) Allergic Trends and Supporting Data

1. Compalati E, Erlewyn-Lajeunesse M, Ali F, et al. Allergen Immunotherapy in the era of SARS-CoV-2. *Journal of Investigational Allergology and Clinical Immunology*. 2020 May 11; 30(6). doi: 10.18176/jiaci.0568
2. Tesch F, Domdey A, Grand T, et al. Healthcare costs associated with allergic rhinitis, asthma and allergy immunotherapy. *European Annals of Allergy and Clinical Immunology*. 2020 July; 52(4). doi: 10.23822/EurAn-nACI.1764-1489.126
3. Yamamoto-Hanada K, Borres M, Aberg M, et al. IgE responses to multiple allergen components among school-aged children in a general population birth cohort in Tokyo. *World Allergy Organization Journal*. 2020 Feb 25; 13(2). doi: 10.1016/j.waojou.2020.100105
4. Cox L, Murphey A, Hankin C. The Cost-Effectiveness of Allergen Immunotherapy Compared with Pharmacotherapy for Treatment of Allergic Rhinitis and Asthma. *Immunology and Allergy Clinics of North America*. Feb 2020; 40(1). doi: 10.1016/j.iac.2019.09.003
5. Chan JC, Peters RL, Koplin JJ, et al. Food challenge and community-reported reaction profiles in food-allergic children aged 1 and 4 years: A population-based study. *Journal of Allergy and Clinical Immunology*. 2017 Mar-Apr;5(2):398-409. doi: 10.1016/j.jaip.2016.12.021.

6. Branum AM, Lukacs SL. Food allergy among children in the United States. *Pediatrics*. 2009 Dec;124(6):1549-55. doi: 10.1542/peds.2009-1210. Epub 2009 Nov 16.
7. Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, Holl JL. The prevalence, severity, and distribution of childhood food allergy in the United States. *Pediatrics*. 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20.

Updated: 12/11/20

©2002-2021 Allergychoices, 2731 National Drive, Onalaska, WI 54650